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CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Chronic Obstructive Pulmonary Disease (COPD) is a disease entity with two identifiable 
types of lung diseases, i.e. chronic bronchitis and emphysema. COPD is characterized by 
airway obstruction, airway inflammation and degradation of lung tissue. Chronic 
bronchitis is hallmarked by hyperplasia and hypertrophy of the goblet cells (mucous gland) 
of the airway, resulting in an increase in secretion of mucus which contributes to airway 
obstruction and respiratory symptoms like chronic cough and phlegm. Emphysema is 
defined histologically as the enlargement of the alveolar spaces at the end of the terminal 
bronchioles, with destruction of alveolar walls. The latter reduces the surface area 
available for gas transport which ultimately leads to insufficient oxygen uptake in the 
bloodstream and provision to body tissues, leading to shortness of breath (dyspnea) and 
exercise limitation in more severe cases of COPD. Most COPD patients display 
characteristics of both chronic bronchitis and emphysema, although the extent of both 
characteristic features may vary between patients. 
Central to the definition of COPD is a reduced level of lung function and this provides the 
most important and robust phenotype of COPD. The Global Initiative for Chronic 
Obstructive Pulmonary Disease (GOLD) has classified the severity of COPD using the 
spirometric measures Forced Expiratory Volume in 1 second (FEV1) and the Forced Vital 
Capacity (FVC) as presented in table 1 1. COPD is a progressive disease that is irreversible, 
and still no medication is available to prevent the accelerated decline in lung function. This 
is important since the decline in lung function predicts progression of the disease and 
overall mortality 2;3• 
Table 1: Spirometric classification of COPD severity based on post-bronchodilator lung function 
measurements 
I: Mild COPD • FEVi/FVC < 70% 
• FEV1 � 80% predicted 
II: Moderate COPD • FEV 1/FVC < 70% 
• 50% S FEV1 < 80% predicted - ----
Ill: Severe COPD • FEV1/FVC < 70% 
• 30% s FEV1 < 50% predicted 
IV: Very Severe COPD • FEV1/FVC < 70% 
• FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic 
respiratory failure 
Abbreviations: FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; respiratory failure: 
arterial pressure of oxygen (PaOz) less than 8.0 kPa {60 mm Hg) with or without arterial pressure of CO2 (PaCO2 
greater than 6. 7 kPa (50 mm Hg) while breathing air at sea level. 
The main risk factor for COPD is smoking: 10-20% of smokers develop COPD, and virtually 
all COPD patients have smoked. Smoking induces chronic inflammation of the airways and 
lung tissue, leading to airway remodeling and degradation of lung tissue. It has been 
shown that this inflammatory process persists after smoking cessation 4;5• Microscopically 
there is infiltration of the airway walls with inflammatory cells, particularly neutrophils 
Chapter l 
and T and B cells 6-9• Chronic inflammation due to persistent smoking is followed by 
scarring and remodeling that thickens the airway walls resulting in narrowing of the small 
airways. Airway remodeling may be accompanied by metaplasia and fibrosis of the lower 
airways. It is generally accepted that several mechanisms contribute to the pathology of 
COPD such as a disturbed oxidant-antioxidant balance, a disturbed protease-antiprotease 
balance, cell apoptosis, and impaired tissue repair. These mechanisms interact and 
inflammation and tissue remodeling occur as a consequence of these phenomena. 
Oxidants are reactive oxygen species that enter the lungs continuously by inhaling air. 
Tissue oxidative stress can normally be counteracted by exogenous antioxidant uptake 
from food and by endogenously present antioxidants like antioxidant enzymes that can 
detoxify reactive oxidant species. Cigarette smoke and air pollution contain excess 
oxidants that cannot be cleared immediately from the lung, leading to an imbalance 
between oxidants and antioxidants, so-called oxidative stress 10-12• Elevated oxidative 
stress levels in induced sputum have been associated with the severity of COPD 13• 
Oxidative stress amplifies inflammation by activating the transcription factor NF-KB, with 
subsequent increase of pro-inflammatory mediators 14• When activated, the inflammatory 
cells produce oxidants themselves as well, thereby giving rise to a loop of oxidative stress 
and chronic inflammation of the airways. 
Emphysematous lungs display breakdown of connective tissue components in the lung 
parenchyma by proteases such as neutrophil elastase, matrix metalloproteases and 
cathepsins 15-21• Cigarette smoke induces release of proteases as well as their inhibitors, 
anti-proteases, to neutralize the protease activity and thus tissue breakdown. It has been 
proposed that in smokers who develop COPD, the balance between proteases and 
antiproteases is disturbed with subsequent parenchymal injury. The best example for this 
imbalance is al-antitrypsin deficiency, which is caused by a polymorphism in the gene 
coding for al-antitrypsin, resulting in a lack of functional al-antitryspin protein in carriers 
of this polymorphism. Loss of the al-antitrypsin protein results in less inhibition of the 
protease elastase, which may lead to alveolar destruction and development of 
emphysema even without cigarette smoke exposure. 
Destruction of extracellular matrix (ECM) can not only be caused by excess protease 
activity, but may also be the consequence of insufficient repair. It has previously been 
shown that elastin and collagens and certain proteoglycans, i.e. decorin and biglycan, are 
less present in lung tissue from COPD patients compared to controls 22-24• The 
Transforming Growth Factor-�1 (TGF-�1)-Smad pathway may play a central role in this 
process since it has been shown to induce ECM protein production. In COPD patients the 
TGF�-Smad pathway is aberrantly expressed compared to healthy controls 25• 
Given the fact that COPD is a heterogeneous disease, it is easy to understand that 
inflammatory patterns with different intensity of the various cell components have been 
described in the literature. Generally, COPD patients have a marked increase in activated 
neutrophils in induced sputum, BAL fluid and bronchial biopsies compared to smokers 
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without airway obstruction 6-8• Increased numbers of CD8+ lymphocytes have been shown 
throughout the airway walls and in lung tissue of COPD patients 26-28• More recently, 
studies focus on the role and implication of B cells in COPD pathogenesis 9;29;30• Eosinophils 
may play a role in COPD pathogenesis as well, since blood eosinophilia itself is an 
independent predictor of reduced lung function levels and accelerated lung function 
decline and indicates worse prognosis in chronic bronchitis 31-33• 
There is an increase in apoptotic alveolar epithelial and endothelial cells in the lungs of 
COPD patients 34;35• Since this is not counterbalanced by an increase in proliferation of 
these structural cells, the net result is disruption of epithelial integrity, destruction of lung 
tissue and the development of emphysema 34• 
GENETICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
The level of lung function and the development of COPD are both environmentally and 
genetically determined. In the past decades, epidemiological studies have analyzed the 
environmental determinants extensively and there is now abundant evidence that the 
major environmental factor contributing to COPD development and excess lung function 
decline in the western world is cigarette smoking. It is, however, less clear why some 
smokers develop COPD and other smokers do not. This may be either due to additional 
environmental factors (e.g. less intake of oxidants in food) or to genetic factors. Clearly, it 
is of major importance to understand why some people are genetically susceptible to 
develop COPD while others are not, since such knowledge may provide new insights in the 
disease, potentially leading to better treatments. The genetic determinants are 
complicated to study, since COPD is a disease that is merely expressed at older ages. 
Therefore, the 'traditional' types of genetic studies, like those performed within families, 
are difficult to perform, because the parents of individuals with COPD often already have 
died and the children of individuals with COPD are likely to be too young to manifest 
airway obstruction already at that age. Case-control studies investigating COPD patients 
and healthy controls are generally used to study the genetics of COPD. So far these studies 
have been of small sample size and the definition of COPD has been variable. As a 
consequence, many studies cannot confirm previously reported genetic associations. 
Furthermore, the disease is only investigated when symptoms are present, without 
acknowledging the different patterns through which lung function loss may have evolved, 
i.e. an abnormally high rate of decline in lung function, a sub maximally attained level of 
lung function, or an abnormally early age of onset of decline. Genetic factors may affect 
any one, or a combination of these different patterns of lung function loss. Therefore, it is 
important to study multiple measurements of lung function in a well-characterized cohort 
that is followed up throughout life. 
Chapter 1 
In our studies, we have chosen to study genetic effects on robust phenotypes, namely 
level of FEV1 and rate of decline in FEV1• A short introduction on genetics and the type of 
genetic variation (Single Nucleotide Polymorphisms (SNPs)) that we study is presented in 
the next paragraphs. 
BRIEF INTRODUCTION IN GENETICS 
Each human cell nucleus contains a set of chromosomes, making up the genome. The 
human genome consists of 23 pairs of chromosomes, consisting of 1 pair of sex 
chromosomes (X and Y). The DNA (deoxyribonucleic acid) molecule consists of two ribbon­
like strands that wrap around each other, resembling a twisted ladder, often described as 
a double helix. The DNA is contained in tightly coiled packets called chromosomes, found 
in the nucleus of every cell. Chromosomes consist of the double helix of DNA wrapped 




Figure 1: Schematic view of a cell with the 
nucleus containing the chromosomes. The 
unwrapped chromosomes contain strands of 
DNA around histones. 
The double helix is made up of repeating units called nucleotides, who are composed of 
one sugar-phosphate molecule (the linear strands or outer rails of the ladder) and one 
base. DNA consists of two nucleotide strands joined by weak chemical bonds between the 
two bases, forming base pairs. A basepair is one step on the ladder of the DNA. The bases 
are called A (for adenine), C (for cytosine), T (for thymine) and G (for guanine). These 
bases always pair up in the following way: A+T and C+G. 
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A single strand of DNA is made of letters: 
ATGCTCGAATAAATGATITGA 
The letters make words of three basepairs that each code for an amino acid: 
ATG CTC GAA TAA ATG ATT TGA 
The words make sentences, the genes: 
<ATG CTC GAA TAA> <ATG A TT TGA> 
Amino acids are the building blocks of proteins. Genes thus contain the information to 
produce proteins. Proteins are required for the structure, function, and regulation of the 
body's cells, tissues, and organs. 
A mutation or polymorphism is a change in the DNA basepairs of a gene or an alteration in 
the chromosomes. Polymorphisms are common differences in the sequence of DNA, 
occurring in at least 1% of the population, whereas so-called 'mutations' occur in less than 
1% of the population. Most DNA variation is neutral (not beneficial or harmful), but 
harmful sequence changes sometimes do occur. Changes within genes can result in 
proteins that do not work normally or do not work at all. In general, such changes can 
contribute to disease development, or diseases severity, and can also affect the response 
to a medicine. In the lungs, changes in genes that are involved in e.g. the oxidant/anti­
oxidant balance and the protease/anti-protease balance within the lung can therefore be 
detrimental for lung tissue damage and repair. 
THE VLAGTWEDDE/VLAARDINGEN COHORT STUDY 
For most studies described in this thesis, we used data from the Vlagtwedde/Vlaardingen 
cohort study, an extensive longitudinal population study carried out in Vlagtwedde and 
Vlaardingen in the Netherlands. The first surveys consisted of a random sample of both 
areas of all men and women aged 40 to 64 years in 1965, and a random sample of all men 
and women aged 15 to 39 years in 1967 at Vlagtwedde and in 1969 at Vlaardingen. The 
cohort for the longitudinal study consisted of the youngest men and women who 
participated in 1965 (40 to 44 years old in the Vlagtwedde population and 40 to 54 years 
old in the Vlaardingen population), and all participants in 1967 and 1969 (aged 15 to 39 
years). After the baseline surveys the cohort participated in follow-up surveys 
approximately every 3 years. The final surveys were organized in 1989 in Vlagtwedde and 
in 1990 in Vlaardingen. All surveys were carried out during the month of October. This 
large cohort of male and female smokers and non-smokers has thus been followed over a 
25 yr period. This did not only allow us to study the contribution of genetic variations to 
decline in lung function but also genes involved in previously well established risk factors 
for lung function course and decline in this population, i.e. bronchial hyperresponsiveness 
(BHR) and blood eosinophilia. In 2003/2004, DNA was isolated from 2467 subjects of the 
Vlagtwedde/Vlaardingen cohort participating in the last survey in 1989/1990. In this thesis 
we have used data from 1390 subjects, selected on DNA availability (>1500 ng isolated 
DNA available). 
Chapter 1 
Although the Vlagtwedde/Vlaardingen population is the main focus of research in this 
thesis, some of the studies were performed using a second population-based cohort, 
respectively 3 distinct COPD patient populations. The Doetinchem cohort is a random 
sample of the larger MORGEN cohort 36;37• This population-based cohort has been 
followed up for 5 years, allowing us to study genetic effects on the decline in lung function 
and development of COPD in the general population. 
The first COPD patient population consisted of individuals who were included in the 
GLUCOLD study (Groningen Leiden Universities Corticosteroids in Obstructive Lung 
Disease), a randomized control trial to analyze short versus long-term effects of steroids 
with and without bronchodilator in patients with mild to moderate COPD (GOLD stage II 
and Il l). A unique feature of this cohort is that bronchial biopsies were collected from all 
participants, as well as sputum, blood and lung function measures. 
The second COPD patient population consisted of a cohort of patients with very severe 
COPD (GOLD stage � Il l). We retrieved longitudinal pulmonary function measurements 
before the patients underwent lung transplantation (LTX) because of COPD. 
Approximately half the patients in the cohort have al-antitrypsin deficiency, which 
enables us to compare genetic effects between patients with and without al-antitrypsin 
deficiency. 
The third COPD study population was derived from a genetically isolated population from 
the south of the Netherlands as part of the Genetic Research in Isolated Populations study 
(GRIP). Since the genetic variation in such an isolate is limited, it is thought that one can 
more easily identify genes involved in disease is such a population than in a general 
population. An overview and brief description of the different study populations is 
presented in table 2. 
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Abbreviations: GLUCOLD Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease; L TX lung 
transplantation; GRIP Genetic Research in Isolated Populations; COPD Chronic Obstructive Pulmonary Disease; 
GOLD Global initiative for Obstructive Lung Diseases; BHR Bronchial Hyperresponsiveness 
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AIMS OF  THIS THESIS 
In this thesis, studies are described that investigate the effects of SNPs in genes on lung 
function level and decline in lung function, COPD development and risk factors for COPD, 
i.e. BHR and blood eosinophilia. These genes are involved in oxidative stress, inflamma­
tion, detoxification of cigarette smoke and destruction of ECM components, like 
proteases. The specific subjects covered are described in the following paragraphs. 
Chapter 2 gives an overview on the genetic epidemiology of reduced lung function, in 
which we present multiple different designs to study the role of genetics in development 
of COPD and reduced lung function. 
Chapters 3, 4 and S present the studies on one gene, i.e. A Disintegrin And 
Metalloprotease 33 (ADAM33} in 3 different populations. ADAM33 has previously been 
identified as candidate gene for asthma in a whole genome wide screen, and has been 
associated with excess FEV1 decline in asthmatics. In chapter 3, the hypothesis is tested 
whether ADAM33 may not only be associated with excess FEV1 decline in asthmatics, but 
that this association might be observed in the general population as well. Since ADAM33 
has previously also been associated with BHR in asthmatics and the majority of COPD 
patients have BHR, we wondered whether ADAM33 plays a role in BHR within a group of 
COPD patients. Therefore, in chapter 4, the effect of SNPs on BHR severity and 
inflammation was studied in sputum and bronchial biopsies in 114 patients with mild to 
moderate COPD from the GLUCOLD study. Finally, in chapter S we studied whether 
ADAM33 SNPs also plays a role in excess FEV1 decline within COPD patients. The effect of 
ADAM33 SNPs on FEV1 decline was therefore investigated in 79 patients with severe COPD 
with and without al-antitrypsin deficiency with longitudinal lung function data prior to 
lung transplantation. 
In chapter 6, the association was studied between SNPs in matrix metalloprotease (MMP) 
genes and their tissue inhibitors and COPD and accelerated FEV1 decline. As described 
previously, one of the most recognized theories behind development and progression of 
COPD is the disturbed balance of proteases and anti-proteases. This may be genetically 
determined. 
In chapter 7, we studied the role of TGF-81 and decorin in COPD development and lung 
function decline. TGF-131 is a cytokine that is an important mediator in tissue proliferation 
and differentiation. From previous studies it is known that levels of TGF-131 are increased 
in sputum and lung tissue from COPD patients, whereas levels of its inhibitor, decorin, are 
decreased. We analyzed whether this imbalance between TGF-131 and decorin has a 
genetic origin and whether SNPs in their genes affect lung function decline and COPD 
development in the general population. 
Cf1dptc1 I 
In chapter 8, the focus lies on the effects of genetic variation in 3 antioxidant enzymes on 
lung function and how they interact with smoking and gender: Glutathione S-Transferases 
(GST) Ml, Pl and Tl. The effect of deletion alleles of GSTMl and GSTTl and 2 SNPs in 
GSTPl on the level and course of lung function was studied in the Vlagtwedde/Vlaardin­
gen population. 
Chapter 9 describes the effects of polymorphisms in the antioxidant enzymes superoxide 
dismutase 2 and 3 on level of lung function, lung function decline and bronchial 
hyperresponsiveness in the Vlagtwedde/Vlaardingen population. 
In chapter 10, we investigated the effects of SNPs in surfactant protein genes on decline in 
lung function and COPD development, and on well-known risk factors of COPD, i.e. BHR  
and blood eosinophilia. The pulmonary surfactant i s  important in alveolar structuring, 
bronchial clearance, and the innate immunity and additionally attracts eosinophils to the 
lungs. Therefore, changes in surfactant quantity or composition may contribute to lung 
function decline and development of COPD. Since a major part of the pulmonary 
surfactant consists of lipids, we analyzed surfactant lipids and their degradation products 
in sputum of COPD patients and controls and studied their association with lung function. 
Chapter 11 describes a candidate gene study for level of airflow limitation in patients with 
mild COPD from a recently isolated population from the southwestern area of the 
Netherlands as part of the GRIP study. It has advantages to try and identify risk genes in 
populations that are homogeneous, like genetically isolated populations. Due to the small 
number of founders in genetically isolated populations, the total gene pool and therefore 
the number of different genes involved in a trait is limited. We analyzed the effects of 33 
SNPs in 13 candidate genes for COPD on level of lung function and aimed to replicate the 
significant associations in COPD patients selected from the Vlagtwedde/Vlaardingen 
population. 
Chapter 12 concludes with a summary and general discussion of the studies described in 
this thesis. Additionally, we describe future perspectives for further research on genetics 
of lung function and COPD development. 
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INTRODUCTION 
Genetic epidemiology of respiratory d isease focuses on identifying genetic determinants 
of d isease development taking environmental factors that preclude, affect or enhance this 
development, into account. The respi ratory d isease Chronic Obstructive Pulmonary 
Disease (COPD) is a lmost fu l ly attributable to the environmenta l factor smoking, with the 
exception of the genetical ly predominance of al-antitrypsine (AAT) deficiency gene, which 
ca rriers need no further environmental smoke exposure to develop a phenotypic expres­
sion of COPD. However, AAT-deficiency is accounting for a min imal number of COPD cases 
worldwide (<1%), since the fast majority of COPD does not have AAT-deficiency but is 
attributable to cigarette smoking. The role of smoking as major determinant of COPD has 
r isen a bove any doubt. However, if 'the whole world' would have been smoking, COPD 
would have been considered to be a genetic d isease, since only a minority of  smokers 
develops COPD. Therefore, those smokers who do develop COPD seem to be genetica l ly 
more susceptible to the de leterious effects of cigarette smoke than smokers who do not 
develop COPD. This chapter focuses on the genetic determinants of d imin ished lung 
function, taking envi ronmental factors that preclude, affect or enhance this development, 
into account, with specific emphasis on d ifferent study designs that a re used in genetic 
epidemiology. 
ENVIRONMENTAL AND GENETIC FACTORS AFFECT LUNG FUNCTION 
COPD is the third cause of death worldwide and is expected to increase in preva lence i n  
the  forthcoming decades 1;2• Reduced leve ls of  lung function, assessed by  lung function 
measu rements, provide the most important and robust phenotypes of COPD and pred ict 
progression of the disease and overa l l  mortal ity 3;4. 
The level of l ung function is both genetica l ly and environmental ly determ ined. In the past 
decades, the environmenta l determinants have been extensively studied, i .e. smoking, a i r  
po l l ut ion, occupational exposure, chi ldhood respiratory i l l ness, diet, and exposure to 
respiratory a l lergens. The genetic determinants have been stud ied less frequently and 
consistently, and they a re more d ifficult to study, since COPD is a d isease that is mere ly 
expressed at later ages. Therefore, the 'trad it ional' types of genetic studies, l i ke those 
performed within fami l ies, are more d ifficu lt to perform, because the pa rents of indivi­
dua ls with COPD often a l ready have d ied a nd the chi ldren of subjects with COPD a re l i kely 
to be too young to man ifest a i rway obstruction a l ready. 
Nevertheless, a number of genetic studies on COPD have been performed, usua l ly 
incl ud i ng smal l  numbers of subjects and various defin itions of d isease status, which makes 
it d ifficu lt to compare resu lts between such stud ies. Because of this low inter-study-
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comparability with regard to COPD disease state, it makes sense to choose a robust 
phenotype like level of pulmonary function, which can be compared more easily between 
studies. Moreover, an accelerated decline in FEV1 is a predictor for mortality from COPD 
3;4, and provides additional information compared to taking only the level of FEV1 into 
account. 
Environmental factors affecting lung function 
The rate of decline in lung function is determined by many environmental factors. Cohort 
studies have shown that adult smokers experience faster decline in FEV1 than nonsmokers 
5 and that this accelerated decline returns to normal levels of aging-related decline after 
smoking cessation 6• Additionally, women have a faster decline in FEV1 in response to 
cigarette smoke than men 7• The rate of FEV1 decline is also related to outdoor and indoor 
air pollution levels 8;9 and occupational exposure to dust, gasses and fumes 10-12. A poor 
level of lung function at a later age is not necessarily caused by excessive lung function 
decline, but can also be the consequence of a diminished maximal attained level of lung 
function, which can be due to many causes. Current and cumulative cigarette smoking, the 
presence of respiratory symptoms, increased numbers of blood eosinophils, and increased 
airway responsiveness were all found to be significant predictors of reduced level of FEV1 
in a large cohort of the general population 13• Another study demonstrated a 10.7% 
reduction in FEV1 among children with a smoking parent compared to children of a 
nonsmoking parent, thereby emphasizing the importance of environmental tobacco 
smoke already in childhood 14• To accurately assess decline in lung function or level of lung 
function at an older age, it is important to keep these environmental factors in mind. 
Genetic factors affecting lung function 
There are many approaches to determine whether there is a genetic component 
contributing to a reduced level of lung function, and if such a genetic component can be 
identified, how big its effect is. In this chapter we will discuss the different approaches to 
study genetic epidemiology of reduced level of lung function, together with the major 
results each method has provided in elucidating the role of genetics in level of lung 
function. 
FAMILY AND TWIN STUDIES 
About 30 years ago, studies already demonstrated that there is a familial resemblance in 
pulmonary function. Cohen et al. showed in 1977 that first degree relatives of COPD 
patients had lower rates of forced expiration than relatives of patients with non­
respiratory disease or community derived controls 15• Many studies have addressed the 
familial component of COPD and found that familial factors account for up to 40-50% of 
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variability in cross-sectional lung function levels. For example, Astemborski et al showed 
that additive genetic variation accounted for 28% of the variation in residual FEV1 in 108 
adult families and 24% of the variation in residual FEVi/FVC adjusted for appropriate 
confounders 16. A number of studies have demonstrated that the risk to develop COPD is 
2-3 fold greater for smokers who have a first degree relative with COPD compared to 
smokers without such a relative (reviewed by Chen 17) . Moreover, lower values of FEF25_75% 
and FEF25_75¾fFVC in smoking and in non-smoking first degree relatives of early onset 
COPD patients compared to controls suggest a genetic susceptibility to develop COPD 
independent of smoking 18. Indeed, this risk may increase according to higher levels of 
exposure to detrimental environments such as cigarette smoke, since smoking relatives 
showed lower FEF2s-7s% and FEF2s-1s%/FVC. 
Some family studies have addressed the familial correlation in decline of FEV1 and found 
no evidence for spousal or parent-offspring correlation for decline in FEV1 (slope) over the 
years. However, there was a strong correlation in slope of FEV1 between siblings, 
especially in smoking-concordant pairs 19. 
Twin studies are an interesting method to study the relative importance of genetic and 
environmental effects on a trait, since monozygotic (MZ) twins share 100% of their DNA 
and dizygotic (DZ) twins only 50%. A higher degree of similarities in MZ than in DZ twins 
suggests a genetic influence, irrespective of environmental influences. Monozygotic twins 
exposed to opposite environmental influences shed a light on the relative importance of 
the environment e.g. cigarette smoking) on a phenotypic trait such as reduced levels of 
lung function. Several studies have shown that intra-pair correlations for spirometric 
measures between MZ twins are high and highly significant, and smaller between DZ twins 
20:21, although one such a study showed no such intra-pair difference in pulmonary 
function between MZ or DZ twins 22. Strong indications for genetic effects on pulmonary 
function come from a study by Redline and colleagues 23. They showed that the strength 
of the correlations in FEV1 and FVC decrease when relatives share less of their genotype, 
i.e. correlations of 0.71 for MZ twins (100% shared genotype), 0.16-0.29 for relatives with 
50% shared genotype, and 0.09-0.27 for relatives with 25% shared genotype 23. A study of 
lung function in 203 twin pairs aged 18-34 years detected significant genetic variation in 
females and males 24. There was evidence that the heritability was lower in males (about 
0.6) than females (about 0.8). An effect of smoking on lung function was detected but 
accounted for less than 3% of the variance. The geometry of the airways may also be 
related to genetic factors, since the difference in Vmax at 60% of total lung capacity (TLC) 
on air and on helium-oxygen is smaller between MZ than DZ twins 25. Two other twin 
studies have suggested that genetic factors are important in susceptibility to airway 
disease in reaction to cigarette smoke. Within identical twins who are raised apart, twins 
concordant for cigarette smoking or non-smoking have highly similar lung function, 
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whereas twin pairs discordant for smoking status have larger differences in pulmonary 
function 26;27• 
In conclusion, these family and twin studies have demonstrated that there is a familial 
aggregation of lung function measures, indicating that genetic factors are important for 
level of lung function. Because twin studies do not require the genotype and phenotype of 
at least 2 generations like the other types of family studies, the late onset of the disease is 
not a problem and twin studies are suitable for studying COPD. 
SEGREGATION ANALYSIS AND HERITABILITY 
Segregation analysis evaluates whether the proportion of affected and unaffected 
offspring in families is consistent with Mendelian expectations. It addresses the question 
whether a disease is caused by a major Mendelian gene or whether different minor gene 
effects account for the disease. 
There are conflicting results for the mode of inheritance of pulmonary function. Rybicki et 
al found evidence for a major gene influencing FEV1 in families ascertained through a 
proband with COPD, but not in randomly ascertained families 28• The Humboldt family 
study showed a major genetic mechanism for inheritance of FVC, but environmental 
factors remained significant in the segregation analyses 29;30• The National Heart, Lung, 
and Blood Institute (NHLBI) Family Heart study also provided evidence for major genes for 
FEV1 and FEVJFVC 
31
• In the 264 members of 26 Utah Genetic Reference pedigrees, major 
locus inheritance was found for the FEVJFVC ratio, although they could not discriminate 
between a dominant or recessive mode of inheritance. No evidence of major locus 
inheritance was found for either FEV1 or FVC 
32
• Similarly, in the Framingham study (5003 
subjects form 1408 families) models with a Mendelian gene for inheritance of FEV1 were 
rejected 33• The familial correlation was greater between mothers and offspring than 
between fathers and offspring in models that assume no major gene. Additionally, sibling 
correlation exceeded parent-offspring correlation. 
The Framingham study is the only study that addresses heritability of longitudinal decline 
in lung function. The authors describe heritability of longitudinal change in lung function 
over at least 15 years in two generations of the general population. Heritability factors 
explained a modest proportion of the population variance, but were higher when analyses 
were restricted to smoking status 34• 
In summary, all studies indicate a significant heritability of pulmonary function, but it is 
not clear whether a major gene causes this effect or that several minor genes exert the 
effect, combined with or without environmental factors. 
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GENOME WIDE LINKAGE ANALYSIS 
Genome wide linkage analysis is an approach to identify which chromosomal areas are 
involved in disease. This method compares the inheritance of disease with inheritance of 
genetic markers in families with multiple affected members. If the disease is co-inherited 
with the marker, this suggests that a disease susceptibility gene is located close to the 
marker of that chromosome. 
The first studies on linkage analyses for COPO were performed in the Boston severe early 
onset COPO population. This population consists of families ascertained through probands 
with severe early onset COPO without AAT deficiency. Given the young age of probands, it 
was possible to include parents to perform these linkage analyses. Multiple chromosomes 
were identified to be linked to different phenotypes, e.g. pre-and postbronchodilator FEV1 
and FVC. These studies will be described in more detail in chapter 13 of this book. An 
overview of the genome wide linkage analyses that have been performed on lung function 
measures so far is given in table 1. 
The Framingham cohort is based on the general population. In a genome wide screen on 
this cohort, FEV1 was most influenced by the locus on chromosome 6 (LOO = 2.4), whereas 
chromosome 21 contained markers with the strongest linkage to FVC (LOO = 2.6) 35• In the 
subsequent fine screen of the linked region, the linkage peak was narrowed to 
chromosome 6q27 and the LOO score for linkage of FEV1 increased from 2.4 to 5.0 
36
. 
A genome-wide scan of pulmonary function measures in the NHLBI Family Heart Study 
identified regions on chromosomes 4 and 18 with LOO scores above 2.5, and these two 
chromosomes were further evaluated by incorporating additional marker genotyping. The 
FEVi/FVC ratio was linked to chromosome 4 with a LOO score of 3.5. FEV1 and FVC were 
suggestively linked to regions on chromosome 18 with multipoint LOO scores of 2.4 for 
FEV1 and 1.5 for FVC at 31 cM (018S843) and a LOO of 2.9 for FVC at 79 cM (018S858) 
37• 
In the Utah CPH, suggestive evidence for linkage of FEV1/FVC was found on chromosome 2 
(heterogeneity LOO 2.36, dominant model) and chromosome 5 (heterogeneity LOO 2.23, 
recessive model). In addition, nonparametric variance component linkage analysis showed 
linkage of FEVi/FVC in both of these regions, providing further support to the results 
32
• 
A genome-wide scan for asthma phenotypes was conducted in 295 French EGEA families 
selected through at least one asthmatic subject. Besides linkage of asthmatic phenotypes, 
they also found linkage for %pred FEV1 to chromosome 6ql4, which appears to be a new 
region potentially linked to %pred FEV1 
38
• Another genome wide screen within 200 
families ascertained through a proband with asthma was performed by Postma et al 39' 
and in addition these authors assessed influences of early-life smoke exposure. Significant 
evidence for linkage of pre- and postbronchodilator FEV1/VC was found for chromosome 
2q32 (LOO 4.9, increasing to 6.03 with additional fine-mapping markers, and 3.2, 
Boston early- FEV1 8p23 (2 from pter) 
onset COPD FEV1 lp21 (136) 
(n=560) 
FEV1 8q24 (163) 
FEV1, FEVJFVC 19q13 (78) 
FEV1, FEVJFVC 2q36 (222) 
FEVJFVC lp31 (118) 
FEVJFVC 17q21 (67) 
Boston early- FEVJFVC 2q (222) 
onset COPD FEVJFVC 1(120) 
(n=585) 
FEVJFVC 17 (67) 
FEV1 12p (37) 
FVC 1 ( 13) 
Framingham FEV1, FVC 4 (76) 
cohort, 1578 FEV1, FVC 6 (qterm) 
members of 330 FEV1, FVC 21 (pterm) 
famil ies 
Framingham, fine FEV1 6q27 (184-190) 
screen 
NHLBI family FEVJFVC 4 (28) 
heart study FEV1, FVC 
31
, 18 (31, 79) 
(n=l327, general FVC 79 
population) --... ·-----. 
264 members of FEVJFVC 2 (222) 
24 Utah CEPH FEVJFVC 5 (295) 
pedigrees FEVJFVC 5 (297) 
FEVJFVC 5 (299) 
FEVJFVC 5 (303) 
Boston early- FEFis-mJFVC 2 (216) 
onset COPD FEFis-1s" 12 (35) 
(n=416) FEFis-1s,JFVC 2 (221) 
FEFis-1s,JFVC 12 (35) 
FEVJFVC 2 (229) 
FEV1 12 (36) 




200 Dutch Pre- and post- 2q32 (195) 
famil ies BDR FEVJFVC 
ascertained for Pre- and post Sq (140) 




resp. 1.94, 1.67 








resp. 1.6, 1.2 
resp. 2.4, 1.1 
resp. 1.2, 2.6 
5.0 
3.5 
resp. 2.4, 1.5, 2.9 
1.02 ( 1.55 in dom model) 
2.64 
1.92 
1.06 (1.54 in rec model) 
1.46 
2.60 
5.03 (smoke only) 
4.12 (smoke only) 




resp. 4.9, 3.2 
resp 1.8, 2.6 
Palmer, 2003 35 
For every l inkage, 
pre-BDR was also 
l inked, but LOD 
score was lower 
Silverman, 2002 36 
Joost, 2002 37 
Wilk, 2003 38 
Wil k, 2003 39 
Malhotra, 2003 32 
DeMeo, 2004 ii 
Bouzigon, 2004 40 
Postma, 2005 4
1 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; FEV1 Forced Expiratory Volume in one second; FVC 
Forced Vital Capacity; VC Vital Capacity; FEF Forced Expiratory Flow; NHLBI National Heart, Lung and Blood 
Institute; EGEA Epidemiological study on the Genetics and Environment of Asthma; BDR Bronchodilator; LOO 
Logarithm of the Odds; Cm Centimorgan 
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respectively), 35 cM proximal from linkage previously observed in families of probands 
with early-onset chronic obstructive pulmonary disease. Linkage existed for chromosome 
Sq for pre- and postbronchodilator VC (LOD 1.8 and 2.6, respectively). Results for pre- and 
postbronchodilator FEV1 were less significant (LOD, 1.5 and 1.6, chromosomes llp and 
lOq, respectively). Results were not affected by passive smoke exposure. Thus, there may 
be multiple genes on chromosome 2q that are important in determining presence and 
degree of airflow limitation in families ascertained for obstructive airway disease. Thus far, 
linkages with lung function on chromosome 2 are on different chromosomal locations in 
the different studies (table 1), which makes it difficult to identify a candidate gene is this 
area. The results from the linkage analyses are clearly inconsistent. Some regions have 
been replicated while most others have not. This indicates that the genetics of lung 
function is a multifactorial and complex matter. The logical next step after linkage analyses 
would be positional cloning of genes in the linked region. Unfortunately, such approaches 
are lacking in genetics of lung function or COPD. In contrast, in asthma, positional cloning 
of genes in linked regions has resulted in identification of 4 candidate genes for asthma, 
namely A Disintegrin and Metalloprotease 33 (ADAM33}, Dipeptidyle peptidase 10 
{DPPlO}, PDH finger protein 11 (DHF11} and G protein coupled receptor 154 (GPRA) 42• The 
only study that examined candidate genes in a region of linkage in COPD (i.e. chromosome 
2q) was performed by Celedon et al. 43, in which the transforming growth factor-81 gene 
was identified as a risk factor for lower FEVi/FVC. Hopefully, positional cloning will provide 
more candidate genes for reduced lung function and COPD in the future. 
CASE-CONTROL STUDIES 
In case-control studies, a large number of candidate genes, chosen for their biological role 
in pathogenesis in COPD, have been associated with lung function or COPD. However, for 
every studied gene there is (at least) one study which results contradict the others. 
Replication is difficult due to population stratification, ethnic differences, and small 
numbers of cases and controls that are usually included in studies. In chapter 14 (of the 
original book, red. cvo), these studies and the candidate genes that have been identified are 
being described in more detail. 
Chapter 2 
POPULATION BASED LONGITUDINAL STUDIES ON DECLINE IN LUNG FUNCTION 
As mentioned earlier, lung function decline is a risk factor for development of COPD, and 
the progression of asthma. Studies that evaluate genetic influences on lung function 
decline in combination with environmental factors are important for identifying subjects 
at risk for these disabling diseases. 
The Lung Health Study group has performed multiple studies on genetics of lung function 
decline. Participants in the genetics study were selected from a larger cohort, which was 
designed to describe the natural history of cigarette-smoke associated COPD. They were 
all smokers with either no decline in FEV1 (n=306, mean decline +14.9 ml/y) or a fast 
decline in FEV1 (n=284, mean decline -153.6 ml/y) over a follow up period of 5 years. The 
reasoning behind selection of such groups was that widely divergent rates of decline in 
lung function would give robust phenotypes for detection of genes that contribute to 
COPD severity. In their initial study, they found associations of the al-antitrypsin gene MZ 
genotype and microsomal epoxide hydrolase (His113/His139 haplotype), in combination 
with a family history of COPD, with rapid decline in FEV1 44• Subsequent studies with this 
same population identified associations with rapid decline in FEV1 of haplotypes of IL-18 
and IL-1 receptor antagonist 45, haplotypes of glutathione 5-transferase (Gsn-M1, -Tl, -Pl 
46
' a SNP in MMP1 and a haplotype of MMP1 and MMP12 47, a SNP in /L-4 receptor 
antagonist 48, and a SNP in 62 adrenergic receptor 49• Since both non-decliners and fast­
decliners had continuously smoked during follow up, these studies suggest that SNPs or a 
combination of risk alleles contribute to the deleterious effects of smoking on FEV1 . SNPs 
or haplotypes in other candidate genes (tumor necrosis factor-a (TNF-a), vitamin-D 
binding protein 44, heme oxygenase-1 46, MMP9 47, /L-13, IL-13 receptor antagonist 1 48) 
were not associated with rapid decline in FEV1• These studies have been described in more 
detail in Chapter 16: Association studies in COPD (in the book 'Genetics of asthma and chronic 
obstructive pulmonary disease', red.). 
In a cohort of firefighters (97% males, 75% Caucasian), longitudinal decline in FEV1 was 
linked to /L-10 SNPs. A SNP at position 1668 was associated with a more rapid decline in 
FEV1 
50
. In this same population, SNPs in TNF-a, and /L-18 were also associated with a 
more rapid decline in FEV1, while SNPs in TGFB1 were not 
51
. Hang et al. have shown that 
gene-environment interactions can influence decline in FEV1 substantially 
52
• They 
investigated whether SNPs in microsomal epoxide hydrolase, resulting in a slow and a fast 
enzyme activity, were associated with rapid decline in FEV1 during 20 years of follow up. 
They were furthermore able to discriminate between non-exposed subjects and subjects 
exposed to airborne cotton dust and gram-negative bacteria endotoxin. Endotoxin 
exposure was associated with faster lung function decline among genotypes with slower 
enzyme activity but not among other genotypes. This indicates that SNPs can modify the 
association between occupational exposure and longitudinal lung function decline. 
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Recently, the effects of GST SNPs and daily fruit intake on decline in FEV1 were studied in 
the Swiss SAPALDIA cohort that was followed up for 11 years 53• Both daily fruit intake and 
SNPs in GST-Ml and GST-Tl had an effect on FEV1 decline in men only, not in women. The 
protective effect of daily fruit intake was restricted to male persistent smokers. These 
results indicate complex gene-environment interactions with additional gender effects. 
After the identification of ADAM33 as a candidate gene for asthma 54, SNPs in this gene 
were also associated with excess decline in FEV1 within asthmatics 
55
. More recently, Van 
Diemen et al showed that these SNPs were associated with accelerated decline in FEV1 
and with development of COPD in the general population 56• 
GENETICALLY ISOLATED POPULATIONS 
Studies in isolated populations can be used in genetic epidemiology to identify candidate 
regions in a relatively small population because of their decreased genetic heterogeneity, 
increased linkage disequilibrium and more homogeneous environmental exposures. 
Studying isolated populations has the advantage that data collecting for phenotyping (e.g. 
lung function measurements) and genotyping can usually be performed in a logistically 
small area, with additionally low cost. The Hutterites of South Dakota are an isolated 
population of European descent from the early lih to 18th century. Candidate loci for 
cardiovascular disease had a similar prevalence in this population compared to two 
samples of outbreed populations, indicating that data gathered in a founder population 
can be extrapolated to the general population 57• However, it is possible that common 
variants in the general population are not present in the isolated population. Conversely, 
it is possible that disease alleles identified in isolated populations may not contribute 
significantly to susceptibility in outbreed populations. This was the case for the 
identification of the cysteinyl /eukotriene 2 ( Cysl T2) receptor as a candidate gene for 
asthma in the population of Tristan da Cunha 58• The SNP was frequent in this population 
(0.13), but had only a minor effect in outbreed populations because of its low frequency 
(0.01-0.03) 59• 
So far, no studies have been performed on COPD in isolated populations, although this 
might be a potential ly efficient approach in identifying candidate regions, which should 
thereafter be explored further in general population samples. 
C/Japte:- 2 
CONCLUSIONS 
Several genes have been studied in relation to reduced level of lung function and COPD. 
Choices about the most appropriate study design, or the population to study are usually 
made dependent of the goal of the study, e.g. whether one sets out to confirm a 
previously found association in a different population, or to search for new genes or 
pathways, that have not been studied before. 
We have discussed several study designs used in genetic epidemiology to study 
determinants of reduced lung function. Overall, every type of design has its restrictions, 
varying e.g. from high cost to relatively low costs, and hypothesis-generating to 
hypothesis-testing. To our opinion, the most fruitful approach for future research seems 
to lie in combining the results of different types of study and study designs, and focusing 
on specific pathways; e.g. identifying candidate regions in isolated or patient populations, 
sequencing these regions and testing SNPs in candidate genes in relation to lung function 
decline in the general population. A logical further step lies in studying functionality of 
identified SNPs, as well as gene expression in tissue. Moreover, genetic epidemiology 
studies should warrant attention for the interactions of genes with the major environ­
mental exposure that play a role in the development of disease, being cigarette smoking. 
Therefore, for future research, excellent longitudinally collected data on phenotype, as 
well as exposures, are as crucial as improving techniques for genotyping. 
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ADAM33 (A Disintegrin and Metalloprotease 33) has been identified as a susceptibility 
gene for asthma and single nucleotide polymorphisms (5NPs) in this gene have been 
associated with excess decline of lung function in asthmatics. 
Objectives 
To assess whether 5NPs in ADAM33 are associated with accelerated lung function loss in 
the general population and with chronic obstructive pulmonary disease (COPD). 
Methods 
We have collected DNA from subjects of the Vlagtwedde/Vlaardingen cohort participating 
in the last survey in 1989/1990 after a follow up of 25 years. Information was collected 
every 3 years, including lung function measurements. We defined COPD as GOLD stage II 
or higher at the last survey. 1390 subjects from the cohort were genotyped for the 
following 5NPs in ADAM33: F+l, Q-1, 5_1, 5_2, T_l, T_2, V_ 4, 5T+S. Differences in 
prevalence of 5NPs were analyzed with chi-square tests. Linear mixed effects models were 
used to analyze FEV1 decline according to genotype. 
Measurements and main results 
In the whole population, mean adjusted decline was 18.7 and 12.7 ml/y in females and 
males respectively. Individuals homozygous for minor alleles of 5NPs 5_2 and Q-1 and 
heterozygous for 5NP 5_1 had a significantly accelerated decline in FEV1 of respectively 
4.9, 9.6 and 3.6 ml/y compared with wild type. We found a significantly higher prevalence 
of 5NPs F+l, 5_1, 5_2 and T_2 in subjects with COPD. 
Conclusions 
We demonstrated that 5NPs in ADAM33 are associated with accelerated lung function 
decline in the general population. These 5NPs are also a risk factor for COPD. 
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INTRODUCTION 
ADAM33 (A Disintegrin And Metal/oprotease 33) has been identified as an asthma 
susceptibility gene 1. In Dutch, American, German and Korean asthma populations this 
finding has been replicated 2-5 in contrast to a Mexican population in which bronchial 
hyperresponsiveness was not tested 6• Recently, we have shown that polymorphisms in 
the ADAM33 gene not only play a role in asthma susceptibility, but also in its progression 
7
• The 5_2 polymorphism was associated with accelerated lung function decline in a Dutch 
asthma population followed for 23 years. It is yet unknown whether this is specific for 
asthma or that polymorphisms in ADAM33 also affect lung function loss in the general 
population. A progressive decline in FEV1 on a population level is partially related with 
asthma 8• Additionally, lung function decline is a risk factor for the development of chronic 
obstructive pulmonary disease (COPD) and cardiovascular diseases 9• Associations of 
polymorphisms in ADAM33 with FEV1 decline may therefore constitute a risk for the 
development of COPD as well. In this study, we have investigated the role of eight single 
nucleotide polymorphisms (SNPs) in the ADAM33 gene on lung function decline in 1390 
subjects of the Vlagtwedde/Vlaardingen cohort. This large population based cohort has 
been followed for a period up to 25 years, during which lung function measurements were 
performed every 3 years. We aimed to establish whether the ADAM33 gene is associated 
with accelerated lung function decline in the general population, and whether it is a 
susceptibility gene for the development of COPD. 
METHODS 
Subjects 
We have used data from the 2467 subjects of the Vlagtwedde/Vlaardingen cohort 
participating in the last survey in 1989/1990. This general population based cohort of 
exclusively Caucasians of Dutch descent started in 1965 and has been followed up for 25 
years. The selection of the cohort has been described previously 10;11. Surveys were 
performed every 3 years, in which information was collected on respiratory symptoms, 
smoking status, age and gender by the Dutch version of the British Medical Council 
standardized questionnaire 12• A blood sample was taken and spirometry was performed. 
Details on pulmonary function measurements are provided in the on line data supplement. 
In 1989/1990 neutrophil depot of spinned blood was collected and stored at -20°C. In 
2003/2004 DNA was extracted from these samples with the QiaAmp® DNA Blood Mini Kit 
and checked for purity and concentration with the NanoDrop • ND-1000 UV-Vis 
Spectrophotometer. The study protocol was approved by the local university hospital's 
medical ethics committee and all participants gave their written informed consent. 
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Genotyping 
We genotyped DNA samples of those subjects with more than 1500 ng isolated DNA 
available (N=1390). There were no differences in characteristics at the last survey between 
the selected and not-selected group (table 1). 
Eight SNPs in ADAM33, previously described to be associated with asthma, airway 
hyperresponsiveness or excess decline in FEV1 were genotyped: F+l (G/A), Q-1 (C/T), S_l 
(Val-lso), S_2 (G/C), ST+S (A/G), T_l (Met-Thr), T_2 (Pro-Ser), V_ 4 (C/G). The SNP causes 
an amino acid change when this is indicated between brackets; otherwise, the base 
change is shown. The genotyping protocol is described in the online supplement; 
sequences of primers and probes are listed in table El in this supplement. 
Males, n (%) 714 (51.4) 559 (51.9) 
Age in years, median (range) 52 (35-79) 54 (35-79) 
Pack-years of smoking, median (range) 8.0 (0-161.4) 6.0 (0-158.4) 
FEV1%pred, mean (sd) 91.5 (14.6) 91.5 (15.9) 
FEV1/VC, mean (sd) 73.9 (8.7) 73.7 (9.1) 
GOLD stage I I  or higher, n (%) 186 (13.4) 168 (15.6) 
Abbreviations: FEV1 Forced Expiratory Volume in 1 second; VC Vital Capacity; GOLD Global initiative for 
Obstructive Lung Diseases 
Statistics 
We identified subjects with COPD based on spirometry according to the GOLD criteria 13• 
Subjects were considered to have COPD when they had an FEV1/VC< 70% and FEV1<80% 
predicted (GOLD stage II or higher) at the last survey. Differences in prevalence of rare 
alleles of SNPs between subjects with and without COPD were tested with chi-square 
tests. Relative risks and population attributable risks for the development of COPD were 
calculated for all SNPs as described in the on line supplement. 
Linear mixed effect models (LME) were used to investigate the effect of polymorphisms in 
the ADAM33 gene on the annual decline in FEV1 
14
• Time was defined as the time in years 
relative to the first FEV1 . FEV1 measurements were included from the age of 30, since an 
individual's maximal achieved lung function is assumed to have been reached before that 
age and lung function is considered to be either in the plateau or in the decline phase 15. 
Variables included in the model were age at entry, gender, pack-years of smoking and the 
first available FEV1 after age 30 and their interaction with time. The outcome of the mean 
annual decline concerns females with age 30 when entered in the LME, a mean FEV1 of 
the population, zero pack-years of smoking and with a wild type genotype. Additional 
information on LME analyses, Hardy Weinberg equilibrium, linkage disequilibrium, 
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haplotype analyses and permutation tests is described in the online supplement. 
Statistical analyses were performed using SPSS (version 12.0.1 for Windows}, the 
statistical package R (version 1.9.1} 16 and Arlequin (version 2.0}. 
RESULTS 
For all 8 SNPs in ADAM33, frequencies for the minor alleles were comparable to those 
reported previously: F+l 0.35; Q-1 0.125; S_l 0.084; 5_2 0.28; ST+5 0.58; T_l 0.21; T_2 
0.17; V_ 4 0.26. All SNPs were in Hardy Weinberg equilibrium and in significant linkage 
disequilibrium (LD}. 
In each LME, the mean adjusted annual decline for subjects with the wild type genotype 
for the SNPs was determined. The mean of these adjusted annual declines was 18.7 ml/yr 
(range 18.2-19.9}. Males declined with 6 ml/yr less than females, which could be 
attributed to the height difference between males and females. Subjects who were 
homozygous for the rare alleles of Q-1 or 5_2 had a significant excess decline in FEV1 of 
respectively 9.6 (p=0.021} and 4.9 ml/yr (p=0.033} compared to the wild type. 
Heterozygous individuals for the S_l SNP demonstrated a significant excess decline of 3.6 
ml/yr (p=0.023} and a non significant excess decline of 6.4 ml/yr for homozygous 
individuals compared to the wild type (figure l}. None of the other SNPs were significantly 
associated with excess decline in FEV1. 
ADAM33 Q-1 ADAM33 8_1 ADAM33 8_2 
1 0  P = 0.021 1 0  P = 0.023 1 0  P = 0.033 
r------, 
5 5- 5 
0 0 = 0 u. 
I I -� � ·- Q) -5 -5 -5 � �  0 u .§.  Ill Ill -1 0  - 1 0  - 1 0  
- 1 5  -1 5 -1 5 
-20 -20 -2 
cc CT TT GG GA AA GG GC cc 
Number of individuals 931 255 24 1 023 1 78 9 693 431 86 
Median number 7.0 7.0 7.5 7.0 7.0 6.0 7.0 7.0 7.0 
(range) (2-8) (2-8) (2-8) (2-8) (2-8) (5-8) (2-8) (2-8) (2-8) 
of FEV1 measurements 
Figure 1: Excess annual decline in FEVi in ml/year (with 95% confidence interval) for SNPs Q-1, 5_1 and S_Z 
compared to the wild type Corrected for gender, age, pack-years of smoking and level of FEV1 at age 30. 
Mean decline of FEV1 for the wild type in the population is set as a reference at zero. Number of individuals 
and median number (range) of FEV1 measurements are presented below the figures 
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Since it would be of interest to know whether the degree of smoking might interact with 
SNPs on the decline in FEV1, we performed LME models with the interaction terms pack­
years*SNP in the model. These interaction-terms were not significant. 
We did not find an association of level of baseline FEV1 with any of the 8 SNPs in ADAM33, 
which implies that the SNPs have an effect on FEV1 decline rather than on maximally 
attained lung function. 
We have carried out permutation tests to assess whether our results were found due to 
chance. We performed 3000 permutations per SNP and ran the analysis on each of these 
datasets. We found the following significant p-values for the observed beta-estimates in 
empiric cumulative distribution: Q-1 CC genotype p=0.012, S_l AT genotype p=0.016, 5_2 
TT genotype p=0.016, V _ 4 TT genotype p=0.038 (figure El in the on line data supplement). 
Thus, for all SNPs that were associated with excess lung function decline in the true 
dataset, the observed beta-estimate occurred less than 5% in the empiric cumulative 
distribution, indicating that our results were not found due to chance. Additionally, the 
V_ 4 SNP, which was borderline significant in the original dataset (p=0.064) appeared to be 
significant from the permutation test. 
Subjects with minor alleles for SNPs F+l, S_l, 5_2 and T_2 had COPD (GOLD stage II and 
higher) more frequently than the remainder (P values 0.023, 0.020, 0.031, 0.039 
respectively, table 2). Relative risks and population attributable risks for the development 
of GOLD stage II or higher are shown in the on line supplement (table E2). 
Table 2: Prevalence of genotypes according to COPD phenotype (GOLD stage II or higher; 
FEV1/VC<70%, FEV1 <80% predicted) 
F+l GG 46.7 38.7 0.023 ST+5 AA 17.5 20.0 
GA 41.4 41.9 AG 46.2 47.1 
AA 11.9 19.4 GG 36.3 32.9 
Q-1 TT 78.2 70.9 0.095 T_l TT 77.0 72.2 
TC 20.2 25.9 TC 21.3 25.0 
cc 1.7 3.2 cc 1.7 2.8 
S_l GG 85.7 77.1 0.020 T_2 GG 76.4 69.4 
GA 13.6 21.7 GA 22.1 26.5 
AA 0.7 1.3 AA 1.5 4.1 
5_2 GG 58.3 48.1  0.031 V_4 cc 58.0 56.1 
GC 35.3 41.7 CG 36.5 35.5 
cc 6.4 10.3 GG 5.5 8.4 





Pulmonary Disease; GOLD Global initiative for Obstructive Lung Diseases; df degrees offreedom; SNP Single 
Nucleotide Polymorphism 
Haplotypes with the highest frequencies are presented in table 3. We found no significant 
difference in prevalence of haplotypes between subjects with and without COPD. We used 
haplotypes with frequencies higher than 0.01 to construct genotypes. Only the genotype 
with at least one minor allele for F+l, Q-1, S_l, 5_2 and V_ 4 was associated with COPD 
(p=0.048). This likely reflects the individual associations found with SNPs F+l, S_l and 5_2 
with COPD. In the whole population, none of the genotypes was associated with a 
significant excess decline in FEV1• Thus, haplotype analysis did not provide additional 
information. 
Table 3: Estimated frequencies of haplotypes in the whole population and in subjects with COPD 
M inor a l leles of the SNPs a re presented; other a l leles in the haplotype a re wi ld type. Haplotypes 
with frequencies higher than 0.01 a re shown 
lmmmrmm :m�mm���-7iffl�!ntliiii�iL�7 
All wild type 
5T+S 
5T+S, V_4 
F+l, 5_2, ST+S, T_l, T_2 
F+l, ST+S 
F+l, Q-1, 5_1, 5_2, V_ 4 
F+l, Q-1, 5_2, 5T+S, V_ 4 ----
F+l 










0.019 0.021 - - - - -
0.012 0.017 
0.068 0.082 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; SNP Single Nucleotide Polymorphism 
DISCUSSION 
We have previously shown that polymorphisms in the ADAM33 gene are associated with 
accelerated decline in lung function in an asthma population 7• Interestingly, we now 
present evidence that polymorphisms in ADAM33 are associated with excess lung function 
decline in the general population as well. This is of great importance because it is well 
established that a low lung function is associated with a higher mortality risk in particular 
due to COPD and cardiovascular diseases 9;17-19. Cardiovascular diseases were the most 
common and COPD the fifth leading cause of death in 2001 worldwide according to the 
WHO 20. Since the prevalence and mortality due to COPD is expected to increase 21, this 
disease will become an even larger social and economic burden. COPD is a progressive 
disease and still poorly manageable with treatment, hence the discovery of new risk 
factors for this disease is important and may provide better treatments in the future 22• 
Together with previously published literature, our data provides evidence that SNPs in 
ADAM33 play a role in the development of asthma and COPD as well as in accelerated 
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lung function loss in the general population. There are no clear biological explanations for 
these observations. The ADAM33 protein is expressed in airway smooth muscle cells and 
fibroblasts and it has been proposed to contribute to the remodeling process present in 
asthma 1 . ADAM33 is a member of the ADAM family, a family of proteins involved in cell 
adhesion, cell fusion, cell signaling and proteolysis 23;24• The latter can be illustrated by the 
capacity to shed cytokines, growth factors or their receptors from the cell surface and the 
role in remodeling of extracellular matrix components. It is unknown whether the 
production or activity of ADAM33 in asthma is increased or reduced, yet overproduction 
or enhanced activity of ADAM33 may lead to excess shedding of inflammatory mediators, 
compatible with the enhanced airway wall inflammation present in asthma. Shedding and 
thereby overproduction of growth factors may furthermore induce proliferation of 
smooth muscle cells and fibroblasts. These features may lead to the remodeling process 
present in the airways of asthmatic patients. However, our data suggest that this may also 
reflect a general phenomenon, since polymorphisms in ADAM33 are associated with 
accelerated lung function loss in the general population. Moreover, subjects carrying 
these polymorphisms are susceptible to COPD. 
SNPs S_l and 5_2 were associated with FEV1 decline and COPD. In contrast, F+l and T_2 
were associated with presence of COPD and not with FEV1 decline, while SNP Q-1 was 
associated with FEV1 decline and not with COPD. Our definition of COPD is based on cross­
sectional data on FEV1 and VC, which is different from FEV1 decline. This may account for 
the difference in the associations found. The number of subjects with COPD may have 
been too small to detect the association with COPD for SNP Q-1, since we did find a trend 
for association (p=0.095). 
In our study, three SNPs were associated with excess annual decline in FEV1 . The strongest 
association was found with the Q-1 SNP, which was associated with an excess decline of 
9.6 ml/yr. SNP Q-1 is located in the intron before exons Q, P and R which comprise the 
epidermal growth factor (EGF) domain 25• EGF signaling is important in lung 
morphogenesis since mice lacking the EGF receptor (EGFR) demonstrate abnormal 
branching and poor alveolization. Kheradmand et al. demonstrated that EGFR signaling 
regulates matrix metalloproteases (MMPs) which mediate epithelial/mesenchymal 
interactions during lung n:iorphogenesis 26• ADAM33 is closely related to MMPs but may 
bind EGF directly. To our knowledge, no studies so far have shown a direct binding of 
ADAMs to EGF or related EGFR ligands. However, some studies do provide evidence for an 
interaction of ADAMs with EGFR ligands. Sahin et al. investigated the role of ADAMs in the 
shedding of EGFR ligands in mouse embryonic cells derived from different ADAM knock­
out mice. They identified ADAM10 as a sheddase of EGF and betacellulin and ADAM17 as a 
major converstase of epiregulin, TGF-a, amphiregulin and heparin-binding EGF-like growth 
factor (HB-EGF) 27• ADAMs 9 and 12 were also implicated in shedding of HB-EGF. 
Mochizuki et al. found evidence of binding of ADAM28 to insulin-like growth factor 
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binding protein-3 with subsequent digestion 28• It is likely that binding of these ligands to 
the EGF-domain of ADAMs precedes shedding by ADAMs. Therefore, if ADAM33 can bind 
EGF ligands to cleave them, it is also possible that it can bind them for activation. An 
indication for the importance of the EGF domain is that the number of mRNA transcripts 
containing a full EGF domain is much higher than the number of transcripts containing a 
full metalloprotease domain in normal airway fibroblasts 29• However, fibroblasts from 
asthmatics or COPD patients may display a very different splice-pattern. 
A disturbance in the EGF domain is likely to affect the regulation of ADAM33. Through 
a Iterative splicing, exon Q can be spliced out, giving rise to the � variant of ADAM33. This 
variant was found in 30% of ADAM33 mRNA transcripts in pulmonary fibroblasts 29• Since 
the EGF domain is incomplete, it has been suggested that the � variant prevents matura­
tion of ADAM33 and may exert a dominant-negative effect on its protease activity 30• The 
intronic SNP Q-1 may influence the splicing of the � variant 31 and thereby disturb the 
maturation of ADAM33. Subsequently, the protease activity may be disturbed resulting in 
a defect in repair of tissue after damage due to inflammation. This may lead to progressive 
destruction of alveolar tissue and thereby enhance accelerated decline in lung function. 
Our data suggest that this process may not only occur in COPD patients but also to a 
smaller extent in the general population depending on environmental factors. 
SNPs S_l and 5_2 were associated with both excess FEV1 decline in the general population 
and development of COPD. These SNPs are located in exon S, which encodes the 
transmembrane region. The S_l SNP causes an amino acid change (Val to l ie), but it is 
unknown whether this also modifies the structure of the protein. If so, the ADAM33 
protein may not be anchored correctly in the membrane and therefore not capable to 
exert its function. The 5_2 SNP is a silent mutation and a biological explanation for the 
effect of this SNP is that it may be in LD with the true causative SNP. Further research on 
ADAM33 should clearly lie in functional studies to elucidate the role of SNPs in ADAM33 in 
lung function loss, asthma and COPD. 
In conclusion, we found that polymorphisms in the ADAM33 gene are associated with an 
accelerated decline in FEV1 in the general population. In addition, we have demonstrated 
that these polymorphisms are not only risk factors for the development of asthma, but 
also for COPD. This is the first study implicating one gene to be involved in the develop­
ment of both asthma and COPD. The SNPs that we have studied are all common with a 
frequency of at least 0.084 for the minor allele. Thus, polymorphisms in ADAM33 
constitute important risk factors for the development of respiratory diseases in a large 
subset of the general population. 
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METHODS 
Spirometry 
Pu lmonary function measurements were performed with a water-sea led spirometer ( Lode 
Spirograph, Lode I nstruments, Groningen, The Netherlands) .  Measurement of inspiratory 
vita l capacity (VC) after a deep expiration was fol lowed by measurement of forced 
expiratory volume in 1 second (FEV1) . The h igher of the va lues obta ined in two technica l ly 
satisfactory tracings was taken as long as the d ifference between the two IVC va lues was 
less than 150 ml  and the d ifference between two FEV1 va lues was less than 100 ml .  
Genotyping 
For a l l  SN Ps, primers and probes were obta ined from Appl ied Biosystems TaqMan® SN P 
Genotypi ng Assays (N ieuwekerk aan de IJssel, The Netherlands), using the Assay-by-Design 
service for which we provided sequences. The design fa i led for SNP 5_2, so we designed 
primers a nd probes with the Primer Express package and obta ined primers from Biolegio 
(Ma lden, The Netherlands) and probes from Appl ied Biosystems. Sequences of all pr imers 
a nd probes a re shown in table El in this on l ine supplement. Reactions were performed in  
5 µ I  volumes and conta ined 10 ng DNA, lx  Taq man  Un iversa l Masterm ix (Applied 
Biosystems), 200 nM of each probe and 900 nM of each primer. Cycl ing conditions on the 
ABI PRISM® 7900HT Sequence Detection System (Appl ied Biosystems) were 10 min 95QC 
fol lowed by 40 cycles of 15 seconds 95QC and 1 minute 60QC. End-point fluorescence was 
measured immediately after cycl ing. Al leles were assigned using SDS 2.1 software (Appl ied 
B iosystems). Genotyping reactions fa i led randomly with a maximum percentage of 4.6% 
and a min imum of 0.6%. There was no relationship between degree of missingness and 
evidence of association.  We regenotyped 6% of the samples and found no errors in the 
genotypes, therefore our data are rel iable and reproducible. 
Cht1pter 3 
Relative risks and population attributable risk percent 
Relative risks (RR) for the development of COPD according to genotype were calculated in 
a recessive model and a dominant model. For the recessive model the RR = incidence (I) of 
COPD in exposed (homozygous mutant)/I in non-exposed (wild type and heterozygous 
individuals); for the dominant model the RR = I of COPD in heterozygotes and 
homozygotes/I in wild type. The population attributable risk percent {PAR%) is defined as 
the percent of the incidence of COPD in the population that is due to carrying a SNP. In the 
recessive model PAR% = (I of COPD in total population - I in wild type and heterozygotes /I 
in total population; in the dominant model PAR% = (I of COPD in total population - I in wild 
type) /I in total population. 
Additional information on LME analyses 
Of the 1390 subjects who were genotyped, 137 had a missing smoking history and 
therefore were excluded from the analyses. Data from on average 1253 subjects were 
included in the LME models, depending on success of genotyping. Since including the level 
of the first FEV1 after age 30 and its interaction with time could introduce bias due to 
regression to the mean, random effects were also estimated for these variables. The 
results of these analyses showed no change in estimates of the variables in the model or a 
better fit of the model, which indicates that there was no bias due to regression-to-the­
mean. Therefore, the results are presented without these random effects. 
Permutation tests 
We performed permutation tests to assess whether our results were found due to chance. 
Genotypes were randomly shuffled among individuals to produce 3000 datasets and the 
LME models were rerun on each of these datasets to generate a distribution of the beta­
estimates under the null hypothesis. If the observed beta-estimate from the true data is 
found in less than 5% of the empiric cumulative distribution (p=0.05), one can assume that 
the observed beta-estimate is not found due to chance. 
Analyses on Hardy Weinberg equi l ibrium, l inkage equil ibrium and haplotype 
analyses 
To determine whether the SNPs were in Hardy Weinberg equilibrium and if they were in 
linkage disequilibrium, tests were performed with the computer program Arlequin 
(version 2.000). We also estimated haplotype frequencies in the whole population and in 
subjects with a COPD phenotype. Differences in proportions between these groups were 
tested with chi square tests. Haplotypes with the highest estimated frequencies in the 
general population were used to construct genotypes. Subjects having at least one minor 
allele of each SNP were selected for the genotype. With chi square tests we determined 
whether there was a difference in prevalence of these genotypes between subjects with 
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and without COPD. Also, the excess decl ine in FEV1 in the whole population was 
determined for each constructed genotype in the LM E .  
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Figure El: Permutation tests of 5NPs ADAM33 Q-1, 5_1, 5_2 and V_ 4.  X-axis represents the beta 
estimates (decline in FEV1 in ml/year) under the null hypothesis with the observed proportion of the 
cumulative distribution of the beta estimate in 3000 permutations of the genotypes on the Y-axis. The 
upper number in the middle of each panel is the value of the observed beta estimate of the true 
dataset with its according proportion in 3000 random permutations below that value. 
Table El: Sequences of primers and probes for genotyped ADAM33 SNPs 
F+l for: GGAGTGGGAATGCTGTATCTATAGC all :  AAGAGA(.8.GGAATTCA 
rev: GACTTCAA T AAAAA TACTGGGACTCGA al2: AGAC§GGAATTCA 
Q-1 for: CCCAGTGTGGACCTAGAATGG all: CCCGAC!;CCTCCTT 
rev: GCCTGCGGGA TTCAAACG al2: ACCCGACICCTCCTT 
5_1 for: TTCCTGCTGGCCATGCT all: CCTCAGC,8TCCTGC 
rev: CTGGGAGTCGGTAGCAACAC a12: CCTCAGC§TCCTGC 
5_2 for: CGCAGACCA TGACACCTTCCT all: CCCAGG!;GCCGGC 
rev: GCACGCAGGGTCCCTTCT al2: TCCCAGG§GCCGGC 
5T+5 for: CAGCACATCTTTTCACTCCATACCA all: CAGCACC§CAGCTG 
rev: GGTCACAGAGAACTGGGTT AAGG al2: CAGCAC(.8.CAGCTG 
T_l for: CCCTGGTGCCTCACTCA all: CACCCCAIGGAGTTG 
rev: CCCAAAGATGGCCCACACA al2: ACCCCA!;GGAGTTG 
T_2 for: CCCTGGTGCCTCACTCA all: CCAGG,8CTGTCCAGTG 
rev: CTGGGCGGCGTTCAC al2: CAGG§CTGTCCAGTG 
V_4 for: GGAAGGAAGGTCCCCAAAA TT ATGT a ll: TCCCCTG!;AGCCTG 
rev: GCCCT ATGGTTCGACTGAGT af 2: TCCCCTG§AGCCTG 
* for: forward primer; rev: reverse primer t bases recognizing the specific sequences are underlined; all: allele 1, 
al2: allele 2 
Table E2: Prevalence of genotypes according to COPD (GOLD stage I I )  and relative and population 
attributable risks (respectively RR and PAR) for COPD in a dominant and a recessive model 
F+l GG 46.7 38.7 0.023 1.32 15.1 1.62 0.74 
GA 41.4 41.9 
AA 11.9 19.4 
Q-1 TT 78.2 70.9 0.095 1.39 8.1 1.70 1.3 
TC 20.2 25.9 
cc 1.7 3.2 
5_1 GG 85.7 77.1 0.020 1.63 8.9 1.66 0.5 
GA 13.6 21.7 
AA 0.7 1.3 
5_2 GG 58.3 48.1  0.031 1.43 15.4 1.54 3.7 
GC 35.3 41.7 
cc 6.4 10.3 
5T+5 AA 17.5 20.0 0.630 1.14 8.1 1.15 2.6 
AG 46.2 47.1 
GG 36.3 32.9 
T_l TT 77.0 72.2 0.373 1.30 2.2 1.54 0.7 
TC 21.3 25.0 
cc 1.7 2.8 
T_2 GG 76.4 69.4 0.039 1.36 8.4 2.25 2.3 
GA 22.1 26.5 
AA 1.5 4.1 
V_4 cc 58.0 56.1 0.364 1.07 3.0 1.46 2.9 
CG 36.5 35.5 
GG 5.5 8.4 
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Chronic obstructive pulmonary disease (COPD) is a respiratory disorder with increasing 
prevalence and mortality. It is associated with airway obstruction, increased airway 
hyperresponsiveness (AHR), and ongoing airway and lung inflammation dominated by 
CDS+ lymphocytes and neutrophils. Single nucleotide polymorphisms (SNPs) in A 
Disintegrin And Metalloprotease 33 (ADAM33} gene have been associated with AHR and 
with COPD. 
Objective 
To assess whether SNPs in ADAM33 are associated with the severity of AHR and airway 
inflammation in COPD. 
Methods 
Eight SNPs in ADAM33 (F+l, Q-1, S_l, S_2, ST+5, T_l, T_2, V_ 4) were genotyped in 111 
patients with COPD (96 males, 69 current smokers, mean age 62 years (SD=S), median 
pack-years 42 (IQR 31-55), mean postbronchodilator FEV1% predicted 63 (SD=9)). PC20 
methacholine, sputum, and bronchial biopsies were collected. 
Results 
Patients with the ST+5 AA-genotype had more severe AHR, higher numbers of sputum 
inflammatory cells and CDS+ cells in bronchial biopsies than patients with the GG­
genotype (p=0.03, p=0.05, p=0.01, respectively). CDS+ cell numbers were lower in subjects 
carrying the minor allele of SNP T_l and T_2, and homozygous minor variants of SNP S_2 
compared to the wild-type (p=0.02, p=0.01, p=0.02, respectively). 
Conclusion 
This is the first study demonstrating that SNPs in a gene that confers susceptibility to 
COPD in the general population, i.e. ADAM33, are associated with AHR and airway 
inflammation in COPD. These findings constitute an important step forward in linking gene 
polymorphisms with COPD pathophysiology, thereby possibly contributing to better future 
treatments for this progressive and disabling disease. 
Chapc'er -1-
I NTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is world-wide highly prevalent and the only 
disease with increasing mortality rates. 1 . The disease is characterized by irreversible 
airflow limitation and associated with an influx of neutrophils, macrophages, and CD8+ T 
lymphocytes in the airways 2'3 • A majority of COPD patients demonstrates airway 
hyperresponsiveness (AHR) 4 an exaggerated airway response to non-specific stimuli 
resulting in airway obstruction. The severity of AHR is positively associated with 
inflammation in lung tissue 5 and numbers of CD8+ cells in bronchial biopsies in COPD 6• 
One study reported an association of AHR with sputum inflammatory cells in COPD 7, 
whereas another study did not find this association 8• 
Cigarette smoking is by far the most important risk factor for COPD but there is a wide 
range in disease severity, irrespective of the number of pack-years smoking. Furthermore, 
only a minority of smokers develops the disease, suggesting that besides smoking an 
underlying genetic constitution plays a role in the development and severity of COPD. A 
Disintegrin And Metalloprotease 33 (ADAM33} gene is a gene of putative interest for 
COPD. It was first identified as a susceptibility gene for asthma and AHR, 9'10 and 
subsequently as a susceptibility gene for COPD in a general population 11• It furthermore is 
associated with accelerated lung function decline in a general 11 and asthma population 12• 
ADAM33 belongs to the ADAM family of membrane-anchored metalloproteinases which 
play a role in a variety of processes such as cell fusion, adhesion, and signalling 13'14• 
ADAM33 is expressed in both airways smooth muscle cells and lung fibroblasts. Although 
the overall substrates and function of ADAM33 are yet unknown, it has been shown to be 
able to cleave armacroglobulin 15'16, which plays a role in pulmonary defence. It is 
suggested that ADAM33 is involved in tissue remodelling 17, a physiologic process 
intricately related to airway inflammation, hyperresponsiveness and airway obstruction. 
The aim of this study was to test the hypothesis that SNPs in ADAM33 are associated with 
the severity of both airway hyperresponsiveness and airway inflammation in sputum and 
bronchial biopsies of patients with COPD. 
METHODS AND MATERIALS 
The extended version of the methods section is available in the on line data repository. 
One-hundred-and-fourteen patients with COPD participating in the GLUCOLD study were 
included 18 Patient characteristics have been described in detail previously 18• In brief, all 
patients had irreversible airflow limitation and chronic respiratory symptoms, and were 
current or ex-smokers with at least 10 pack-years of smoking. Patients did not use a course 
of inhaled or oral corticosteroids within 3 months, or maintenance treatment with these 
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drugs within 6 months prior to randomisation. None of the patients had a history of asthma. 
The medical ethics committees of the Leiden Un iversity Medica l  Centre and the Groningen 
U n iversity Medical Centre approved the study, and all patients gave their written informed 
consent. 
Pu lmonary function tests have been described previously 18• Spirometry and reversibi l ity to 
salbutamol were measured. Methachol ine chal lenge tests were performed with the 2-
minute tidal breath ing method 19 and expressed as the provocative concentration of 
methachol ine causing a 20% fa l l  in FEVi ( PC20) . 
Sputum induction and whole sample processing were performed accord ing to a val idated 
technique 20] as described in deta i l  p reviously 18 Deta i ls  on biopsy col lection, processing 
and immunohistology have been pub l ished previously 21• I n  brief, we col lected the two 
best biopsies out of four  pa raffin embedded biopsies per patient, and used specific 
antibodies against T lymphocytes (CD3, CD4, and CD8), macrophages (CD68), neutrophi l  
elastase (NE), mast cel l tryptase (AAl), and eosinophils (EG2) .  
DNA was extracted from periphera l  b lood. Genotyping was performed as described 
previously 11 using primers and probes from Applied Biosystems Taq Man® SNP Genotyping 
Assays (N ieuwekerk aan de IJssel, The Netherlands) . 
Figure 1 shows the 8 SNPs in ADAM33 genotyped: F+l (G/A), Q-1 (C/T), S_l (Va l-lso), 5_2 
(G/C), ST +5 (A/G), T _1 (Met-Thr), T _2 (Pro-Ser), V _ 4 (C/G). We based the selection of the 
SNPs on previous associations with a i rway hyperresponsiveness, excess decl ine in  FEV1, 
and/or presence of COPD 9'11'12'22'23• 
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Figure 1: The exon intron structure of ADAM33 (the eight genotyped SNPs are indicated above the gene) 
and the domain organization of ADAM33 
We used Arlequin (version 2.000) to test whether SNPs were in Hardy Weinberg 
equ i l ibrium and l inkage disequ i l ibr ium ( LD) .  We investigated whether ADAM33 SNPs a re 
associated with PC20 and number and subset of inflammatory cel ls in sputum and 
Ch.,pter t 
bronchial biopsies. Our primary genetic model for all SNPs was a dominant model 
(homozygotes and heterozygotes for the minor allele being compared as a group with 
homozygotes for the major allele). Additionally, SNPs with a minor allele frequency of � 
0.30 were entered in 1) a codominant model (three genotype groups per SNP separately) 
and 2) a recessive model (homozygotes and heterozygotes for the major allele being 
compared as a group with homozygotes for the minor allele). PC20 and inflammatory cells 
in sputum, and bronchial biopsies were log transformed to obtain a normal distribution. 
We performed univariate analyses using t-test and ANOVA. Multiple linear regression 
analyses were performed to investigate the association of polymorphisms in ADAM33 
with PC20, sputum inflammatory cells, and inflammatory cells in biopsies as dependent 
variables. Independent variables included in the model were gender, smoking status, lung 
function, genotype, and the interaction of smoking status and genotype. In order to 
determine whether the regression estimates (with standard errors) and p values were not 
due to chance, we performed bootstrapping by re-sampling rows of the original data 
frame (using n=5000 bootstrap replicates) on the main significant outcome variables. 
RESULTS 
Results of univariate analyses and multiple regression analyses assuming a recessive 
model are shown in the online data supplement. Multiple regression analyses assuming a 
dominant and codominant model are presented below. The low number of subjects per 
haplotype did not allow haplotype analysis. 
Prevalence of ADAM33 SNPs 
DNA was available from 111 out of 114 COPD patients. Clinical characteristics are 
presented in table 1. All genotyped SNPs were in Hardy Weinberg equilibrium and in 
significant LD. Table 2 shows the prevalence of the 8 SNPs. SNPs ST +5, F+l, and 5_2 had a 
minor allele frequency � 0.30, therefore these SNPs were analyzed both in a dominant 
model and codominant model. The frequency of SNP ST +5 in our group was 50% for each 
allele. We use the term AA-genotype for the wild-type and GG-genotype for the 
homozygous mutant genotype, as previously published 23• 
Multivariate association of ADAM33 SNPs with AHR 
Dominant model Subjects with a G-allele for SNP ST +5 had a significantly higher PC20 
compared to the AA-genotype (geometric mean (gm) 0.61 versus 0.27 mg/ml, p=0.04). 
SNPs F+l, Q-1, S_l, 5_2, T_l, T_2, and V_ 4 were not significantly associated with level of 
AHR. 
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-1- median (25th-75th percenti le) .  
Male/female 96/15 
Age (years) 61.5 ± 7.7 ---------------- -----
Current smokers, n (%) 69 (62) ----,_----------
Smoking history (pack-years) 42.0 (31.3-54.5) 
FEV1 (% pred.) 56.4 ± 9.8 
FEVJIVC (%) 49.9 ± 8.5 
Postbd. FEV1 (% pred.) 63.2 ± 8.8 
Postbd. FEVJIVC (%) 50.7 ± 8.5 
PC20 methacholine (mg/ml) * 0.5 (0.2-2.4) 
Abbreviations: FEV1 forced expiratory volume in one second; % pred percentage of predicted value; 
Postbd. postbronchodilator; FEVJ/IVC forced expiratory volume in one second/inspiratory vital capacity; 
PC2o methacholinethe provocative concentration of methacholine causing a decrease in FEV1 of 20%. 
Table 2: Prevalence of ADAM33 SNPs in patients with COPD DNA was ava i lable from 111 out of 114 
COPD patients. Different numbers for the SNP genotypes ( ra nging from 101 to 110) a re due to 
missing genotype data_. --==----==,-----�--==,----, 
F+l GG 34.9 (38) ST+5 AA 23.7 (26) 
GA 46.8 (51) 
I 
AG 53.6 (59) 
AA 18.3 (20) L GG 22.7 (25) 
Q-1 TT 67.3 (70) 
I 
T_l TT 80.3 (86) 
TC 28.9 (30) TC 17.8 ( 19) 
cc 3.8 (4) cc 1.9 (2) 
S_l GG 72.9 (78) T_2 GG 80.8 (88) 
GA 26.2 (28) GA 17.4 ( 19) 
AA 0.9 (1) AA 1.8 (2) --
5_2 GG 44.6 (45) V_4 cc 51.0 (55) 
GC 44.6 (45) CG 44.4 (48) 
cc 10.8 (11) GG 4.6 (5) 
Abbreviations: SNP Single Nucleotide Polymorphism; COPD Chronic Obstructive Pulmonary Disease 
Codominant model Subjects with the GG-genotype for SNP ST +5 had a significantly higher 
PC20 compared to the AA-genotype (figure 2a). SNPs F+l and 5_2 were not significantly 
associated with level of AHR. 
Multivariate association of ADAM33 SNPs with inflammatory cells in sputum 
Dominant model Patients with one or more G-alleles of SNP ST +5 had a significantly lower 
total cell count in sputum than the AA-genotype (gm 176 versus 287*104 cells/ml; p=0.04). 
Individuals with minor alleles for SNPs F+l, Q-1, S_2 had lower numbers of sputum 
neutrophils compared to the wild-type for those SNPs (F+l gm 103.0 versus 134.9 * 104 
Ch.1pie1 ,f 
cells/ml; p=0.05; Q-1 gm 84.5 versus 122.5*104 cells/ml, p=0.01; 5_2 gm 94.0 versus 
127.9*104 cells/ml, p=0.02). SNPs S_l, T_l, T_2, and V_ 4 were not significantly associated 
with the number of sputum inflammatory cells. 
Codominant model Patients with the GG-genotype for SNP ST +5 had a significantly lower 
total cell count in sputum than the AA-genotype, and subjects with the AG-genotype 
tended to have a lower total cell count (figure 2b). 
Heterozygous individuals for SNP 5_2 had higher numbers of sputum macrophages than 
the wild-type (5_2 GG: gm (95% Cl) 27.7*104/ml (20.3-37.8); GC: 39.5*104/ml (28.7-54.5), 
p=0.03; CC: 29.6*104/ml (17.6-49.7); p=0.80). Heterozygous individuals for SNP 5_2 had 
also lower numbers of neutrophils (5_2 GG: gm (95% Cl) 127.9*104/ml (97.5-168.3); GC: 
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Figure Z: Association of ADAM33 SNP ST+S with airway hyperresponsiveness (PC20 methacholine), 
sputum inflammatory cells, and CDB+ cells in bronchial biopsies in patients with COPD 
A: PC20 methacholine per SNP ST+S genotype B: Total sputum cell count per SNP ST+S genotype * 
C: The number of COB+ cells in bronchial biopsies per SNP ST +5 genotype 
* Total sputum cell count refers to the total of non-squamous cells in induced sputum. 
Squares represent the geometric mean; vertical bars represent the 95% confidence interval. Different 
numbers for the SNP genotypes are due to missing genotype data. 
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Multivariate association of ADAM33 SNPs with inflammatory cel ls in bronchial 
biopsies 
Dominant model Individuals with a minor allele for SNPs T_l and T_2 had a significantly 
lower number of CD8+ cells than the wild-type (T_l: p=0.02; T_2: p=0.01). We only present 
the results of SNP T_2 in figure 3a given the fact that SNPs T_l and T_2 are in complete LD 
(p= 10 -16) (see online data repository; figure El) and the association of these SNPs with 
the number of CD8+ cells in bronchial biopsies was similar. 
Codominant model Patients with the GG-genotype for SNP ST +5 had significantly lower 
numbers of CDS+ cells in bronchial biopsies than the AA-genotype (figure 2c). Homozygous 
individuals for the minor allele of SNP 5_2 had significantly lower numbers of CDS+ cells in 
bronchial biopsies compared to the wild-type (figure 3b) and lower numbers of plasma 
cells (5_2 GG: gm (95% Cl) 13.5/0.1 mm2 (8.9-20.7); GC: 11.8/0.1 mm2 (7.7-18.2), p=0.54; 
CC: 6.5/0.1 mm2 (3.3-12.9); p=0.04). Heterozygous subjects for SNP 5_2 had significantly 
lower numbers of CD4+ cells compared with the wild-type (5_2 GG: gm (95% Cl) 28.5/0.1 
mm2 (19.9-41.0); GC: 21.8/0.1 mm2 (16.9-28.2), p=0.04; CC: 25.6/0.1 mm2 (17.0-38.3); 
p=0.59). No significant associations were found with SNP F+l. 
We found no significant associations between SNPs in ADAM33 and the number of mast 
cells or eosinophils in bronchial biopsies. 
Results of bootstrapping confirmed the above presented main outcome results, with 
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Figure 3: Association of SNPs in ADAM33 with the number of CDS+ cells in bronchial biopsies in COPD 
A: Per genotype for SNP T_2 
B: Per genotype for SNP 5_2 
Squares represent the geometric mean; vertical bars represent the 95% confidence interval. Different 
numbers for the SNP genotypes are due to missing genotype data. 
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DISCUSSION 
The important message of this study is that SNPs in ADAM33 are associated with the 
pathophysiology of COPD. Patients with the AA-genotype for SNP ST +5 had more severe 
AHR, higher numbers of sputum inflammatory cells, and higher numbers of CDS+ cells in 
bronchial biopsies than those with the GG-genotype. Moreover, individuals with the minor 
allele of SNP T_l and T_2, and homozygous individuals for the minor allele of SNP 5_2 had 
significantly lower numbers of CDS+ cells in bronchial biopsies, cells relevant to the 
pathology of COPD. 
Prevalences of the ADAM33 SNPs found in our COPD population are comparable to those 
recently reported by van Diemen et a/.11• We also confirm their findings that minor alleles 
for SNPs F+l, S_l, and 5_2 are more prevalent in patients with COPD than in healthy 
subjects. Regarding SNP Q-1 we demonstrate a significantly higher prevalence of the 
minor allele in patients with COPD compared with healthy controls, whereas van Diemen 
et al. demonstrated a trend in the same direction (see on line data repository). In addition, 
we found a higher prevalence for the A-allele in SNP ST +5 in patients with COPD. As far as 
we know, this is the first study suggesting that a COPD susceptibility gene is also 
associated with the pathophysiological process in COPD. 
ADAM33 is member of the ADAM family, a group of membrane-anchored 
metalloproteinases which contain both a disintegrin and a metalloproteinase domain and 
is expressed in multiple tissues, including lung tissue 24• Since its function has not been 
unravelled yet, we can only speculate about its role in COPD. It is conceivable that 
ADAM33 plays a role in both remodelling and inflammation by shedding growth factors, 
cytokines, and their receptors from the cell surface. If a SNP alters ADAM33 function to 
increased protein production this may thus result in enhanced airway inflammation. 
Alternatively, when ADAM33 has a diminishing effect on the release of pro-inflammatory 
cytokines, inflammation would increase by a decrease in ADAM33 production or function. 
The same could be true for the role of ADAM33 in airway remodelling, in case an 
alteration in ADAM33 results in an increase in growth factors resulting in proliferation of 
airway smooth muscle cells and lung fibroblasts. Whatever the functions of ADAM33 turn 
out to be, our data suggests that it is associated with inflammation and AHR. 
We demonstrated an association between ADAM33 and the severity of AHR in COPD. 
AHR is important to COPD given its association with accelerated FEV1 decline 
25 and 
increased risk of COPD mortality 26• The exact pathophysiology underlying AHR is unclear, 
but it is thought to result from an inflammatory process in the airways in addition to 
geometric changes due to airway remodelling. As discussed above, it is possible that 
ADAM33 plays a role in both these processes thereby contributing to the severity of AHR. 
ADAM33 SNP ST +5 is associated with the total sputum cell count in our COPD population. 
When we replaced this by numbers of sputum neutrophils or macrophages, we found 
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significant associations with SNPs 5_2, F+l, and Q-1 but not with the other SNPs. This 
suggests that not one specific cell type was predominantly accounting for the association 
of total cell count with SNP ST+S. Several studies have shown an increase in the number of 
neutrophils and macrophages and concentrations of pro-inflammatory cytokines like IL-S 
and TNF-a in induced sputum of patients with COPD 27-29 • Intuitively one would think that 
the severity of AHR is associated with the degree of inflammation and in fact, we 
previously did demonstrate an independent, positive association between severity of AHR 
and total sputum cell counts in these COPD patients 30] : perhaps ADAM33 is the missing 
link. 
O'Shaughnessy et al. demonstrated an increased number of neutrophils and CDS+ 
lymphocytes in bronchial biopsies of smokers with airflow limitation, and this increase was 
inversely associated with level of lung function 31• The authors therefore hypothesized that 
individuals with a genetic predisposition for a higher number of CDS+ cells were more 
susceptible to a further increase in CDS+ cells which might finally result in airflow 
limitation. Interestingly, we found an association of SNP ST +5 with both presence of COPD 
(see online data repository) and the number of CDS+ cells within our COPD patients. 
ADAM33 has previously been associated with asthma in some 9'22'23, but not all studies 
32'33 • We would like to emphasise that we are confident that our COPD patients genuinely 
have COPD and no asthma given the fact they all had moderate to severe airflow 
limitation after bronchodilation, �10 pack-years of smoking, and no history of doctor 
diagnosed asthma. We selected S SNPs in ADAM33 based on previous literature. One 
could argue that we did not genotype all known SNPs in ADAM33. However, we did find 
consistent and significant associations between the genotyped SNPs and the severity of 
AHR and airway inflammation in our COPD population, indicating linkage of ADAM33 with 
pathophysiological features of COPD. 
A potential criticism of our study is that the sample size of 111 patients with COPD is 
relatively small. From a practical point of view, biopsy studies are very demanding and the 
issue of sample size would especially be of concern in case we did not find any 
associations. However, we did find significant associations between ADAM33 and features 
of COPD. We set out with the a priori hypothesis that the same SNPs in ADAM33 
previously shown to be associated with COPD are also associated with its pathophysiology. 
In order to investigate our hypothesis, we performed a number of analyses to assess the 
association of ADAM33 with hyperresponsiveness and airway inflammation and found 
associations of moderate significance. This has impact on the interpretation of the results. 
One could raise the issue of multiple testing being responsible for the current results and 
that we should have adjusted for this in our analyses. We do not agree with this for a 
number of reasons. Firstly, the independent variables in our analyses (e.g. sputum total 
cell count and differential cell count) are mutually related, indicating that a rigid statistical 
procedure like e.g. a Bonferroni correction for multiple testing would not do justice to 
their biologically linked nature. Secondly, we did not randomly test for associations 
between ADAM33 and features of COPD but had a predefined hypothesis based on 
previous literature. 
ADAM33 is a highly polymorphic gene containing at least 58 SNPs of which we 
investigated 8, based on previous literature 9'11'12'22'23• We found an association of SNP 
ST +5 with the severity of AHR and airway inflammation in induced sputum and bronchial 
biopsies in COPD. The ST +5 SNP is an intron SNP between the S-exon (transmembrane 
region) and the T-exon (which includes a SH3 domain and a phosporylation site). This may 
have functional relevance, since non-coding intrans can exert their effect by influencing 
alternative splicing, splicing efficiency or messenger RNA turnover. 
We furthermore found an association of SNP 5_2 with the inflammatory cell profile in 
sputum and the number of inflammatory cells in bronchial biopsies. A higher number of 
airway wall CDS+ cells is associated with more severe AHR 6, by itself a risk factor for 
accelerated lung function loss 25• Van Diemen et al 11 showed an association of the minor 
allele of SNP 5_2 with accelerated lung function decline in a general population and of the 
minor allele of SNP T_2 with presence of COPD. Yet in the present study the minor alleles 
of these SNPs were associated with a lower number of CDS+ cells. How can we reconcile 
these seemingly discordant findings? SNP 5_2, a silent mutation, is located in the 5-exon 
and SNP T_2 is located in the T-exon. Both SNPs are in close proximity to SNP ST+S. The 
significant LD between SNPs 5_2, ST +5, and T_2 may suggest that the part of ADAM33 
involved in genetic susceptibility and pathophysiology of COPD lies in the 3' region. 
Alternatively, it still may be either at a different location within ADAM33 or at an adjacent 
gene. Our study was not designed to address this question and clearly, it needs further 
research. 
In conclusion, our study confirms ADAM33 as a COPD susceptibility gene and is the first to 
extend this observation by demonstrating an association of ADAM33 with the severity of 
both airway hyperresponsiveness and airway inflammation in COPD-affected individuals. 
These findings constitute an important step forward in linking gene polymorphisms with 
COPD pathophysiology, thereby possibly contributing to better future treatments for this 
progressive and disabling disease. 
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EXTENDED METHODS 
Statistical analysis 
We used Arlequin (version 2.000) to test whether SNPs were in Hardy Weinberg 
equilibrium and linkage disequilibrium (LD). Figure El illustrates the LD patterns with D', r 
and P-values in ADAM33. We investigated whether ADAM33 SNPs are associated with 
PC20 and number and subset of inflammatory cells in sputum and bronchial biopsies. Our 
primary genetic model for all SNPs was a dominant model (homozygotes and 
heterozygotes for the minor allele being compared as a group with homozygotes for the 
major allele). Additionally, SNPs with a minor allele frequency of ?. 0.30 were entered in 1) 
a codominant model (three genotype groups per SNP separately) and 2) a recessive model 
(homozygotes and heterozygotes for the major allele being compared as a group with 
homozygotes for the minor allele). PC20, sputum inflammatory cells, and inflammatory 
cells in bronchial biopsies were log transformed to obtain a normal distribution. We 
performed univariate analyses using t-test and ANOVA. Multiple linear regression analyses 
were performed to investigate the association of polymorphisms in ADAM33 with PC20, 
sputum inflammatory cells, and inflammatory cells in biopsies as dependent variables. 
Independent variables included in the model were gender, smoking status, lung function, 
genotype, and the interaction of smoking status and genotype. We entered sputum total 
cell count (centered around the mean of the total population) to the model when 
analyzing the differential cell count in sputum, and the number of CD3+ cells (centered 
around the mean of the total population) when analyzing CD4+ and CD8+ cells in bronchial 
biopsies. 
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EXTENDED RESULTS 
Univariate association of ADAM33 SNPs with AHR 
To provide our readership with all information, we show below the results of the 
dominant, codominant and recessive genetic models. 
Dominant model Subjects with a G-allele for SNP ST +5 had a significantly higher PC20 
compared to the AA-genotype (geometric mean (gm) 0.74 versus 0.27 mg/ml, p=0.02). 
SNPs F+l, Q-1, S_l, 5_2, T_l, T_2, and V_ 4 were not significantly associated with AHR. 
Codominant model There was a significant difference in PC20 methacholine between the 
three genotypes for SNP ST+5 (AA: gm 0.27 mg/ml; AG: 0.64 mg/ml; GG: 1.04 mg/ml; 
p=0.04). SNPs F+l and 5_2 were not significantly associated with AHR. 
Recessive model Homozygous individuals for the minor allele of SNP 5_2 had a significantly 
lower PC20 than subjects with one or more major alleles (gm 0.26 versus 0.72 mg/ml, 
p=0.008). SNPs F+l and ST +5 were not significantly associated with AHR. 
Univariate association of ADAM33 SNPs with inflammatory cells in sputum 
Dominant model Patients with a G-allele for SNP ST +5 had a significantly lower total 
sputum cell count compared to the AA-genotype (gm 121 versus 204*104 cells/ml; 
p=0.04). 5NPs F+l, Q-1, S_l, 5_2, T_l, T_2, and V_ 4 were not significantly associated with 
sputum inflammatory cells. 
Codominant model SNPs F+l, 5_2, and ST +5 were not significantly associated with 
inflammatory cells in sputum. 
Recessive model SNPs F+l, 5_2, and ST+5 were not significantly associated with 
inflammatory cells in sputum. 
Univariate association of ADAM33 SNPs with inflammatory cells in bronchial 
biopsies 
Dominant model Individuals with a minor allele for SNP 5_2 had lower numbers of CD4+ 
cells than the wild-type for that SNP (gm 41.9 versus 56.1 /0.1 mm2, p=0.05). 
Codominant model There was a significant difference between the three genotypes for 
5NP 5T+5 and SNP 5_2 in the number of CD8+ cells in bronchial biopsies (gm ST+5 AA: 
27.7/0.1 mm2; AG: 21.6/0.1 mm2; GG: 8.2/0.1 mm2, p=0.003; 5_2 GG: 21.8/0.1 mm2; GC: 
20.4/0.1 mm2; CC: 6.2/0.1 mm2; p=0.03). No significant associations were found with SNP 
F+l. 
Recessive model Homozygous individuals for the G-allele of SNP ST+5 had a significantly 
lower number of CD8+ cells and a significantly higher number of eosinophils, compared to 
individuals with one or more A-alleles for SNP ST +5 (gm 8.2 versus 23.3, p=0.03 and gm 
2.4 versus 0.8/0.1 mm2, p=0.04, respectively). 
Multivariate association of ADAM33 SNPs with AHR and inflammatory cells in 
sputum and bronchial biopsies, assuming a recessive model 
For completeness, we present below the outcome of the multivariate linear regression 
analyses assuming a recessive model. 
SNPs F+l, 5_2, and ST+S were not significantly associated with PC20, total sputum cell 
count, or sputum differential cell counts. The number of CDS+ cells in bronchial biopsies 
was significantly lower in individuals with the GG-genotype for SNP ST+5 compared with 
individuals with one or more A-alleles in SNP ST+5 (gm (95% Cl) 7.7 (3.9-13.5) versus 
18.7 /0.lmm2 (12.3-28.3), p=0.002), lower in individuals with the CC-genotype for SNP 5_2 
compared with individuals with one or more G-alleles in SNP 5_2 (5.3 (2.4-12.0) versus 
16.5/0.1 mm2 (10.5-26.0), p= 0.007), and lower in individuals with the AA-genotype in SNP 
F+l compared with individuals with one or more G-alleles in SNP F+l (8.3 (4.4-15.4) versus 
17.0/0.1 mm2 (11.1-26.0), p=0.02). The number of eosinophils in bronchial biopsies was 
significantly higher in individuals with the GG-genotype for SNP ST +5 compared with 
individuals with one or more A-alleles in SNP ST +5 (3.5 (1.2-9.8) versus 1.2/ 0.1 mm2 (0.6-
2.5), p=0.04) 
Differences in SNP prevalence between patients with COPD and controls 
Previously, it has been demonstrated by van Diemen et al. that SNPs in ADAM33 are 
associated with the presence of COPD in a general population 1. In addition to the data 
presented in the current manuscript with regard to the association of ADAM33 with 
airway hyperresponsiveness and airway inflammation in patients with COPD, we 
compared the distribution of ADAM33 SNPs of our COPD patients with that of a 
population based control group. 
As a control group, we selected 1097 Caucasians of Dutch descent without airflow 
limitation (FEV1> 80% pred, and FEV1/forced vital capacity> 70%) from the Vlagtwedde­
Vlaardingen cohort 2'3• Genotyping of the control group has been previously described in 
detail 1• Differences in prevalence of rare alleles of SNPs between the COPD patients 
described in the current manuscript and controls were tested using chi-square tests. 
DNA was available from 1097 controls. All genotyped SNPs were in Hardy Weinberg 
equilibrium and in significant linkage disequilibrium. Clinical characteristics of the controls 
are presented in table El. 
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Current smokers, n (%) 
Smoking history (pack-years) * - --
1097 
535/562 
50.8 ± 9.5 
378 (34) 
6.6 (0-18.4) 
FEV1 (% pred.) 94.9 ± 11.3 
FEV1/IVC (%) 75.8 ± 6.1 
*Data are presented as mean ± standa--;:d deviation or; * median (25th-75th percenti le). 
Definition of abbreviations: FEV1 = forced expiratory volume in one second; % pred = percentage of predicted 
value; FEV,/JVC = forced expiratory volume in one second/inspiratory vital capacity. 
Table E2 shows that the prevalence of the minor allele of SNPs F+l, Q-1, S_l, and 5_2 was 
significantly higher in the COPD group than the control group (p=0.04, p=0.03, p=0.003, 
and p=0.02, respectively), whereas the prevalence of the minor allele of SNP ST +5 was 
lower (p=0.02). The prevalence of SNPs T_l, T_2, and V_ 4 was not significantly different 
between both groups. With these findings, we confirm the findings by van Diemen et al 1 
i.e. minor alleles for SNPs F+l, S_l, and 5_2 are more often prevalent in patients with 
COPD than in subjects without airflow limitation. Regarding SNP Q-1 we found a 
significantly higher prevalence of the minor allele in patients with COPD compared with 
healthy controls, whereas van Diemen et al. demonstrated a trend in the same direction. 
In addition, we found a higher prevalence for the A-allele in SNP ST +5 in patients with 
COPD. 













34.9 (38) 46.1 (491) 0.04 ST+5 AA 
46.8 (51) 42.1  (455) AG 
18.3 (20) 11.8 (128) GG 
67.3 (70) 77.9 (844) 0.03 T_l TT 
28.9 (30) 20.3 (220) TC 
3.8 (4) 1.8 (19) cc 
72.9 (78) 85.3 (934) 0.003 T_2 GG 
26.2 (28) 14. 1 (154) 
0.9 (1) 0 .6 (7) 
--- --- ---
44.6 (45) 58.5 (626) 0.02 
44.6 (45) 34.9 (374) 







23.7 (26) 17.7 (193) 0.02 
53.6 (59) 46.9 (511) 
22.7 (25) 35.4 (386) 
80.3 (86) 77.2(795) 0.70 
17.8 (19) 21.2 (219) 
1.9 (2) 1.6 (17) 
80.8 (88) 76.7 (817) 0.56 
17.4 (19) 21.8 (232) 
1 .8 (2) 1.5 (16} 
-- -- --
51.0 (55) 58.2 (631) 0.26 
44.4 (48) 36.4 (394} 
4.6 (5) 5 .4 (58) 
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Forced Expiratory Volume in 1 second (FEV1) declines with ageing in the general 
population, which is accelerated in COPD and asthma. Single nucleotide polymorphisms 
(SNPs) in ADAM33 have been associated with airway inflammation in COPD and with 
accelerated FEV1 decline in asthma and the general population. It is yet unknown whether 
this occurs in COPD, nor if ADAM33 is expressed in COPD lung tissue. We therefore 
studied ADAM33 polymorphisms and ADAM33 expression in severe COPD. 
Methods 
We collected longitudinal lung function data from 79 COPD patients prior to their lung 
transplantation (median (IQR) age=49 (44-53) years; FEV1=0.7 (0.5-0.85) L; 6 (3-11) FEV1 
measurements per patient; 50% male; 42 had al-antitrypsin (AAT)-deficiency). Genotype 
effects on FEV1 decline prior to transplantation were assessed using linear mixed effect 
models. lmmunohistochemical ADAM33 expression was performed in frozen lung tissue 
from patients and controls. 
Results 
ADAM33 ST +5 and T_2 SNPs were associated with excess FEV1 decline (ST+5: AA genotype 
-37.8 ml/yr vs. GG -9.5 ml/yr, p=0.04; T_2: GG -15.5 ml/yr vs. GA/AA +15.2 ml/yr, p=0.02). 
Stratified analyses according to AAT-status showed similar results. ADAM33 expression 
was demonstrated in airway smooth muscle, endothelium, mesenchyma and epithelium in 
all tissues. 
Conclusions 
ADAM33 SNPs predict excess FEV1 decline in patients with severe COPD with and without 
AAT-deficiency. Combined with well-known associations of ADAM33 SNPs with excess 
FEV1 decline in asthma and the general population, we propose that ADAM33 is not a 




Chronic Obstructive Pulmonary Disease (COPD) is the fifth cause of death worldwide 
according to the World Health Organization and its incidence is still increasing 1. The 
disease is characterized by persistent inflammation and narrowing of the airways, 
destruction of lung tissue, and increased mucus secretion. Although the severity of each of 
these conditions varies per patient, they all contribute to the accelerated decline in lung 
function over time in COPD patients compared with the general population 2• Cigarette 
smoking is the most important risk factor for the development and progression of COPD. 
However, only a minority of smokers develops COPD, suggesting a genetic contribution to 
COPD development. One of the genes involved may be A Disintegrin and Metal/oprotease 
33 (ADAM33}, since single nucleotide polymorphisms (SNPs) in this gene have been 
associated with excess decline in lung function in the general population as well as with 
development of COPD 3• Recently, we have shown that specific SNPs in ADAM33 are also 
associated with increased inflammation in induced sputum and bronchial biopsies in a 
group of patients with moderate to severe COPD 4• We therefore hypothesize that 
ADAM33 SNPs may also contribute to accelerated lung function decline in patients with 
established COPD. 
Although SNPs in ADAM33 have been associated with asthma and COPD in multiple 
studies, the function of this gene is still unknown. It is highly expressed in airway 
fibroblasts and airway smooth muscle cells, whereas low or no expression has been 
observed in the airway epithelium from asthmatic patients and healthy controls 5•9_ So far, 
it is unknown which cells of the lung express ADAM33 in COPD. In the present study, we 
investigated the expression of ADAM33 in lung tissue of patients with severe COPD with 
and without al-antitrypsin (AAT)-deficiency. AAT-deficiency is a genetic constitution, 
thought to be the main factor for development of COPD in its carriers. Excess lung 
function decline may develop in AAT-deficient subjects even without cigarette smoking. 
We hypothesized that ADAM33 SNPs contribute to the annual decline in forced expiratory 
volume in 1 second (FEV1} in severe COPD, but not in patients with AAT-deficiency, and 




We collected longitudinal lung function data from 79 patients who had lung 
transplantation because of severe COPD. Lung function data were collected prior to 
transplantation from lung function centers where patients attended regular visits to their 
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lung physicians. 53% of the subjects had AAT-deficiency with either the SZ or ZZ genotype. 
Subject characteristics are presented in table 1. 
Table 1 :  Characteristics of patients with severe COPD before they underwent lung transplantation 
Data a re presented as median ( interquart i le range) 
sex, male/female 
pack-years smoking 
age first FEV1, years 
age last FEV1, years 
first FEV1 ( L) 
last FEV1 (L) 
















Abbreviations: FEV1: Forced Expiratory Volume in 1 second; AAT: a1-antitrypsin 
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Genomic DNA was extracted from frozen lung tissue using the Qiagen • DNeasy Tissue Kit 
(Qiagen, Hilden, Germany) and checked for purity and concentration with the NanoDrop • 
ND-1000 UV-Vis Spectrophotometer (Nanodrop Technologies, Wilmington, Delaware, 
USA). Based on previous associations with FEV1 decline, COPD, and severity of 
inflammation in COPD, we selected and genotyped 8 SNPs in ADAM33: F+l, Q-1, S_l, 5_2, 
ST +5, T _1, T _2, and V _ 4 3;10• The genotyping protocol and sequences of primers and 
probes are presented in the online supplement and table El. 
lmmunohistochemistry 
COPD lung tissue was obtained from 79 individuals who underwent lung transplantation 
and control lung tissue from tumor resection surgery. Frozen lung sections were cut at 4 
µm, dried for 20 minutes and fixed in acetone (100%). Affinity purified polyclonal 
antibodies designated to the cytoplasmic (n=3; Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands; Triple Point Biologics, Forest Grove, OR, USA; Everest Biotech, Oxfordshire, 
UK) and catalytic (n=l; Sigma-Aldrich Chemie BV) domains of ADAM33 were commercially 
obtained. The immunizing peptides were the same for the two cytoplasmic antibodies 
from Sigma-Aldrich and Triple Point Biologics. Both antibodies and the antibody 
designated against the catalytic domain were produced in rabbits. The third cytoplasmic 
antibody was a goat produced antibody and with a different immunizing peptide. Sections 
were stained in a Dako autostainer Universal Staining System (Dako, Copenhagen, 
Denmark). Endogenous peroxidase was blocked with peroxidase blocking reagent (Dako) 
for 5 minutes. Sections were incubated for 1 hour with polyclonal antibodies for ADAM33 
in 1:200 dilutions. Subsequently, sections were incubated for 30 minutes with peroxidase 
conjugated rabbit-anti-goat (RAGP0) polyclonal (Dako). Finally, sections were incubated for 
30 minutes with peroxidase conjugated goat-anti-rabbit polyclonal (GARP0) (Dako). 
---� -------------------------------------
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Sections were rinsed in PBS for 5 minutes after each incubation step. Peroxidase activity 
was revealed by Dakocytomation 3-amino-4-ethylcarbazole Substrate-Chromogen (Dako) 
for 7 minutes. Sections were counterstained with Mayer's haematoxylin for 1 minute and 
imbedded with Kaiser's glycerin and a cover glass. 
Statistics 
With the statistical program R, package "genetics", we calculated whether the ADAM33 
SNPs were in Hardy Weinberg equilibrium, and whether they were in linkage 
disequilibrium. We used linear regression models to study SNP effects on first and last 
FEV1, adjusting for sex, age, pack-years, AAT-deficiency. Linear mixed effect (LME) models 
were used to investigate SNP effects on annual FEV1 decline 
11
. We modeled FEV1 decline 
from age 30 onwards, since an individual's maximal achieved lung function is reached 
before that age and lung function is considered to be either in the plateau or in the 
decline phase 12• Variables in the model were sex, genotypes, AAT-deficiency, pack-years, 
baseline FEV1 (centered on the population mean), and their interaction with time. 
Additionally, we stratified models according to AAT-deficiency status. The mean annual 
decline presented refers to females aged 30, with mean population baseline FEV1, no AAT­
deficiency, zero pack-years, and the wild type genotype. 
Instead of performing pre- or post-hoc power analysis and correction for multiple testing, 
we performed permutation tests to assess whether our results were due to chance, as 
described previously 2• Statistical analyses were performed with 5-Plus® version 7.0, R 
version 1.9.1 13, and SPSS version 14.02. 
RESULTS 
Association of SNPs with decline in FEV1 in patients with severe COPD 
The minor allele frequencies of the tested ADAM33 SNPs in the group of 79 patients with 
severe COPD were similar to those observed in previous studies: F+l 0.39, Q-1 0.18, S_l 
0.13, 5_2 0.32, ST+S 0.55, T_l 0.13, T_2 0.10, V_ 4 0.26. Since some SNPs have a low 
prevalence, and our study population is small, we decided to analyze SNPs F+l, 5_2, ST+S 
in dominant and co-dominant models, and the other SNPs in dominant models only. All 
stratified analyses were performed assuming a dominant model. The SNPs F+l and ST+S 
deviated significantly from Hardy Weinberg equilibrium (p values respectively 0.009 and 
0.02). However, our study population consists only of COPD patients, and Hardy Weinberg 
equilibrium should actually be determined in a non-diseased population. Because the 
allele frequencies and distribution of the alleles were similar compared to our previously 
published study of the Dutch general population 3, in which these SNPs were in Hardy 
Weinberg equilibrium, we decided to analyze F+l and ST+S. The SNPs F+l, Q-1, S_l, 5_2 
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and V _ 4 were in strong LD, and ST +5, T _1 and T _2 as well (see figure E 1 in the additional 
supplement}. 
We determined the adjusted annual FEV1 decline for the wild type of each SNP. The mean 
FEV1 decline for the wild types was 17.2 ml/yr (range 11.5 - 38.8 ml/yr}, with 0.5 ml/yr 
extra per pack-year smoked. SNPs ST +5 and T_2 were associated with excess lung function 
decline (ST +5 : AA genotype -37.8 ml/y vs. GG -9.5 ml/y, p=0.04; T_2: GG -15.5 ml/y vs. 
GA+AA +15.2 ml/y, p=0.02} (figure l}. Stratification according to AAT-deficiency status 
showed that SNP ST+5 was significantly associated with excess FEV1 decline in a dominant 
model in the group without AAT-deficiency, but not in the group with AAT-deficiency 
(figure 1). The size of the estimated effect of the T _2 SNP was similar in subjects with and 
without AAT-deficiency, although not significantly different from the wild type (figure 1). 
The permutation tests confirmed the significant findings (data not shown), indicating that 
these results were not found due to chance. 
I ST+5total population I I ST+5dominantAAT I I ST+5 dominllnt noAAT I 
IIO 
P = 0.034 
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Figure 1: Association of ADAM33 SNPs ST+S and T_2 with excess FEVi decline in the total population of 
patients with severe COPD and stratified by AA T-deficiency status 
Estimates present total decline in FEV1 per genotype, adjusted for sex, pack-years of smoking, baseline FEV1, 
and AA T; error bars represent 95% confidence interval. 
Abbreviations: ADAM33 A Disintegrin And Metalloprotease; SNP Single Nucleotide Polymorphism; FEV1 
Forced Expiratory Volume in 1 second; AAT a1-antitrypsin deficient 
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lmmunohistochemistry of ADAM33 in COPD and control lung tissue 
We observed ADAM33 expression in endothelium, airway smooth muscle, alveoli and 
inflammatory cells with all antibodies and in all tissue samples tested. In contrast to 
previous reports, we were also able to detect ADAM33 expression in bronchial epithelium, 
predominantly at the basal side (figure 2). We observed no differences in localization or 
intensity of expression between the groups of patients with and without AAT-deficiency, 
or between COPD and healthy control tissue, or with antibodies designated to the 
catalytic and cytoplasmic domain of ADAM33. 
Figure 2: lmmunohistochemical staining of ADAM33 in subjects with and without AA T-deficiency, 
and a control, with antibodies directed to the catalytic and cytoplasmic domain of ADAM33 
Subject control tissue: male, current smoker, tumor lobectomy 
Abbreviations: ADAM33: A Disintegrin And Metalloprotease ; AAT: al-antitrypsin deficient 
ADAlvf33 is aJSociated with excess lung function decline, irrespective of,.1. l dntitr,psin deficiu1cy 81 
DISCUSSION 
In our group of relatively young COPD patients who underwent lung transplantation, we 
found significant effects of ADAM33 SNPs ST+5 and T_2 on longitudinal decline in FEV1 . 
We hypothesized that ADAM33 SNPs contribute to the annual decline in FEV1 in severe 
COPD, but not in patients with AAT-deficiency. However, these ADAM33 SNPs predict 
additional FEV1 decline independently from the effects already present due to AAT­
deficiency. This is a remarkable finding, since it has been generally accepted that AAT­
deficiency is the main underlying cause of rapid FEV1 decline in this disease. 
Previous publications have shown that genetic variations in ADAM33 are associated with 
development of asthma, allergy, and impaired childhood lung function 14-20• In the current 
paper, we show that ADAM33 SNPs are associated with FEV1 decline in patients with 
severe COPD. Since we previously found these SNPs to be associated with FEV1 decline in 
asthmatics and the general population, we hypothesize that the ADAM33 gene may be a 
gene that affects FEV1 decline irrespective of disease. This may in addition imply that 
carriers of one or more ADAM33 SNPs may develop different types of respiratory disease 
dependent on environmental factors and other genetic risk factors. 
It is likely that SNPs Q-1, S_l and 5_2 in ADAM33 constitute general risk factors for FEV1 
decline, since they were associated with FEV1 decline in the general population 
3• The ST +5 
SNP, however, may be specific for COPD. This SNP was only associated with excess FEV1 
decline in COPD patients, and not in the general population or asthmatics. Additionally, 
we previously published that within patients with mild to moderate COPD, the ST +5 SNP is 
associated with more severe airway hyperresponsiveness, a clinical characteristic 
predicting lung function loss in COPD 4• This shows that in established COPD the ST +5 may 
play a role specifically in progression of the disease as demonstrated by the severity of 
airway hyperresponsiveness and lung function loss. 
Notwithstanding the relatively small study population, we were able to find significant 
associations. A potential drawback of a small population size is that it may confer a type I I  
error. However, we have performed permutation tests that confirmed our significant 
findings. Another potential explanation for the association of ADAM33 SNPs with FEV1 
decline is that significant differences in a person's first or last FEV1 cause the association. 
However, we found no significant associations (i.e. cross-sectionally) between the SNPs 
and the level of FEV1 at the first or at the last survey in linear regression models (data not 
shown), indicating that this was not the case. 
ADAM33 protein and mRNA expression have already been demonstrated in fibroblasts, 
airway smooth muscle and mesenchymal cells from asthmatics and recently to a smaller 
extent in epithelial cells from both asthmatics and controls 
s-9;21• However, so far it has 
remained unclear if and where ADAM33 is expressed in COPD lung tissue. We have 
--- - � - -
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therefore performed immunohistochemical staining with antibodies against both the 
cytoplasmic and catalytic domain of ADAM33 on lung tissue of severe COPD patients as 
well as control tissue. We found similar expression profiles in smooth muscle, 
mesenchymal and epithelial cells in healthy and COPD lung tissue. 
The function of ADAM33 is largely unknown so far. Based on the integrin domain of 
ADAM33 and the shedding capacities of ADAM33, we speculate that it plays a role in 
remodeling of the airways. SNPs in this gene may alter transcription levels, the function, 
folding or activity of the protein, leading to disease, together with other genetic and 
environmental factors 22. Therefore, different SNPs can have different effects on ADAM33 
and may thus lead to different expressions of disease. In asthma for example, ADAM33 
expression increases with disease progression 21• However, the current study did not link 
ADAM33 expression to specific ADAM33 SNPs. Since we did not observe differences in 
expression levels between COPD and healthy lung tissue, we hypothesize that ADAM33 
undergoes a functional change or change in activity in COPD. 
In conclusion, we found that genetic variation in ADAM33 is associated with FEV1 decline 
independent of AAT-deficiency in a unique population of patients with severe COPD 
followed longitudinally prior to lung transplantation. Since we previously found these 
SNPs to be associated with FEV1 decline in asthmatics and the general population, we 
propose that the ADAM33 gene may be a gene that affects decline of lung function 
irrespective of health status. 
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METHODS 
Genotyping 
For all SNPs, primers and probes were obtained from Applied Biosystems TaqMan® SNP 
Genotyping Assays (Nieuwekerk aan de IJssel, The Netherlands), using the Assay-by-Design 
service for which we provided sequences. Since the design failed for SNP 5_2, we designed 
primers and probes with the Primer Express package and obtained primers from Biolegio 
(Malden, The Netherlands) and probes from Applied Biosystems. Sequences of all primers 
and probes are shown in table El in this online supplement. Reactions were performed in 
5 µI volumes and contained 10 ng DNA, lx Taqman Universal Mastermix (Applied 
Biosystems), 200 nM of each probe and 900 nM of each primer. Cycling conditions on the 
ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems) were 10 min 95°C 
followed by 40 cycles of 15 seconds 95°C and 1 minute 60°C. End-point fluorescence was 
measured immediately after cycling. Alleles were assigned using SDS 2.1 software (Applied 
Biosystems). Genotyping reactions failed randomly a maximum of 6% and a minimum of 
0%. There was no relationship between degree of failure and evidence of association. We 
regenotyped 6% of the samples and found no errors in the genotypes, therefore our data 
are reliable and reproducible. 
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Table El: Sequences of primers and probes for genotyped ADAM33 SNPs 
F+l for: GGAGTGGGAATGCTGTATCTATAGC a ll :  AAGAGAC8GGAATTCA 
rev: GACTTCAAT AAAAATACTGGGACTCGA a12: AGAC§GGAATTCA 
Q-1 for: CCCAGTGTGGACCT AGAA TGG a ll :  CCCGAC�CCTCCTT 
rev: GCCTGCGGGATTCAAACG a12: ACCCGA(ICCTCCTT 
S_l for: TTCCTGCTGGCCATGCT a ll :  CCTCAGC8TCCTGC 
rev: CTGGGAGTCGGTAGCAACAC al2: CCTCAGC§TCCTGC 
5_2 for: CGCAGACCATGACACCTTCCT all:  CCCAGG�GCCGGC 
rev: GCACGCAGGGTCCCTTCT al2: TCCCAGG§GCCGGC 
ST+S for: CAGCACATCTTTTCACTCCATACCA all :  CAGCACC§CAGCTG 
rev: GGTCACAGAGAACTGGGTT AAGG al2: CAGCACC8CAGCTG 
T_l for: CCCTGGTGCCTCACTCA all:  CACCCCAIGGAGTTG 
rev: CCCAAAGATGGCCCACACA al2: ACCCCA�GGAGTTG 
T_2 for: CCCTGGTGCCTCACTCA all :  CCAGG8CTGTCCAGTG 
rev: CTGGGCGGCGTTCAC al2: CAGG§CTGTCCAGTG 
V_4 for: GGAAGGAAGGTCCCCAAAA TT ATGT a ll :  TCCCCTG�AGCCTG 
rev: GCCCT ATGGTTCGACTGAGT al2:  TCCCCTG§AGCCTG 
* for: forward primer; rev: reverse primer t hoses recognizing the specific sequences are underlined; all: allele 1, a/2: allele 2 
Linkage Disequilibrium 
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Genetic variation in TIMPI but not in 
MMPs predict excess FEV1 decl ine in 
two populations 
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An imbalance in Matrix MetalloProteases {MMPs) and Tissue Inhibitors of MMPs {TIMPs) 
contributes to Chronic Obstructive Pulmonary Disease {COPD) development. Prospective 
studies investigating Single Nucleotide Polymorphisms {SNPs) in MMPs and TIMPs with 
respect to COPD development and lung function decline in the general population are 
lacking. 
Methods 
We genotyped SNPs in MMPl {G-1607GG), MMP2 {-1306 C/T), MMP9 {3  tagging SNPs), 
MMP12 {A-82G and Asn357Ser) and TIMPl {Phe124Phe and lle158lle) in 1390 Caucasians 
with multiple FEV1 measurements from the general population. FEV1 decline was analyzed 
using linear mixed effect models adjusted for confounders. Analyses of the X­
chromosomal TIMPl gene were stratified according to sex. All significant associations 
were repeated in an independent general population cohort {n=1152). 
Results 
MMP2 -1306 TT genotype carriers had excess FEV1 decline {-4.0 ml/yr, p=0.03) compared 
to wild type carriers. TIMPl lle1581 1e predicted significant excess FEV1 decline in males 
and females. TIMPl Phe124Phe predicted significant excess FEV1 decline in males only, 
which was replicated in the second cohort. The MMP2 and TIMPl llel581 1e associations 
were not replicated. 
Discussion 
We for the first time show that TIMPl Phe124Phe contributes to excess FEV1 decline in 
two independent prospective cohorts. MMPs evidently do not contribute to FEV1 decline 
in the general population. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic airway 
inflammation, associated with extracellular matrix (ECM) degradation and loss of elastic 
recoil of lung tissue. The Matrix Metalloprotease (MMP) gene family is thought to 
participate in the excessive collagenolytic and elastolytic activity that contributes to ECM 
destruction. MMPs are a family of secreted and membrane associated zinc-dependent 
endopeptidases, capable of cleaving ECM and non-matrix proteins. Many studies have 
shown that MMPl, MMP2, MMP9, MMP12 protein and mRNA levels are higher in lung 
tissue and induced sputum of COPD patients than of controls 1-6• Proteolytic activities of 
the MMPs are normally tightly controlled in several ways, e.g. by transcriptional 
regulation, activation of latent zymogen and interaction with endogenous inhibitors of 
MMPs, the Tissue Inhibitors of MMPs (Tl MPs). Especially the imbalance between MMPs 
and Tl MPs has been proposed to play a major role in ECM destruction and development of 
COPD, a pulmonary disease strongly associated with smoking. Since virtually all COPD 
patients have smoked, yet only a subset of smokers develops COPD, it is plausible that the 
susceptibility to smoking is genetically determined. It is thus reasonable that a genetic 
origin in the imbalance between MMPs and TIMPs contributes to COPD development. 
Single nucleotide polymorphisms (SNPs) have been described in the promoter regions of 
MMPl, MMP2, MMP9 and MMP12 and they can alter their expression levels 7-10• Joos et 
al. showed that SNPs in the MMPl and MMP12 promoter regions are more prevalent in 
subjects with fast FEV1 decline compared to subjects with no FEV1 decline in a cohort of 
current smokers with mild to moderate airway obstruction 11• The MMP9 promoter SNP 
has been associated with emphysema in a case-control study in a Japanese 12, and with 
COPD in a Chinese population 13• In contrast, the promoter SNP in MMP2, a biologically 
plausible candidate for COPD, as well as TIMPl SNPs have not been studied in relation to 
COPD development or FEV1 decline. In TIMPl, no SNPs are known that alter its function or 
expression. Interestingly, two synonymous TIMPl SNPs in the gene region responsible for 
binding and inactivating of MMP9 have been associated with asthma 14• Given the 
function of TIMPl, these TIMPl SNPs conceivably also play a role in COPD development. 
Synthetic MMP inhibitors are being developed as new treatments for COPD, especially 
since animal studies have shown protective effects of such inhibitors against smoke­
induced COPD 15• Unraveling the genetics of MMPs and TIMPs in COPD development may 
identify subjects who may specifically benefit from such treatments. Therefore, we 
studied SNPs in MMP1, MMP2, MMP9, MMP12, and TIMPl and their interaction in 
relation to accelerated FEV1 decline and COPD development in a general population 
cohort. To verify our findings, we investigated whether the significant associations could 
be replicated in an independent cohort of the general population. 




We genotyped DNA from 1390 subjects of the Vlagtwedde/Vlaardingen cohort that 
participated in the last survey in 1989/1990 16.This general population-based cohort of 
Caucasians of Dutch descent started in 1965 and surveys were performed at three year 
intervals. At each survey, lung function measurements were performed using standardized 
protocols and questionnaires were completed (see online supplement). The selection of 
the cohort and details of the study have been described previously 16• The study protocol 
was approved by the local university hospital's medical ethics committee and participants 
gave written informed consent. 
As a replication cohort we used data from a random sample of 1152 subjects from the 
Doetinchem cohort, which is part of the larger MORGEN study 17;18• The MORGEN study 
was a random sample of the general population of the Netherlands. Participants of the 
Doetinchem study underwent spirometry in 1994-1997 and 5 years later in 1999-2003. 
Characteristics of both study populations are presented in table 1. 
Table 1: Characteristics of the Vlagtwedde/Vlaardingen and Ooetinchem cohorts 
Age, years 52 (35-79) 
Males, % 51 
Pack-years 9.0 (0-262.1) 
last FEV1%pred* 93.5 (36.0-138.1) 
tiFEV1, ml/yr t -21.1 (-121;155) 
FEV1 values, n 7 (1-8) 
GOLD stage <!! I I , % 13.4 
Data are presented as median (range) 
-
so (31-71)  
47 
5 (0-84) 
106.6 (39. 1-150.7) 
-28.7 (-292; 130) 
- - -
2 (2-2) 
3.2 - - -
* FEV1 % predicted at the last surveys of Vlagtwedde/Vlaardingen cohort (1989/1990) and the Doetinchem 
cohort (1999-2003) t calculated as last-first FEV1/years participated 
Abbreviations: FEV1 Forced Expiratory Volume in 1 second; GOLD Global initiative for Obstructive Lung Diseases 
DNA col lection and genotyping 
DNA collection and the genotyping protocol of the Vlagtwedde/Vlaardingen study are 
described in the additional data supplement. We genotyped G-1607GG in MMP1, C-1306T 
in MMP2, A-82G and Asn357Ser (A/G) in MMP12. For TIMP1 no tagging SNPs are known, 
therefore we decided to genotype two noncoding SNPs, previously associated with 
asthma 14, Phe124Phe (T/C) and lle158lle (C/T) in TIMP1. With Haploview, using genotype 
data from the HapMap project 19;20, we selected 3 haplotype tagging SNPs for MMP9 that 
tag haplotypes with a frequency above 5% in MMP9 including 5 kb flanking regions at both 
the 3'UTR and S'UTR: rs6065912, rs3918278 and rs8113877. Characteristics of the 
genotyped SNP are presented in table 2. 
Chapler 6 
The SNPs that were significantly associated with excess FEV1 decline or COPD 
development in the Vlagtwedde/Vlaardingen population were genotyped in the 
Doetinchem cohort by KBioscience (www.kbioscience.co.uk) using a patent-protected 
system (KASPar). Characteristics of the genotyped SNPs are presented in table 2. We used 
the statistical software R, "genetics" package (version 1.9.1) to determine whether the 



















rs1799750 llq22-q23 G-insertion generates a new 5'-GGA-3' core recognition 
sequence for members of the E26 transformation-specific 
(ETS) family of transcription factors 
rs243865 16q23 T-al lele disrupts a Stimulating Protein (SP)-1 binding site, 
thereby lowering the promoter activity approximately 
twofold in macrophages and epithelial cells 
rs6065912 20qll.2-13.l tagging SNP for MMP9 gene 
rs3918278 tagging SNP for MMP9 gene 
rs3918278 tagging SNP for MMP9 gene 
rs2276109 11q22.2-22.5 A-al lele has h igher affinity for transcription factor Activator 
protein (AP)-1 and and h igher gene expression in reporter 
gene assays 
rs652438 located in the cod ing region of the hemopexin domain that 
is responsible for MMP12 activity, while the function of this 
polymorphism remains unknown 
rs4898 Xpll.3-11.23 unknown 
rs11551797 unknown 
- -
Abbreviations: SNP Single Nucleotide Polymorphism; MMP Matrix Metalloprotease; TIMP Tissue Inhibitor of MMP 
Statistics 
All TIMP1 analyses were stratified according to sex, since this gene is located on the X­
chromosome. To investigate the effect of SNPs on annual FEV1 decline in the 
Vlagtwedde/Vlaardingen, we used Linear Mixed Effect (LME) models with adjustment for 
potential confounders (e.g. sex, first FEV1 after age 30, pack-years) (see online data 
supplement) 16;21• We tested whether there was an interactive effect of TIMP1 and MMP 
SNPs on FEV1 decline by introducing their interaction term into the model. We used 
ANOVA and linear regression models to study SNP effects on first and last available FEV1 
and FEV1/VC (adjusted for sex, age, pack-years, and height in regression models). We 
identified subjects with COPD at the last 2 surveys using the GOLD criteria (GOLD stage II 
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or higher, i.e. FEVi/VC< 70% and FEV1<80% predicted) 
22
• Differences in genotype 
frequencies of single SNPs for all genes and additionally haplotype frequencies in MMP9 
between subjects with and without COPD were tested using Chi-square tests. 
The SNPs that were significantly associated with excess FEV1 decline or COPD 
development in the Vlagtwedde/Vlaardingen population were genotyped in the 
Doetinchem cohort for verification. FEV1 decline in the Doetinchem cohort was calculated 
based on FEV1 decline between the two surveys and genotype effects were tested using 
linear regression analyses, adjusted for sex, age, pack-years and baseline FEV1. 
Statistical analyses were performed using SPSS (version 14.0.1 for Windows), S-Plus 
(version 7), the statistical package R (version 1.9.1) 23, and Chaplin 24;25• 
RESULTS 
Allelic frequencies for the minor alleles of the MMP and TIMP SNPs in the 
Vlagtwedde/Vlaardingen population were comparable to those reported in the NCBI 
dbSNP database: MMPl G-1607GG 0.51, MMP2 C-1306T 0.27, MMP9 rs3918278 0.03, 
MMP9 rs6065912 0.12, MMP9 rs8113877 0.40, MMP12 A-82G 0.15, MMP12 Asn357Ser 
0.03, TIMPl lle15811e in males 0.01, in females 0.01, and TIMPl Phe124Phe in males 0.50, 
and in females 0.53. All SNPs were in Hardy Weinberg equilibrium. The SNPs in MMP9 
were in high LO (pairwise r2 >0.8). 
Association of MMP SNPs in Vlagtwedde/Vlaardingen 
MMP2 C-1306T was significantly associated with accelerated longitudinal decline in FEV1 
in the total population (TT-genotype -4.0 ml/yr excess decline compared to CC-genotype, 
p=0.027, figure 1), and was also associated with a lower mean FEV1 % predicted (CC: 92.5, 
CT: 93.5, TT: 88.5 % predicted; p=0.013) at the last survey. This association remained 
significant after adjustment for pack-years of smoking in linear regression models. SNPs in 
MMPl, MMP12 and SNPs and haplotypes in MMP9 were not associated with longitudinal 
FEV1 decline, level of lung function or presence of COPD (GOLD � stage II) (table El). 
Since smoking upregulates MMP activity 26, we also analyzed FEV1 decline with respect to 
interaction of the SNPs and smoking. These interaction-terms were not significant. 
Association of TIMP1 SNPs in  Vlagtwedde/Vlaardingen 
The TIMPl Phe124Phe SNP was associated with excess FEV1 decline in males only (-4.2 
ml/yr excess FEV1 decline compared to wild type (p value 0.041, figure 2). We found that 
the TIMPl lle158lle SNP was associated with excess longitudinal FEV1 decline in both 
males and females (-30.7 ml/yr respectively -9.5 ml/yr excess FEV1 decline compared to 
wild type, p values respectively 0.001 and 0.031, figure 2). The minor allele of the lle158lle 
SNP was more prevalent in females with COPD than without COPD: CT genotype, 7.3% and 
1.5% respectively, p=0.051 (online data supplement, table El). SNPs in TIMPl were not 
associated with level of lung function cross-sectionally. 
Interaction of TIMP1 and MMP on FEV1 decline in Vlagtwedde/Vlaardingen 
We found significant associations of TIMPl and MMP2 SNPs with FEV1 decline. To test for 
interaction between these genes, we included interaction terms of TIMPl and MMP2 
SNPs in our models on FEV1 decline, and stratified the analyses by sex. These interaction 
terms were not significant. 
MMP1 G-1 607GG MMP2 C-1306T MMP9 rs3918278 MMP9 rs6065912 
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Figure 1: Effect of SNPs in MMP genes on longitudinal decline in FEVi Mean adjusted declines in FEV1 (in ml/yr) 
are shown per genotype; bars represent 95% confidence intervals 
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Figure 2: Effect of SNPs in TIMP1 on longitudinal decline in FEV11 stratified by sex Mean adjusted declines 
in FEV1 (in ml/yr) are shown per genotype; bars represent 95% confidence intervals 
Replication of significant findings in an independent population cohort 
To investigate whether results were not found due to chance, we analyzed genes that 
were significantly associated with FEV1 level or decline in the Vlagtwedde/Vlaardingen 
cohort, i.e. MMP2 and TIMPl, in an independent cohort of the general population. 
Genotype frequencies in the Doetinchem population were similar and not statistically 
different from the Vlagtwedde/Vlaardingen population (see online supplement, table E2). 
The TIMPl Phe124Phe SNP was associated with excess FEV1 decline in males (T allele -7.6 
ml/yr compared to wild type, p=0.10), similarly to the findings in the 
Vlagtwedde/Vlaardingen cohort, although with lower significance. In contrast to the 
findings in Vlagtwedde/Vlaardingen, TIMPl l le158lle was not associated with excess 
decline, but with less FEV1 decline in females (42.9 ml/yr less decline compared to wild 
type, p=0.008), but not in males. The MMP2 C-1306T was not significantly associated with 
excess FEV1 decline or lower FEV1% predicted in the Doetinchem cohort. 
DISCUSSION 
Our study is the first to show that one SNP in TIMPl predicts excess FEV1 decline in two 
independent populations, implying that the imbalance between MMPs and Tl MPs in lung 
tissue of patients with COPD may be at least partially explained by SNPs that alter the 
function and/or expression levels of these genes. We could not replicate the association of 
MMP2 with excess FEV1 decline in the second independent population, indicating that the 
role of genetic variation in MMP2 on rate of FEV1 decline is still debatable. In contrast to 
previous reports from case-control studies, that showed an association of MMPl, MMP9 
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and MMP12 with presence of COPD, decreased levels of FEV1, and/or excess decline in 
FEV1 1
2;13, we found no indication whatsoever for a role of MMPl, MMP9 or MMP12 in the 
development of COPD or FEV1 decline in these prospective cohort studies. Consequently, 
our data suggest that the imbalance in MMPs and Tl MPs is likely not disturbed due to 
genetic variation in the MMP genes. This does not rule out that MMPs could play a role in 
the imbalance in MMPs and TIMPs in COPD. Genetic variation in genes that are involved in 
regulation of MMPs and TIMPs levels, such as interleukin(IL)-10, IL-13, endothelial growth 
factor (EGF) and tumor necrosis factor-a (TNF-a) 27;28, may clearly influence the imbalance 
of MMPs and Tl MPs in COPD. Future studies are needed that address the effect of these 
genes on decline in FEV1 in the general population. 
We show for the first time that genetic variation in TIMPl may accelerate the normally 
occurring FEV1 decline in the general population. We found that the common SNP 
Phe124Phe was associated with excess FEV1 decline in males only. Since the TIMPl gene is 
located on the X-chromosome, carriage of one mutant allele may already account for an 
effect in males, whereas one mutant allele may be compensated by the other allele in 
females. Of importance, this association was replicated in the Doetinchem cohort with a 
larger genotype effect (-9.0 ml/yr excess FEV1 decline compared to wild type in 
Doetinchem vs. -4.2 ml/yr excess decline in Vlagtwedde/Vlaardingen), but with somewhat 
lower significance (p values respectively 0.10 and 0.04 in Doetinchem and 
Vlagtwedde/Vlaardingen). The Phe124Phe SNP is a synonymous mutation and is therefore 
unlikely to have a functional effect on protein structure or function. It thus should be 
regarded as a marker for genetic variation in TIMPl. Future studies are warranted to 
identify SNPs that have a functional effect in this gene. Such SNPs may alter TIM Pl protein 
structure, resulting in an altered/diminished affinity for MMP9 and subsequently excess 
MMP9 activity leading to parenchymal destruction. 
We observed opposite effects of the TIMPl lle1581 1e SNP in the two populations under 
study. In Vlagtwedde/Vlaardingen the SNP was associated with excess FEV1 decline in both 
females and males, whereas in the Doetinchem cohort we found the opposite effect in 
females (less FEV1 decline), and no effect was shown in males. The SNP has a very low 
prevalence and therefore type I errors can easily occur. By testing the SNP in an 
independent population, we can conclude that the significant effect in the Vlagtwedde/ 
Vlaardingen population is possibly found by chance. 
The MMP2 C-1306T genotype effect on FEV1 decline is small in the Vlagtwedde/ 
Vlaardingen cohort, but we observed no effect at all in the Doetinchem cohort, which may 
indicate that the association in Vlagtwedde/Vlaardingen may possibly be a spurious result 
that is not relevant on a population level. On the other hand, we can not completely rule 
out a genetic effect of MMP2 since the power to detect small genotype effects is much 
larger in the Vlagtwedde/Vlaardingen population with a median of 7 survey points 
compared to 2 survey points in Doetinchem. This may explain the lack of replication. 
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Further studies with comparable power as in Vlagtwedde/Vlaardingen are warranted to 
elucidate the role of MMP2 in FEV1 decline in the general population. 
MMP9 SNPs were not associated with development of COPD or FEV1 decline in our study. 
We did not genotype the MMP9 C-1562T SNP that was previously associated cross­
sectional ly with the presence of emphysema or COPD in Japanese and Chinese individuals 
in a case-control study 12;13, due to technical problems. Therefore, we cannot rule out a 
genetic role of MMP9 in COPD development. However, we tagged the whole MMP9 gene 
for haplotypes with a frequency above 10%, and found strong LO in the whole region. We 
are therefore confident that we also tagged the C-1562T SNP and that we did not miss 
information. Alternatively, the causative factor for higher levels of MMP9 in COPD lung 
tissue does not necessarily have to be genetical ly determined. MMP9 is amongst others 
regulated at the level of transcription by I L-10, IL-13, EGF, and TNF-a 27;28• It is therefore of 
interest to analyze SNPs in these genes in the future as wel l. 
We did not confirm previous associations of the MMP1 and MMP12 SNPs and lung 
function decline as previously described by Joos et al. 11• However, in the latter study the 
MMP12 Asn357Val SNP was only associated with rate of decline in FEV1 in combination 
with the MMP1 G-1607GG SNP. We performed the same type of analyses and found no 
association. 
To our surprise, we did not find any association of MMP1� MMP9 and MMP12 SNPs and 
FEV1 decline or COPD development in the general population. Although the role of MMPs 
in COPD pathogenesis has clearly been demonstrated, we are the first to analyze the 
effects of SNPs in a cohort of the general population, whereas previous studies have used 
case-control designs. Moreover, differences in phenotypes make the comparison of our 
study and previous studies difficult. For example, several studies have investigated the 
effect of the C-1562T SNP in MMP9 in smokers and nonsmokers on emphysematous 
phenotypes using chest CT scans 12;13;29. We do not have CT scans available in 
Vlagtwedde/Vlaardingen or in Doetinchem, so we can not assess such genetic effects since 
pulmonary function tests are not very sensitive to detect (mild) emphysema 30• 
We feel we did not miss any clinical ly relevant associations of e.g. 5 ml/year excess FEV1 
decline due to lack of power. For example: for the MMP9 rs8113877 SNP with 
approximately 1000 subjects with the wild type genotype and on average a mean annual 
decline in FEV1 of 17 ml/yr we have 80% power to detect an excess decline of 5.5 ml/yr in 
FEV1 in mutant carriers (n=300), assuming a SD of 3.0 (derived from the actual SE=l.166) 
in both groups . 
In conclusion, our study shows that genetic variation in TIMP1 is associated with excess 
FEV1 decline in two independent general populations. Further research is needed to assess 
the functionality of this finding. We could not confirm a role for MMP SNPs in excess FEV1 
decline and COPD development in the general population, although our study had 
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sufficient power to detect genetic effects. Since SNPs in MMP do no contribute to COPD, it 
is of interest to assess the genetic contribution of MMP modifying genes, like IL-10, IL-13, 
EGF, and TNF-a that regulate transcription of MMPs. In addition, SNPs in other TIMPs, 
such as TIMP2, may also affect the MMP-TIMP balance and thereby exert an effect on 
FEV1 decline in the general population. 
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Online supplement to paper: 
Genetic variation in TIMPT but not MMPs predict excess FEV1 decline 
in the population 
Cleo C van Diemen, Dirkje S Postma, Mateusz Siedl i nski, Henriette A Smit, 
Anneke B lokstra, H Marike Boezen 
METHODS 
Spirometry 
Pulmonary function measurements were performed with a water-sealed spirometer { Lode 
Spirograph, Lode Instruments, Groningen, The Netherlands). Measurement of inspiratory 
vital capacity {VC) after a deep expiration was followed by measurement of forced 
expiratory volume in 1 second {FEV1). The higher of the values obtained in two technically 
satisfactory tracings was taken as long as the difference between the two IVC values was 
less than 150 ml and the difference between two FEV1 values was less than 100 ml. 
DNA col lection and Genotyping 
During the 1989/1990 survey of the Vlagtwedde/Vlaardingen cohort, neutrophil depot of 
spinned blood was collected and stored at -20°C. In 2003/2004 DNA was extracted from 
these samples with the QiaAmp" DNA Blood Mini Kit and checked for purity and 
concentration with the NanoDrop" ND-1000 UV-Vis Spectrophotometer {Nanodrop 
Technologies, Wilmington, Delaware, USA). 
For all SNPs, primers and probes were obtained from Applied Biosystems TaqMan® SNP 
Genotyping Assays {Nieuwekerk aan de Ussel, The Netherlands), using the Assay-on 
demand service. Reactions were performed in 5 µI volumes and contained 10 ng DNA, lx 
Taqman Universal Mastermix {Applied Biosystems), 200 nM of each probe and 900 nM of 
each primer. Cycling conditions on the ABI PRISM® 7900HT Sequence Detection System 
{Applied Biosystems) were 10 min 95QC followed by 40 cycles of 15 seconds 95QC and 1 
minute 6QQC. End-point fluorescence was measured immediately after cycling. Alleles 
were assigned using SOS 2.1 software {Applied Biosystems). Genotyping reactions failed 
randomly with a maximum percentage of 6% and a minimum of 0%. There was no 
relationship between degree of missingness and evidence of association. We regenotyped 
6% of the samples and found no errors in the genotypes, therefore our data are reliable 
and reproducible. 
- -- - -- --- -- - --------,,,.---,---
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Linear Mixed effect models 
Time was defined as time in years relative to the first FEV1, starting from the age of 30. 
Variables included in the model were sex, pack-years, the first FEV1 after age 30, and their 
interaction with time. Since including the level of the first FEV1 after age 30 and its 
interaction with time could introduce bias due to regression to the mean, these variables 
were also included in the model as random effect variables. The results of these analyses 
showed no change in estimates of the variables in the model or a better fit of the model, 
which indicates that there was no bias due to regression-to-the-mean. Therefore, the 
results are presented without these random effects. 
Table El: MMP SNPs and COPD development in Vlagtwedde/Vlaardingen (GOLD stage � I I )  
MMP1 G 295 (26.4) 44 (24.7) 0.845 
G-1607GG G&GG 565 (50.6) 94 (52.8) 
GG 257 (23.0) 40 (22.5) 
MMP2 cc 609 (52.8) 103 (55.4) 0.180 
C-1306T CT 466 (40.5) 65 (34.9) 
TT 77 (6.7) 18 (9.7) 
MMP12 AA 1054 (93.1) 171 (94.0) 0.673 
Asn357Ser AG 78 (6.9) 11 (6.0} 
GG 0 (0) 0 (0) 
MMP12 AA 812 (72.2) 130 (71.4) 0.831 
A-82G AG 281 (25.0) 48 (26.4) 
GG 32 (2.8) 4 (2.2) 
MMP9 TT 873 (77.0) 145 (80.1) 0.576 
rs6065912 TC 245 (21.6) 18 (33.2) 
cc 16 (1.4) 3 (1.7) 
MMP9 TT 408 (35.8) 76 (40.6) 0.137 
rs8113877 TC 559 (49.0) 77 (41.2) 
cc 174 (15.2) 34 (18.2) 
MMP9 GG 1078 (94.7) 177 (96.7) 0.122 
rs3918278 GA 59 (5.2) 5 (2.7) 
AA 1 (0.1) 1 (0.6) 
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Table E2: TIMP1 SNPs and development of COPD in Vlagtwedde/Vlaardingen (GOLD stage ;:: I I ), 
stratified by sex 
8 • II Cl • D 
TIMP1 cc 572 {98.5) 43 {93.5) 0.051 TIMP1 C 533 {98.9) 130 (99.2) 0.724 
l le158lle CT 9 (1.5) 3 (6.5) l le158lle T 6 (1.1) 1 (0.8) 
TT 0 (0) 0 (0) 
TIMP1 TT 122 (21.1) 12 (25.0) 0.298 TIMP1 T 264 (50.4) 60 (45.8) 0.348 
Phe124Phe TC 308 (53.2) 20 (41.7) Phe124Phe C 260 (49.6) 71 (54.2) 
cc 149 (25.7) 16 (33.3) 
104 
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Decorin, an extracellular matrix (ECM) proteoglycan, and TGF-�1 are both involved in lung 
ECM turnover. Decorin and TGF-�1 expression are decreased respectively increased in 
COPD lung tissue. Interestingly, they act as each other's feedback regulator. We 
investigated whether single nucleotide polymorphisms (SNPs) in decorin and TGF-81 
underlie accelerated decline in FEV1 and development of COPD in the general population. 
Methods 
We genotyped 1390 subjects from the Vlagtwedde/Vlaardingen cohort. Lung function was 
measured every 3 years for a period of 25 years. We tested whether five SNPs in decorin 
(3'UTR and four intron SNPs) and three SNPs in TGF-81 (3'UTR rs6957, C-509T rs1800469 
and Leu10Pro rs1982073), and their haplotypes, were associated with COPD (last survey 
GOLD stage � II). Linear mixed effects models were used to analyze genotype associations 
with FEV1 decline. 
Results 
We found a significantly higher prevalence of carriers of the minor allele of the TGF-�1 
rs6957 SNP (p=0.001) in subjects with COPD. Additionally, we found a significantly lower 
prevalence of the haplotype with the major allele of rs6957 and minor alleles for 
rs1800469 and rs1982073 SNPs in TGF-81 in subjects with COPD (p=0.030), indicating that 
this association is due to the rs6957 SNP. TGF-81 SNPs were not associated with FEV1 
decline. SNPs in decorin, and haplotypes constructed of both TGF-81 and decorin SNPs 
were not associated with development of COPD or with FEV1 decline. 
Conclusions 
Our study shows for the first time that SNPs in decorin on its own or in interaction with 
SNPs in TGF-81 do not underlie the disturbed balance in expression between these genes 
in COPD. TGF-81 SNPs are associated with COPD, yet not with accelerated FEV1 decline in 
the general population. 
Chiipter 7 
BACKGROUND 
Chronic obstructive pulmonary disease (COPD} is characterized by irreversible airway 
obstruction and persistent airway inflammation. Transforming growth factor-f31 (TGF-f3i} is 
one of the important cytokines involved in this inflammatory process, which has been 
associated with cell proliferation and differentiation. It is furthermore involved in repair of 
the extracellular matrix (ECM} after inflammation and tissue injury amongst others by 
promoting synthesis of elastin and collagen. Studies have shown that TGF-f31 expression is 
increased in the airways of COPD patients 1;2• In contrast, a recent article from Pons et al 
showed that alveolar macrophages from COPD patients release less TGF-f31 in response to 
lipopolysaccharide than smokers with normal lung function and non-smokers 3• This may 
lead to a reduced anti-inflammatory and anti-elastolytic response in COPD patients, 
subsequently contributing to progressive ECM destruction. 
Decorin is a component of the ECM that regulates collagen fibrillogenesis 4-6. In addition, 
it can interact with a wide variety of growth factors, cytokines and adhesion molecules 
through its extensive binding area, thereby not only playing a role in ECM assembly but 
also in control of cell proliferation and tissue morphogenesis 7• TGF-f31 has been shown to 
downregulate synthesis of decorin in fibroblasts and decorin can in turn inhibit TGF-f31 
8
• 
Decorin may thus act as a negative feedback regulator of TGF-f31 mediated repair 
responses. Conversely, TGF-f31 can downregulate expression of decorin in fibroblasts from 
emphysema patients 9• We have shown previously that decorin expression is diminished in 
the peribronchiolar area of lung tissue from patients with severe emphysema, while TGF­
f31 production from fibroblasts of these patients is increased 
10
• Noordhoek et al. showed 
that TGF-f31 and basic fibroblast growth factor give a stronger reduction of decorin 
production in the culture supernatant of fibroblasts from patients with severe emphysema 
than from patients with mild emphysema 9• It thus appears that the regulation of decorin 
production is disturbed in lung tissue from patients with severe emphysema. This will lead 
to diminished binding and neutralization of TGF-f31 by decorin followed by higher TGF-f31 
concentrations and activity with lower decorin production as a result. 
We hypothesized that the reciprocal regulation of the TGF-81 and decorin genes is 
disturbed in COPD due to a genetic mutation in one or both of these genes. We have 
tested this hypothesis by investigating three single nucleotide polymorphisms (SNPs} in 
TGF-81 and five SNPs in decorin on the development of COPD and on lung function decline 
in a large cohort derived from the general population (the Vlagtwedde/Vlaardingen 
cohort}. 
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METHODS 
Subjects 
We used data from 2467 subjects of the Vlagtwedde/Vlaardingen cohort participating in 
the last survey in 1989/1990. This general population-based cohort of Caucasians of Dutch 
descent started in 1965. Surveys, during which pulmonary function measurements were 
performed, were held every three years. The selection of the cohort has been described 
previously 11;12;13 . Surveys were performed every 3 years during which information was 
collected on respiratory symptoms, smoking status, age and gender by the Dutch version 
of the British Medical Council standardized questionnaire. A blood sample was taken and 
spirometry was performed. Details on pulmonary function measurements are provided in 
the additional file 1. The methodology for standardization and equipment used for lung 
function measurements was the same throughout the study. In 1989/1990 neutrophil 
depot of centrifuged blood was collected and stored at -20°C. In 2003/2004 DNA was 
extracted from these samples with the QiaAmp® DNA Blood Mini Kit and checked for 
purity and concentration with the NanoDrop• ND-1000 UV-Vis Spectrophotometer. The 
study protocol was approved by the local university hospital's medical ethics committee 
and participants gave written informed consent. 
Genotyping 
We genotyped DNA of those subjects with more than 1500 ng isolated DNA available 
(N=1390). Three SNPs, previously associated with COPD or level of lung function were 
genotyped in TGF-81: rs6957 in the 3'UTR, rs1800469 in the promoter region (C-509T) and 
a coding SNP rs1982073 ( LeulOPro, G/T) 14-16• Coding SNPs in decorin have been identified 
in the NCBI and Celera databases, but are only prevalent in African populations (frequency 
0.05-0.12) but not in Caucasian populations (frequency 0.00). According to the HapMap 
database there are two large LD blocks in the decorin gene, and a region including the 
3'UTR that forms no LD block 17• There are 4 haplotype tagging SNPs located in intrans, 
resulting in 3 major haplotypes, which cover the information of the gene. Therefore, we 
genotyped one SNP in the 3'UTR (rs1803343), and the 4 haplotype-tagging SNPs: 
rs11106030, rs741212, rs566806, rs516115 and rs3138241. The genotyping protocol is 
described in the additional file 1; the characteristics of the genotyped SNPs in additional 
file 2. To determine whether the SNPs were in Hardy Weinberg equilibrium and whether 
they were in linkage disequilibrium, tests were performed with the statistical package R 
(version 1.9.1). 
Statistics 
We identified subjects with COPD using the GOLD criteria (GOLD stage II or higher, i.e. 
FEV1/VC< 70% and FEV1<80% predicted ) at the last survey 
18
• Characteristics of subjects 
with and without COPD at the last survey are presented in table 1. Differences in allele 
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Table 1: Characteristics of genotyped subjects in the 1989/1990 survey 
Males, n (%) 554 (47.9) 137 (72.9) 
Age in years, median ( IQR) so (35-79) 59 (35-76) 
Pack-years of smoking, median ( IQR) 7.5 (0-21.6) 25.5 (6.6-35.7) 
FEV1%pred, median (IQR) 95.8 (87.9-104.5) 71.1 (61.1-77.1) 
FEVJVC, median ( IQR) 76.6 (62.1-80.5) 60.0 (54.5-65.7) 
Abbreviations: FEV, Forced Expiratory Volume in 1 second; VC Vital Capacity 
frequencies and haplotype frequencies between subjects with and without COPD were 
tested using Chi-square tests. We used ANOVA and linear regression models to study the 
effect of SNPs on first and last available FEV1 and FEV1/VC (adjusted for gender, age, pack­
years, and height in regression models). 
Linear Mixed Effect (LME) models were used to investigate the effect of SNPs in TGF-61 
and decorin on annual FEV1 decline in the general population, like published previously 
19:20
• Time was defined as time in years relative to the first FEV1, starting from the age of 
30 21• Variables included in the model were age at entry, gender, pack-years, the first FEV1 
after age 30, and their interaction with time. Since including the level of the first FEV1 after 
age 30 and its interaction with time could introduce bias due to regression to the mean, 
these variables were also included in the model as random effect variables. The results of 
these analyses showed no change in estimates of the variables in the model or a better fit 
of the model, which indicates that there was no bias due to regression-to-the-mean. 
Therefore, the results are presented without these random effects. To test whether SNPs 
were associated with FEV1 decline within subjects with COPD, we performed LME analyses 
on these subjects only. Since Celedon et al. found stronger linkage results of TGF-61 SNPs 
and lung function in smokers only, we additionally performed LME models stratified to 
smoking status 14• We also included interaction terms of TGF-61 SNPs and decorin SNPs to 
test for genetic interaction of these SNPs. 
Instead of performing pre- or post-hoc power analysis and correction for multiple testing, 
we performed permutation tests to assess whether our results might have been found 
due to chance. Genotypes were randomly shuffled among individuals to produce 3000 
datasets. The LME models were rerun on each of these datasets to generate a distribution 
of the beta estimates for additional FEV1 decline of the homozygous minor allele genotype 
compared to FEV1 decline of the homozygous wild type allele genotype under the null 
hypothesis, being no association of the SNPs under study and FEV1 decline. If the observed 
beta estimate from the true data is found in the lower 5% percentile of the empiric 
cumulative distribution (p<0.05), one can assume that the observed beta estimate is not 
found due to chance. 
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We also estimated TGF-81 haplotype frequencies in the whole population and in subjects 
with a COPD phenotype. Estimated haplotype frequencies for TGF-81 higher than 1% in 
the general population were used to construct phased multi-locus genotypes of TGF-81• 
For decorin, we constructed the phased multi-locus genotypes as known from the 
HapMap database. With Chi-square tests we determined for each haplotype whether 
there was a difference in prevalence of carriers between subjects with and without COPD. 
Also, the excess decline in FEV1 in the whole population was determined for each phased 
multi-locus genotype in the LME. 
Statistical analyses were performed using SPSS (version 12.0.1 for Windows), the 
statistical package R (version 1.9.1) and Arlequin 22• 
RESULTS 
Allelic frequencies for the minor alleles of the TGF-81 and decorin SNPs in this population 
were comparable to those reported in the Celera and/or in the NCBI dbSNP database: 
TGF-81 rs6957 0.18, rs1800469 0.28, rs1982073 0.38, decorin rs1803343 0.02, rslll06030 
0.06, rs741212 0.12, rs566806 0.26, rs516115 0.22 and rs3138241 0.06. All SNPs were in 
Hardy Weinberg equilibrium. The TGF-81 rs1800469 SNP was in significant LD with 
rs1982073 and rs6957. Rs6957 was in almost significant LD with rs1982072 (p=0.06). The 
decorin SNPs were in significant LD. Graphs of the LD patterns with D', r and P-values in 
both genes are presented in the additional file 3. 
Prevalence of SNPs and haplotypes in TGF-61 and decorin in COPD and control 
subjects 
The distribution of the TGF-81 rs6957 genotypes was significantly different between 
subjects with and without COPD (p=0.001, table 2). The other TGF-81 SNPs were not 
associated with COPD. We also found no association of SNPs in decorin with the 
prevalence of COPD. 
We used estimated haplotype frequencies higher than 0.01 to construct phased multi­
locus genotypes for TGF-81• The haplotype consisting of the minor allele for TGF-81 rs6957 
and the wild type alleles for TGF-81 rs1800469 and rs1982073 was more prevalent in 
subjects with COPD (p=0.014). Because the prevalence of carriers of other haplotypes 
containing the minor allele at TGF-81 rs6957 was also increased in subjects with COPD, this 
finding only reflects the individual association of the TGF-81 rs6957 SNP with COPD. 
Carriers of at least one haplotype with the minor alleles for TGF-81 rs1800469 and 
rs1982073 and the wild-type allele for rs6957 were less prevalent in COPD (p=0.030). We 
found no significant associations of phased multi-locus genotypes in decorin with the 
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prevalence of COPD (table 3). We also did not find associations of haplotypes containing 
SNPs of both TGF-81 and decorin with COPD (data not shown). 
Table 2: Prevalence of genotypes according to COPD phenotype (GOLD stage II or higher; 
FEVJVC<70%, FEV1 <80% predicted) 
.;::;::::;-------;;;�-� ..... �----�"""""llli!tii.ii��- --..��-�- �  
TGF-B1 GG 584 (52) 106 (58) 0.541 Decorin AA 878 (76) 131 (76) 0.913 
rs1800469 GA 474 (40) 67 (36) rs741212 AG 242 (22) 43 (22) 
AA 87 (8) 10 (6) GG 15 (2) 4 (2) 
TGF-B1 AA 382 (36) 75 (44) 0.297 Decorin AA 614 (55) 102 (55) 0.949 
rs1982073 AG 533 (49) 72 (42) rs516115 AG 431 (38) 65 (38) 
GG 156 (15) 23 (14) GG 79 (7) 15 (7) 
TGF-B1 GG 771 (69) 103 (56) 0.001 Decorin GG 863 (88) 136 (89) 0.733 
rs6957 GA 327 (29) 71 (39) rs3138241 GA 114 (12) 10 (11)  
AA 30 (2) 10 (5) AA 3 (O) 1 (1)  
Decorin cc 996 (87) 170 (91) 0.217 Decorin AA 1079 (94) 173 (93) 0.507 
rs11106030 CA 142 (12) 8 (8) rs1803343 AG 69 (6) 13 (7) 
AA 4 ( 1) 1 ( 1) GG 0 (0) 0 (0) 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; FEV1 Forced Expiratory Volume in 1 second; VC Vital 
Capacity; TGF-B1 Transforming Growth Factor-Bi; df, degrees of freedom 
Table 3: Prevalence of TGF-61 and decorin haplotypes in subjects with and without COPD (GOLD 




























































# P value of Chi-square test for difference in prevalence of haplotype between subjects with and without COPD 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; FEV1 Forced Expiratory Volume in 1 second; VC Vital 
Capacity; TGF-B1 Transforming Growth Factor-Bl 
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Lung function 
We found no significant associations { i .e. cross-sectional )  between the SNPs tested and 
FEV1 and FEV1/VC at the first or at the last survey in  l inear regression models {data not 
shown) .  The mean adjusted annual  decl ine in lung function {expressed as decrease in FEV1 
in m l/yr) was determined for subjects with the wild-type genotype for the SNPs in TGF-61 
and decorin using LM E models. The outcome of the mean annua l  decl ine concerns fema les 
with age 30 when entered in the LM E, a mean first FEV1 of the popu lation, and zero pack­
years. The mean of these adjusted annua l  declines was 19.2 m l/yr {range 18. 7-19 .6) .  We 
did not find any sign ificant association of SNPs in e ither TGF-81 or decorin with accelerated 
lung function decl ine {table 4). We added interaction terms of TGF-61 en decorin SNPs in 
the model, but found no sign ificant interactions. In addition, we did not fi nd any 
sign ificant association of haplotypes of either TGF-61 or decorin with accelerated lung 
function decl ine { resu lts not shown) .  We a lso tested whether SNPs were associated with 
l ung function decl ine within subjects with COPD or with in smokers, but found no 
significant associations {table 4 and additional fi le 4) . To test whether resu lts were not 
missed due to chance, we performed permutation tests. We ran 3000 permutations on 
our sample of 1390 subjects and performed LME ana lyses on each of these permutations. 
The lack of associations with lung function decl ine was confirmed in these ana lyses. 
DISCUSSION 
Decorin and TGF-131 can act as each other's feedback regu lators in ECM turnover and their 
expression is respectively decreased and increased in  lung tissue of COPD patients. We 
assessed whether polymorphisms in decorin and TGF-61 are associated with the 
development of COPD and accelerated l ung function decl ine in  the general popu lation .  
Th is  is the first study assessi ng SNPs in decorin and we did not fi nd any association with 
COPD or lung function loss. Contra ry to our hypothesis, the observed d istu rbed balance 
between decorin and TGB-131 in COPD is not caused by a com bination of SNPs in their 
genes, since we found no significant interaction terms of decorin and TGF-61 SNPs with 
respect to FEV1 decl ine. Moreover, we found no associations of phased multi-locus 
genotypes contain ing SNPs of both TGF-61 and decorin with the presence of GOLD stage I I 
and I l l  COPD in  our popu lation.  Th is distu rbed ba lance may be affected by SNPs in TGF-61 
a lone since the 3'UTR SNP in TGF-81 is predictive of COPD {stage GOLD I I } .  We found, 
however, no association of SNPs in TGF-81 with longitudina l  decl ine in lung function .  In  
addition, no associations were observed of SNPs in TGF-61 with leve l of FEV1 or FEVi/VC 
cross-sectiona l ly. 
It is puzzling that we observed that the TGF-61 rs6957 SNP and a haplotype in TGF-81 were 
associated with COPD, but not with excess decl ine in FEV1 or with leve l of FEV1 and 
FEV1/VC at  the last survey. We have tested whether there were d ifferences in  first 
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Table 4: Annual decline in FEV1 according to genotypes of TGF-81 and decorin 
Changes in decl ine between genotypes in the total population and in subjects who developed COPD 
(GOLD stage II or higher; FEV1/VC<70%, FEV1 <80% predicted) are presented. ----===--------, 
rs6957 AA 918 -19.2 103 -37.1 
AG 399 -18.3 +0.9 0.511 71 -33.5 +3.6 0.297 
GG 40 -18.2 +1.0 0.778 10 -28.8 +8.3 0.239 
rs1800469 GG 716 -18.9 106 -34.3 
GA 555 -17.6 +1.2 0.501 67 -36.2 -1.9 0.587 
AA 103 -20.3 -1.5 0.437 10 -31.9 +2.4 0.698 
rs1982073 GG 477 -19.1 75 -34.8 
GA 623 -17.9 +1.2 0.309 72 -33.9 +0.9 0.876 
AA 185 -17.9 +1.2 0.593 23 -35.1 -0.3 0.959 
rs1803343 GG 1293 -18.7 173 -35.9 
GA 85 -18.3 +0.4 0.874 13 -33.6 +2.3 0.698 
rsl1106030 cc 1206 -18.9 170 -35.2 
CA 162 -19.6 -0.7 0.688 8 -38.3 -3.1 0.577 
AA 6 -30.5 -11.6 0.285 1 -39.9 -4.7 0.797 
rs741212 AA 1039 -18.6 131 -35.1 
AG 198 -20.1 -1.5 0.287 43 -38.2 -3.1 0.439 
GG 20 -14.1 +4.5 0.346 4 -23.2 +11.9 0.282 
rs516115 AA 737 -18.8 102 -34.4 
AG 519 -18.5 +0.3 0.814 65 -35.9 -1.5 0.669 
GG 96 -18.9 +0.1 0.969 15 -35.0 -0.6 0.930 
rs3138241 GG 1187 -18.8 136 -35.7 
GA 157 -19.5 -0.7 0.694 10 -38.7 -3.0 0.588 
AA 5 -25.7 -6.8 0.589 1 -31.6 +4.1 0.888 
• decline in FEV1 adjusted for gender, first FEV1 after age 30 years, pack-years, �nd age; t P value indicates 
significance of the effect of the genotype on decline in FEV1 compared to wild-type 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; FEV1 Forced Expiratory Volume in 1 second; VC Vital 
Capacity; TGF-61 Transforming Growth Factor-Bl; WT Wild Type 
available FEV1 (which might suggest a relation to maximal attained lung function level) 
between the genotypes that could explain the lack of association with FEV1 decline but 
this was not the case. Another possibility would be that the FEV1 decline is only affected 
by SNPs in certain subgroups, such as smokers. Our stratified analyses showed no such 
effect. 
Although the functionality of the TGF-61 rs6957 SNP is not known yet, it has previously 
been associated with lower pre- and post-bronchodilator FEV1 and with lower FEV1/FVC 
14• 
Similarly, we have shown here that this SNP is associated with development of COPD. 
Various studies have indicated that the rs1800469 and rs1982073 SNPs are functional and 
result in higher levels of circulating TGF-�1 
23-26. Since TGF-�1 has anti-inflammatory and 
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pro-repair activities, these SNPs are thought to  be protective against the development of 
COPD. Indeed, we and others have found that (carriers of haplotypes of) the minor alleles 
of these SNPs are significantly less prevalent in COPD patients compared to controls 14;16• 
Similar to Celedon et al, we found an association of a haplotype with at least one minor 
allele of the rs1800469 and rs1982073 TGF-81 SNPs and COPD, while they also found 
associations with these SNPs separately 14;16. The differences in study populations may 
explain these dissimilarities, e.g. our subjects had milder COPD (FEV1<80% predicted) than 
the COPD patients in the Celedon study (FEV1<45% predicted). Despite the differences in 
associations, it is still conceivable that carrying both of the SNPs decreases the risk to 
develop COPD. The two other studies linking TGF-81 SNPs and COPD have also 
demonstrated that these SNPs are less prevalent in COPD, though these studies did not 
test haplotypes 15;16• 
Many SNPs have been described in the TGF-81 gene, but only a few have been intensively 
studied in genetic association studies. Cross-sectional studies have found associations of 
SNPs in TGF-81 with the presence of COPD, and with lower levels of FEV1 and FEVi/FVC in 
several populations 14-16. We did not analyze every SNP in the TGF-81 gene that was 
previously reported to be associated with COPD. However, since Celedon et al. found 
strong LD (r2=0.98) between promoter SNPs and 3'UTR SNPs in a Caucasian population, we 
are confident that any association that might exist would have been revealed by the SNPs 
or by their haplotypes 14• 
This is the first study on SNPs in decorin in a general population or in COPD patients. We 
were interested in polymorphisms in this gene, since decorin expression in COPD patients 
is diminished 9;10• Decorin plays a direct role in the repair processes after inflammation 
through its regulation of matrix metalloproteases and tissue inhibitors of 
metalloproteases 27;28• Furthermore, decorin is the natural inhibitor of TGF-�1 and may 
therefore influence the repair process in the lung indirectly. We hypothesized that these 
processes may be genetically influenced. Since the coding SNPs in decorin described in the 
NCBI and Celera databases were not prevalent in Caucasians (but only in African 
populations), we genotyped four tagging SNPs, located in intrans, and additionally a 3'UTR 
SNP. Although we found no significant associations of these SNPs with COPD or lung 
function decline, we can not rule out completely that there is no genetic defect in decorin 
that increases the risk to develop COPD. However, since we selected tagging SNPs that 
cover the genetic information of the decorin gene according to Hap Map and given the 
large population under study, we assume that we would have observed an association of 
SNPs or haplotypes in decorin if there existed one in this population. 
The lack of a genetic association of SNPs in the decorin gene does not rule out an 
important role of the decorin protein in COPD development. Decorin is a member of the 
proteoglycan family, a family of macromolecules composed of a protein core with 
glycosaminoglycan side chains which are produced post-translationally. It is possible that 
------------------------------- --
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the function or activation of decorin is disrupted through an altered posttranslational 
modification of this glycosaminoglycan chain. In this case, modifications in the protein 
core, which might be caused by SNPs, may not be important and will not be detected. 
Decorin can be expressed in six splice variants, but the function of these splice variants is 
not known yet. Nevertheless, a shift in prevalence of one of these splice variants may 
affect the biological role that decorin exerts in TGF-�1 regulation, thereby influencing the 
pathology within the lung. 
CONCLUSIONS 
Contrary to our hypothesis, we were not able to identify the decorin gene as a genetic risk 
factor for the development of COPD. Consequently, SNPs in decorin do not seem to 
underlie a disturbed regulation of this gene and TGF-81 resulting in COPD, nor can they be 
held responsible for the development of COPD and decline in FEV1 in the general 
population. We found that TGF-81 SNPs are associated with the development of COPD but 
not with accelerated lung function decline or other lung function measures in the general 
population. Together with previous findings, this study establishes the TGF-81 gene as a 
risk factor for the development of COPD. 
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Additional fi les to paper: 
Decorin and TGF-81 polymorphisms and development of COPD in a 
general population 
Cleo C van Diemen, Dirkje S Postma, Judith M Vonk, Marcel Bruinenberg, 
l lja M Nolte, H Marike Boezen 
ADDITIONAL FILE 1 - METHODS 
Pulmonary function measurements 
Pulmonary function measu rements were performed with a water sealed spriometer ( Lode 
Spirograph D53, Lode I nstruments, Groningen, The Nether lands) .  An inspiratory vita l 
capacity ( IVC) was measured after a deep expi ration and fol lowed by measurement of 
forced expiratory volume in 1 second (FEV1) .  Subjects performed the manoeuvre unti l two 
technical ly satisfactory tracings were produced . The higher va lue  of the two tracings was 
taken as the basel ine measurement. For a tracing to be acceptable, the difference 
between two IVC va lues could not be more than 150 ml ,  and  the d ifference between two 
FEV1 measurements not more than 100 ml .  All va lues were recorded at ATPS. The su rveys 
a lways took place in October. 
Genotyping protocol 
Primers and probes of a l l  SNPs were obta ined from Appl ied B iosystems TaqMan® SNP 
Genotyping Assays (N ieuwekerk aan de IJssel, The Netherlands), using the  Assay-by-Design 
service, for which we provided sequences, or the Assay-on-demand service when assays 
were a l ready designed by Appl ied B iosystems. Reactions were performed in 5 µI volumes 
and conta i ned 10 ng DNA, lx Taqman Un iversa l Mastermix (Appl ied Biosystems), 200 n M  
of each probe and 900 n M  of each primer. Cycl ing cond itions o n  the ABI PRISM ® 7900HT 
Sequence Detection System (Appl ied Biosystems) were 10 min 95°C fol lowed by 40 cycles 
of 15 seconds 95°C and 1 minute 60°C. End-point fluorescence was measured after cyc l ing. 
Alle les were assigned using SDS 2 .1  software (Appl ied B iosystems) .  Genotyping reactions 
fa i led randomly with a min imum of 0.02% and a maximum percentage of 6.4% per SNP .  
There was no  relationship between degree of  missing genotypes and evidence of 
association .  We regenotyped 6% of the samples and found no errors in any of the 
genotypes . 
Ctuptc ? 
ADDITIONAL FILE 2 - CHARACTERISTICS OF GENOTYPED SNPs 
TGF-61 rs1800469 promoter - 0.282 associated with For: GGAGAGCAA nm ACAGGTGTCT 
C-509T 509 increased levels Rev: GGAGAAGAGGGTCTGTCAACATG 
of TGF-131 Vic: ACACCTGAGGGATGG 
Fam: ACACCTGAAGGATGG 
TGF-61 rs1982073 exon 1, 0.376 associated with For: CGCGCTCTCGGCAGT 
LeulOPro +29 increased levels Rev: AGGCGTCAGCACCAGTAG 
of TGF-131 i n  Vic: CAGCAGCGGCAGCA 
serum Fam: CAGCAGCAGCAGCA 
TGF-61 rs6957 locus 0.178 unknown AB assay C_7818385_10 
3'UTR 28344 
3'UTR 
Dec_intl rs741212 intron 0.120 unknown AB assay C_2309576_10 
before 
exonl 
Dec_int2-3 rs566806 intron 0.262 unknown AB assay C_2675824_10 
between 
exons 2-3 
Dec_int3-4 rs516115 intron 0.223 unknown For: GGGCATGGGAACCAACAAG 
between Rev: GCTCTGAGACCCTCAAATTffiCTA 
exons 3-4 Vic: CACTGTGAAGCACCCA 
Fam: CACTGTGAGGCACCCA 
Dec3'UTR rs1803343 3'UTR 0.024 unknown AB assay C_7561184_10 
*Sequences of primers and probes are listed when the assay was designed by Applied Biosystems (AB) assay by 
design, otherwise sequences are known by AB 
Abbreviations: SNP, Single Nucleotide Polymorphism; MAF, Minor Allele Frequency; AB assay, Applied Biosystems 
assay on demand; TGF-611 Transforming Growth Factor-6,; UTR, Untranslated Region 
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ADDITIONAL FILE 4: ASSOCIATION OF ANNUAL DECLINE IN FEV 1 ACCORDING 
TO GENOTYPES OF TGF-81 AND DECORIN 
Changes in decl ine between genotypes i n  never smokers and current and past smokers. 
rs6957 AA -20.4 -21.7 
AG -21.0 -0.6 0.736 -19.5 +2.2 0.230 
GG -25.3 -4.9 0.312 -18.1 +3.6 0.426 
rs1800469 GG -21.3 -20.8 
GA -20.2 +1.1 0.512 -19.6 +1.2 0.498 
AA -20.6 +0.7 0.831 -19.6 +1.2 0.712 
rs1982073 GG -21.3 -20.2 
GA -20.0 +1.3 0.588 -19.2 +1.0 0.673 
AA -20.9 +0.4 0.864 -22.4 -2.2 0.402 
rs1803343 GG -21.0 -30.3 
GA -23.2 -2.2 0.469 -17.7 +2.6 0.421 
rs11106030 cc -20.9 -20.4 
CA -21.2 -0.3 0.918 -21.1 -0.7  0.793 
AA -29.5 -8.6 0.594 -29.8 -9.3 0.511 
rs741212 AA -21.2 -19.9 
AG -20.5 +0.7 0.708 -22.7 -2.8 0.165 
GG -18.3 +2.9 0.533 -9.5 +10.4 0.246 
rs566806 AA -21.3 -20.9 
AG -21.3 -0.0 0.992 -20.1 +0.8 0.639 
GG -20.2 +1.1 0.691 -19.6 +1.3 0.701 
rs516115 AA -21.4 -20.5 
AG -21.1 +0.3 0.873 -19.6 +0.9 0.613 
GG -20.6 +0.8 0.779 -20.7 -0.2 0.849 
rs3138241 GG -20.9 -20.3 
GA -21.2 -0.3 0.881 -20.8 -0.5 0.865 
AA -29.3 -8.4 0.598 -21.0 -0.7 0.969 . 
decline in FEV1 adjusted for gender, first FEV1 after age 30 years, and age; t P value indicates significance of the 
effect of the genotype on decline in FEV1 compared to wild-type 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; FEV1 Forced Expiratory Volume in 1 second; VC Vital 
Capacity; TGF-61 Transforming Growth Factor-61; WT Wild-Type 
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GSTMI and GSTTI nul l  a l leles are 
risk factors for excess lung function 
decl ine: a longitudinal cohort study 
of the general population 
Cleo C van Diemen 
H Marike Boezen 
Marcel Bru inenberg 
Dirkje S Postma 




Cigarette smoke induced oxidative stress plays an important role in the onset of Chronic 
Obstructive Pulmonary Disease (COPD). Males and females respond differently to 
cigarette smoke. Polymorphisms of the antioxidative and detoxifying Glutathione S­
Transferase (Gsn genes have been associated with lung function decline and COPD. 
Aim 
To study whether null alleles of GSTM1 and GSTT1 and Single Nucleotide Polymorphisms 
(SNPs} in GSTP1 are associated with COPD development and excess FEV1 decline in the 
general population, and whether associations are affected by gender and smoking. 
Methods 
1390 Caucasians from a longitudinal cohort study were genotyped for null alleles of 
GSTM1 and GSTT1, and SNPs lle105Val and Ala114Val in GSTP1 . The risk to develop COPD 
(defined as GOLD stage 2! II) was analyzed using logistic regression. FEV1 decline according 
to genotype was analyzed using linear mixed effect models. All analyses were adjusted for 
appropriate confounders. We additionally performed stratified analyses according to 
smoking and sex. 
Results 
Subjects heterozygous for the GSTT1 null allele had a significantly higher risk to develop 
COPD (odds ratio 2.03, 95% Cl 1.29 - 3.19, p=0.002} and also a significant excess FEV1 
decline (-17.3 vs. -20.7 ml/yr, p=0.035} compared to subjects with homozygous wild type 
null allele. Subjects homozygous for the GSTM1 null allele had excess FEV1 decline 
compared to carriers of at least one wild type allele (-16.5 vs. -18.9 ml/yr, p=0.023). 
Stratified analyses according to smoking (never vs. ever) and sex showed that only ever 
smoking males with the GSTT1 null allele had a significant excess FEV1 decline. This was 
also the case for ever smoking males with the GSTM1 null allele. The GSTM1 and GSTT1 
null alleles were not associated with excess FEV1 decline in females, irrespective whether 
we stratified according to smoking habits. 
Conclusions 
The GSTM1 and GSTT1 null alleles confer risk for excess FEV1 decline. Especially males 
have an increased risk when carrying these null alleles, an effect that is enhanced by 
smoking. The GSTT1 null allele additionally confers risk to develop COPD. GSTP1 SNPs do 
not appear to play a role in COPD development or FEV1 decline in the general population. 
INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by irreversible airway 
obstruction, chronic airway inflammation, and degradation of lung tissue. The patho­
genesis of COPD encompasses a number of injurious processes, including an abnormal 
inflammatory response in the lungs to inhaled cigarette smoke and other particles and 
gases. The major toxic compounds in cigarette smoke are the reactive oxygen species, 
inducing oxidative stress 1-3• There is solid support for increased lung and systemic 
oxidative stress in COPD, based on markers in peripheral blood cells, bronchoalveolar 
lavage (BAL) and sputum 4• The importance of oxidative stress has recently become more 
eminent given its link with cellular damage/response and transcriptional control of 
inflammation 5 • There are several endogenous antioxidant defenses that counterbalance 
the effects of oxidants, amongst others the glutathione system. Glutathione is the most 
abundant non-protein thiol in BAL and its levels are increased in smokers 6• Glutathione 
can neutralize small reactive oxygen species by itself, but can also be conjugated to larger 
xenobiotic compounds by enzymes called Glutathione S-Transferases (GST). 
There are some well-known functional polymorphisms in GST genes, i.e. GSTM1, GSTT1, 
GSTP1, and especially deletions are of importance. Null alleles have been described for 
GSTM1 and GSTT1, resulting from a partial gene deletion. The deletions cause an enzyme­
tic defect in detoxification of carcinogens, especially polycyclic aromatic hydrocarbons 
present in cigarette tar 7;8• The GSTM1 null allele has been associated with clinical 
symptoms of chronic bronchitis in smokers 9, development of COPD 10 and lower lung 
function growth in children 11• The GSTT1 null allele alone or in combination with the 
GSTM1 homozygous gene deletion has been associated with excess decline in FEV1, both 
in smokers and non smokers in the general population 12• The single nucleotide 
polymorphism (SNP) in the GSTP1 gene, lle105Val, is known to affect the catalytic 
efficiency of the GSTPl enzyme for certain compounds in cigarette smoke. Enzymes with 
valine at 105 have 7-fold higher catalytic efficiency for dial epoxides of polycyclic aromatic 
hydrocarbons, but are 3-fold less effective using 1-chloro-2,4,-dinitrobenzene as a 
substrate 13• Interestingly, genotypes containing l ie at position 105 are more prevalent in 
COPD 14. For the Ala114Val substitu-tion in GSTP1, no functional effect has been 
described, but it has been suggested to aug-ment the lle105 substitution and it has been 
associated with lower lung function and COPD 15• 
In the current study, we aimed to expand the knowledge on genetic effects of the descri­
bed polymorphisms in GSTs on lung function. We investigated the effect of the null alleles 
of GSTM1 and GSTT1 and the Val1051 1e and Ala114Val SNPs in GSTP1 on longitudinal 
decline in lung function and development of COPD in a large prospective cohort of the 
general population. Since the GSTs play a particular role in detoxification of cigarette 
smoke, we tested for interaction of the genotypes and smoking. Additionally, a previous 




study by Imboden et al. demonstrated effect modification of the GSTMl and GSTTl nu l l  
a l le les by sex 12, we therefore performed additional ana lyses on interaction of  GST al le les 
and  sex. 
METHODS 
Subjects 
We genotyped DNA from 1390 subjects of the Vlagtwedde/Vlaa rdingen cohort that 
pa rticipated in the last survey in 1989/1990 16;17 .Th is genera l  population-based cohort of 
Caucasia ns of Dutch descent started in 1965 and surveys were performed at 3-year 
interva ls. At each su rvey, l ung function measurements were performed using standardized 
protocols and questionnaires were completed . The selection of the cohort and deta i ls of 
the study have been described previously 16;17. The study protocol was approved by the 
loca l un iversity hospita l 's medica l  eth ics committee and participants gave written 
informed consent. Cha racteristics of a l l  subjects a re presented in table 1. 
Table 1: Characteristics of the study population Med ian  va lues ( interquartile range) a re presented 
Number of 1390 945 445 714 676 
ind ividuals 
Age, years 52 (43 - 60) so (43-59) 53 (44-61) so (42-59) 53 (44-60) 
Sex, %male 51.4 65.5 23.3 100 0 
Smokers 
% Ever 67.8 100 0 85.4 49.6 
% Never 32.2 0 100 14.6 50.4 
Pack-years 9.0 (0 - 24.0) 18.9 (8.7-30.9) 0 20.4 (6.9-32.9) 0 (0-10.7) 
smoking 
FEV1%pred 93.5 (83.8-104.0) 91.4 (82.0-100.4) 97.9 (88.6-106.2) 90.6 (80.9-99.7) 96.6 (87.1-105.2) 
FEVi/VC, % 75.1 (69.6-79.8) 73.4 (67.8-78.8) 77.8 (73.7-81.6) 73. 1  (66.7-78.3) 77.2 (71.7-80.9) 
FEV1 values, n 7 (S-8) 7 (S-8) 7 (5-8) 7 (5-8) 7 (5-8) 
Abbreviations: FEV1: Forced Expiratory Volume in 1 second;VC: Vital Capacity 
DNA col lection and genotyping 
DNA col lection and the genotyping protocol a re described in the additional data 
supplement. We genotyped GSTPl l lelOSVa l ( rs1695) and Ala114Va l ( rs1138272) using 
Taq Man® SNP Genotyping Assays (Appl ied B iosystems, USA). For GSTMl and GSTTl nu l l  
a l le les we designed primers (Biolegio BV, N ijmegen, The Netherlands) and probes (Biolegio 
BV, Appl ied B iosystems, Warrington, U K) for mu ltiplex rea l-time PCR, using �-globul in as 
internal control. Primers, probes and the genotyping protocols a re ava i lable upon request. 
PCR reactions were performed on the Taqman® 7900 HT system (Appl ied Biosystems). 
Statistics 
We identified subjects with COPD at the last 2 surveys using the GOLD criteria (GOLD stage 
II or higher, i.e. FEVi/VC< 70% and FEV1<80% predicted) 
18
• We used logistic regression 
analyses to test for association of the genotypes with COPD development, adjusted for 
sex, age, pack-years of smoking. Linear Mixed Effect (LME) models were used to 
investigate the effect of SNPs on annual FEV1 decline, with adjustment for potential 
confounders sex, first FEV1 after age 30, and pack-years of smoking 
16;19• We tested for 
interaction of the genotypes and smoking by introducing the interaction term genotype 
*smoking status (ever vs. never smokers) in the model. Similarly, we tested for interaction 
between genotypes and sex by introducing the interaction term genotype*sex in the 
models. When we found a significant interaction, we performed stratified analyses 
according to smoking status and/or sex to analyze the effects of genotypes within certain 
groups. We additionally tested whether carrying a combination of GSTMl and GSTTl null 
alleles was associated with increased risk for COPD or excess FEV1 decline. Statistical 
analyses were performed using SPSS (version 14.0.1 for Windows), S-Plus (version 7) and 
the statistical package R (version 1.9.1) 20. 
RESULTS 
The allelic frequencies of the GST polymorphisms were: GSTMl null 0.51; GSTTl null 0.08, 
GSTPl lle105Val 0.39, GSTPl Ala114Val 0.10. All polymorphisms were in Hardy Weinberg 
equilibrium. 
COPD development 
The GSTTl null allele heterozygous genotype was associated with increased risk to 
develop COPD compared to wild type, adjusted for age, sex, and pack-years smoking (OR 
2.02, 95% Cl 1.29-3.19) (table 2). In a dominant model the GSTTl null allele was 
significantly associated with COPD development with an OR 1.65 (95% Cl 1.10-2.48, 
p=0.016) of the heterozygous and double deletion compared to homozygous wild type. 
GSTMl null allele, GSTPl lle105Val, GSTPl Ala114Val and the combination of GSTMl and 
GSTTl null alleles were not associated with COPD (table 2). 
Decline in lung function 
The GSTMl and GSTTl null alleles were significantly associated with excess FEV1 decline in 
the total general population compared to the wild type alleles (GSTMl: wild type -16.5 vs. 
null allele -18.9 ml/yr, p=0.023 and GSTTl: wild type -17.3 vs. heterozygous genotype 
-20. 7 ml/yr, p=0.035, see figure 1). There existed a significant interaction between the 
GSTMl and GSTTl null alleles and smoking (p<0.05). 
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Table 2: Association of GST SNPs and COPD (GOLD stage 2: I I )  development in the Vlagtwedde/ 
Vlaardingen cohort Odds ratios with 95% confidence interva ls a re presented for the risk to develop 
COPD compared to wild type, adjusted for age, sex and pack-years 
GSTMl nul l  0/0 
GSTTl nul l  wt/0 
0/0 
GSTPl l le105Val AG 
GG 
GSTPl Ala114Val CT 
TT 
- -
1.03 0.73 - 1 .45 0.873 
2.03 1.29 - 3 .19 0.002 
0.89 0.39 - 2 .04 0.783 
1.12 0.79 - 1.61 0.525 
0.81 0.47 - 1.38 0.435 
0.99 0.64 - 1 .54 0.946 
1.67 0.43 - 6.43 0.457 
Abbreviations: GST Glutathion S trans/erase; COPDChronic Obstructive Pulmonary Disease; GOLD Global initiative 
for Obstructive Lung Diseases; OR Odds Ratio; Cl Confidence Interval; wt wild type 
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Stratified analyses according to ever versus never smoking showed a significant 
association of the GSTMl null allele with excess 
FEV1 decline in ever smokers, but not in never smokers (figure 1). For the GSTTl null allele, 
we found a borderline significant effect on excess FEV1 decline in ever smokers (p=0.098), 
whereas no effect was shown in never smokers. The combination of GSTMl and GSTTl 
null alleles was not associated with excess FEV1 decline. 
When stratifying according to sex, the GSTMl and GSTTl null alleles were associated with 
accelerated FEV1 decline in males, but not in females. Stratified analyses in males 
according to ever versus never smokers showed a significant association of the GSTMl 
null allele in male ever smokers, but not in never smokers (figure 2). We did not find 
significant effects in females, nor when the analyses were stratified according to smoking. 
DISCUSSION 
This study shows significant associations of GSTTl and GSTMl null alleles with excess lung 
function decline in the general population. Interestingly, we found that these genetic 
effects were modified by smoking and sex. The GSTMl and GSTTl null alleles were 
associated with excess FEV1 decline in male smokers exclusively and do not appear to 
affect FEV1 decline in females at all. 
Our study confirms the general message of the recent study by Imboden et al., which 
demonstrated gender and smoking modification of GST null alleles on FEV1 decline 
12
. We 
can confirm certain conclusions from their studies, but we also demonstrate different 
results. We showed a significant effect of the GSTTl null allele in the general population, 
but this effect was actually driven by the association in males, in whom significant effects 
on FEV1 decline were observed, which were not present in females. The association in 
males remained significant within male ever smokers, but not in male never smokers, 
which indicates a modifying effect of smoking on the genetic effect. The results from 
Chaptcr 8 
Imboden et al. demonstrated that the GSTT1 null allele was associated with FEV 1 decline 
in males independently of smoking. Our results are thus somewhat different. 
Notwithstanding this, we did find a larger genetic effect in never smokers than in ever 
smokers in our population (respectively -6.1 ml/yr vs. -14.6 ml/yr of the heterozygous 
allele compared to wild type), but this did not reach significance. This may be explained by 
a lack of power to detect differences between genotypes, since the group of male never 
smokers was small (n=104). 
A major difference between our study and the study by Imboden et al. is that we found a 
significant effect of GSTM1 null in the total general population, whereas they only showed 
a significant effect when the GSTM1 null genotype was combined with the GSTT1 null 
genotype. In our study, the effect of the GSTM1 null allele on FEV1 decline in the total 
population is likely caused by the association in male ever smokers who displayed excess 
FEV1 decline (-5.0 ml/yr excess decline compared to wild type). A similar effect was shown 
in female ever smokers (-2.8 ml excess decline), but this was not significant. 
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Figure 1: Association of GSTM1 and GSTT1 null alleles with FEVi decline in the total Vlagtwedde/Vlaardingen 
population, and stratified by smoking status. Mean declines per genotype are presented adjusted for sex, 
baseline FEV1 and pack-years of smoking (when appropriate), with 95% CJ. 
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Figure 2: Association of GSTM1 and GSTT1 null alleles with excess FEV1 decline stratified by sex and smoking 
status. The wild type (WT} genotype is set at zero, and excess declines per genotype are presented, adjusted for 
baseline FEV1 and pack-years of smoking (when appropriate), with 95% Cl. 
The difference in effects of the GSTTl and GSTMl null alleles in males compared to 
females may be partially explained by the fact that more males had smoked and they had 
smoked more pack-years than females (see table 1). Thus, males in our study were more 
at risk to smoke induced FEV1 decline if they missed the protective effects of antioxidant 
enzyme activity due to the GSTMl and GSTTl null alleles. Furthermore, it has been 
suggested that women are better protected against oxidative stress since they display 
higher baseline levels of antioxidants in plasma compared to men 21• Another protective 
mechanism may be that women have been reported to consume more food with high 
antioxidants content 22 . It is unknown how much of digested antioxidants reach the lung, 
and to what extent this protects the lung. However, a high vitamin C (a potent anti­
oxidant) intake has been associated with a higher lung function in some studies, but not all 
22-24• The better protection against oxidative stress in women may thus compensate the 
lack of GSTMl and GSTTl enzyme activity. We do not have dietary information of our 
general population; therefore we can not assess such effects. Further studies in larger 
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populations are warranted to assess these gene-environment interactions in males and 
females. 
Although the null alleles of GSTM1 and GSTT1 do not appear to affect FEV1 decline or risk 
to develop COPD in women, even not when they smoke, this does not refute the general 
held opinion that females are more susceptible to develop COPD 25-27• There were fewer 
females with COPD in our cohort, yet they developed COPD with lower doses of cigarette 
smoke compared to males. In addition women may display a different phenotype of COPD 
compared to men. It has been demonstrated that women have less severe overall 
emphysema, particularly in the periphery of the lung, but that they have thicker airway 
walls and smaller lumens, whereas men display more emphysema 28;29• These results 
suggest that men and women may respond differently in the type and location of lung 
damage due to tobacco exposure. This may be either due to a different deposition of 
cigarette smoke in the lung due to differences in lung growth and development in males 
and females, a different inhalation pattern, or different response mechanisms to the 
inhaled toxic substances. Subsequently, other mechanisms than oxidative stress may play 
a more prominent role in COPD development in women, such as airway remodeling by 
inflammatory cells, in interaction with proteins, proteolytic enzymes and cytokines. 
The GSTP1 llel0SVal SNP has previously been associated with COPD 14• He et al. showed 
that GSTP1 llel0SVal was associated with lower lung function and with excess FEV1 decline 
in subjects who had a high baseline lung function at inclusion in the study 30• We found no 
association of the GSTP1 SNPs with lung function and COPD cross-sectionally or with 
longitudinal FEV1 decline, also not in interaction with smoking or gender (data not shown). 
We can thus conclude from our study that the effect of the GSTP1 SNPs is unlikely to 
contribute to FEV1 decline at a general population level. This conclusion is supported by 
Imboden et al. who also did not find association of the GSTP1 llel0SVal SNP and FEV1 
decline in their general population study. 
In conclusion, we confirm that GSTM1 and GSTT1 null alleles are important predictors for 
excess lung function decline in the general population. We show that especially males are 
at increased risk for excess FEV1 decline, which is further enhanced when they smoke. 
Further studies have to assess whether these sex differences are due to different 
underlying types of COPD with different pathologic substrates and pathophysiology 
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Oxidative stress is an important causative factor in the onset and progression of smoking­
related lung diseases like chronic obstructive pulmonary disease (COPD). Superoxide 
dismutases (SODs) prevent the elevation of oxidative stress by degradation of superoxide 
anions. Therefore we aimed to investigate the association of single nucleotide 
polymorphisms (SNPs) located in SODs (SOD-2 and 50D-3) with development of bronchial 
hyperresponsiveness (BH R) and COPD, and the longitudinal course of forced expiratory 
volume in 1 second (FEV1) over time. 
Methods 
1390 subjects from the prospective Vlagtwedde-Vlaardingen cohort were genotyped for 2 
haplotype-tagging SNPs in 50D-2 and 3 nonsynonymous SNPs in SOD-3. COPD was defined 
as GOLD stage � II at the last survey. BHR was expressed dichotomously as a PC10S 8 mg/ml 
of histamine. Presence of COPD and/or BHR was analyzed using binary and multinomial 
logistic regression analyses. FEV1 decline was analyzed using linear mixed effect models. 
Results 
The C7693T SNP, located in intron 3 of 50D-2, was significantly associated with the 
presence of COPD and BHR in the total population. Multinomial logistic regression 
analyses showed that the T/T genotype for this SNP and the Val/Val genotype for the 50D-
2 Ala16Val substitution were risk factors for BHR in individuals without COPD. 50D-3 
Arg213Gly substitution was associated with slower FEV1 decline in never-smokers 
exclusively. 
Conclusions 
Both 50D-2 SNPs are risk factors for BHR in absence of COPD while the 50D-2 C7693T SNP 
is subsequently a risk factor for COPD in the total population. 50D-3 Arg213Gly SNP is 
protective for FEV1 decline in never-smokers. 
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INTRODUCTION 
An imbalance between oxidants and antioxidants is considered to be an important 
causative factor in onset and progression of chronic obstructive pulmonary disease 
(COPD)1' 2• A key molecule in the regulatory process of oxidative stress is superoxide anion, 
which is inhaled with cigarette smoke and additionally generated during numerous cellular 
reactions 3• Free superoxide anion is a substrate for the synthesis of highly reactive oxygen 
species which can damage epithelial cells, impair epithelial ciliary function, alter 
expression of cellular adhesion molecules, and increase airway smooth muscle contraction 
in response to histamine and other stimuli in in vitro and in in vivo models 4• Therefore, 
impaired superoxide metabolism may contribute to the development of bronchial 
hyperresponsiveness (BHR) and the subsequent onset of COPD 5' 6• Indeed we have 
previously shown that patients with COPD have increased production of superoxide anion 
by blood leukocytes, which was associated with more severe hyperresponsiveness 7• 
However, this cross-sectional study did not elucidate whether the increased production of 
superoxide anion was the cause or consequence of BHR and COPD. So far, studies on the 
relation between superoxide anion and both the development of COPD and BHR in the 
general population are lacking. 
The family of superoxide dismutases (SODs) is the sole unique enzymatic system able to 
degrade a superoxide anion 8• Impairment of the mitochondrial superoxide dismutase 
(SOD-2) activity was related to asthma pathophysiology 9 and extracellular superoxide 
dismutase (SOD-3) was shown to protect lungs against oxidant-mediated injury 10• 11 . 
Therefore it is of interest to study whether Single Nucleotide Polymorphisms (SNPs) in 
these SOD genes contribute to the development of BHR and/or COPD. SOD-2 contains one 
prevalent nonsynonymous SNP (nsSNP) i.e. Ala16Val which is localized in a protein signal 
sequence, thus possessing a possibly functional role 12' 13. This substitution has been 
associated with a higher lung cancer risk in Caucasians 14-16, but not with the presence of 
COPD in Caucasian and Chinese smokers 17' 18. SOD-3 contains three nsSNPs i.e. Ala40Thr, 
Phe131Cys and Arg213Gly. The Arg213Gly substitution has been associated with elevated 
SOD-3 levels in human plasma 19 and with protection against COPD development in 
Caucasians 17' 20, whereas Ala40Thr and Phe131Cys have not yet been studied in this 
context. 
This study links the well-known risk factors for COPD development, i.e. BHR and smoking, 
with polymorphisms located in genes involved in response to oxidative stress, a key 
manifestation in COPD pathogenesis. The study was performed in a population-based 
cohort that was prospectively followed for 25 years with lung function measurements 
every 3 years. 




A tota l of 1390 subjects of the Vlagtwedde-Vlaa rd ingen cohort who participated in the last 
survey (1989-1990) were incl uded in the study. This general popu lation-based cohort of 
Caucas ian ind ividua ls, of Dutch descent, sta rted in 1965 and has been fol lowed-up for 25 
years. Surveys were performed at 3 yea r  interva ls. Deta i ls on the cohort have been 
described previously (see also the on l ine supplement for deta i ls) 21-23 . The study protocol 
was approved by the local un iversity hospita l medica l  eth ics committee and a l l  
partic ipants gave the i r  written informed consent. 
DNA extraction and genotyping 
See the on l ine supplement for a description of DNA extraction and the genotyping 
protocol. Five SNPs in two SODs genes were genotyped, i .e . :  Ala 16Va l ( rs4880) and C7693T 
( rs2842958) in 50D-2 and Ala40Thr ( rs2536512), Arg213Gly ( rs1799895) and Phe131Cys 24 
in SOD-3. The C7693T SNP (see AY267901 sequence in GenBank•) was included to be able 
to tag 50D-2 haplotypes, as described previously 25• 
Presence of COPD and bronchial hyperresponsiveness (BHR) phenotype 
We identified subjects with COPD accord ing to the Global In itiative for Chronic Obstructive 
Lung Disease (GOLD) criteria, i .e. an FEV1/VC < 70% and an FEV1 < 80% predicted (GOLD 
stage I I  o r  h igher) 26 at the last survey. Bronchia l  responsiveness to h istamine was assessed 
in the random subsample of the tota l cohort as described previously (30 seconds method) 
23• BHR at the last su rvey was expressed dichotomously (as a PC10S 8 mg/ml h istam ine) .  
Statistics 
Differences in  preva lence of ra re a l le les of SNPs between subjects with and without COPD 
or BHR were tested with X2 test and logistic regression. Additiona l ly, we performed a l l  
mentioned ana lyses stratified accord ing to smoking habits (never- and ever-smokers), 
s ince we expected the SODs effects to depend on smoking habits. 
I n  order to d isentangle the phenotypes COPD  and BHR, subjects were classified into 4 
phenotypic groups according to the presence of COPD and/or BHR ( i .e . : 'COPD-/BH R-', 
'COPD-/BH R+', 'COPD+/BHR-' and 'COPD+/BHR+'). Mu lt inomia l  l ogistic regression, 
adjusted for packyears of smoking, was performed for al l SNPs separately, with the 4 
groups as dependent variable. These a na lyses a l lowed us to pred ict if subjects with certa in 
genotypes were more l ikely to develop a COPD phenotype or a BHR phenotype. 
Statistical ana lyses were performed using SPSS (version 14.0. 1  for Windows; SPSS, 
Chicago, I L) .  LME models from the statistica l package R (version 1 .9 .1) 27 were used to 
estimate longitud ina l  changes in l ung function in the total cohort as wel l  as in the ever-
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and never-smokers subgroups. PHASE (version 2.1) 28' 29 was used to estimate SODs 
haplotype frequency. P values < 0.05 were considered to be significant. 
RESULTS 
Study population and distribution of SODs SNPs 
The study population characteristics and genotype frequencies are shown in table 1. All 
SNPs were distributed according to Hardy Weinberg Equilibrium in the total population. 
The Phe131Cys substitution in 50D-3 was not present in our cohort. We found no 
homozygotes mutants for the Arg213Gly SNP in 50D-3 in our population. 
Table 1: Characteristics of the sample of the Vlagtwedde-Vlaardingen cohort at the last survey 
Males, n (%) 
Age in years, median (range) 
Pack-years of smoking, median ( range) 
FEV1%predicted, mean (SD) 
FEVJVC %, mean (SD) 
COPD- GOLD stage I I  or higher, n (%) 
BHR- PC1o!.8 mg/ml histamine, n (%)
§ 
Genotype frequency (%heterozygotes / 
%homozygotes mutant): 








92.6 ( 15.3) 
73.9 (8.7) 
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Abbreviations: SD Standard Deviation; BHR Bronchial Hyperresponsiveness; COPD Chronic Obstructive Pulmonary 
Disease; GOLD Global Initiative for Chronic Obstructive Lung Disease; FEVi Forced Expiratory Volume in one 
second; VC Vital Capacity;PC10 = the histamine concentration causing an FEV1 decrease of 10% or more from 
baseline 
SODs SNPs and the presence of COPD 
The 50D-2 C7693T SNP was significantly associated with COPD in the total population and 
in ever-smokers (table 2 and table S2 in supplementary data), but not in never-smokers 
(data not shown). No significant associations were found for the other investigated SNPs 
(table 2). 
SODs SNPs and the presence of BHR 
The 50D-2 C7693T SNP was significantly associated with the presence of BHR within the 
total population (table 2 and table S3 in supplementary data). Mutant homozygotes had a 
significantly higher risk of having BHR compared to wild types. The Ala16Val substitution 
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in 500-2 was borderline significantly associated with BHR (p=0.07 for mutant vs. wild type 
homozygotes, table 2). Stratified analyses according to smoking showed no significant 
associations for these two SNPs. The Ala40Thr SNP was significantly associated with BHR 
only in never-smokers (OR [95% C. I. ] for the presence of BHR: Ala/Thr vs. Ala/ Ala 2.84 
[1.08-7.48]; and Thr/Thr vs. Ala/Ala 14.40 [2.92-71.08] adjusted for packyears of smoking 
and FEV1% predicted, see also table 54 in supplementary data), but not in the total 
population and in ever-smokers (table 2). 
Table 2: Odds ratios {95% C.1.) for the presence of COPD respectively BHR, in the total population 
and in ever-smokers, according to SODs SNPs Logistic regression ana lysis with OR for COPD adjusted for 





























































Abbreviations: BHR Bronchial Hyperresponsiveness; SNP Single Nucleotide Polymorphism; MAF Minor Allele 
Frequency in the investigated group; OR Odds Ratio ; C./. Confidence Intervals; COPD Chronic Obstructive 
Pulmonary Disease; SOD Superoxide Dismutase 
SODs SNPs and the presence of COPD and/or BHR phenotype 
Two hundred and thirteen subjects had neither COPD nor BHR (COPD-/BHR-), 154 subjects 
had COPD-/BHR+, 6 subjects COPD+/BHR-, and 36 subjects had COPD+/BHR+. Subjects 
with the homozygous Ala16Val substitution in 500-2 were most likely to be COPD-/BHR+ 
(OR=2.1; 95% C. I.: 1.1-3.8 for the Val/Val variant compared to Ala/Ala), indicating that the 
Ala16Val substitution was predictive for the presence of BHR and not for COPD or their 
combination. Likewise, subjects with the homozygous mutant 500-2 C7693T SNP were 
most likely to have COPD-/BHR+ (OR=3.1; 95% C. I.: 1.03-9.51 for the homozygous mutant 
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variant compared to the wild type). The polymorphisms in the 50D-3 gene were not 
associated with any of the 4 phenotypic outcome groups. 
SODs SNPs and longitudinal change in FEV1 
The annual FEV1 decline was similar in all genotype subgroups of the investigated SNPs 
(see table 55 in the online supplement). Stratification according to smoking habits 
revealed that the 50D-3 Arg213Gly substitution was associated with slower FEV1 decline in 
never-smokers, e.g. 9.3 ml less decline per year in carriers of the Arg/Gly genotype while 
compared to the wild type (figure 1). The other SNPs were not associated with excess FEV1 
decline in stratified analyses. 
SOD-2 and SOD-3 haplotypes 
Within SOD-3 three major haplotypes existed i.e.: Ala-Arg (frequency 66%), Thr-Arg {32%) 
and Thr-Gly (2%) (the first amino acid corresponds to the Ala40Thr substitution, the 
second to the Arg213Gly substitution). 
We identified three major SOD-2 haplotypes in the total population, i.e. CC (frequency 
51%), TC {28%) and TT (21%), which is in agreement with another study performed in a 
Caucasian population [25] . The mutant allele of C7693T SNP (i.e. "T" allele) coexisted only 
with the mutant variant of the Ala16Val substitution (i.e. "T" allele corresponding to the 
valine), and consequently, is present only in the TT SOD-2 haplotype. Therefore, the 
associations found with the "T" allele of the C7693T SNP can represent the effect of the TT 
haplotype as well. 
DISCUSSION 
Of all human tissues, the lungs are most directly and particularly exposed to noxious free 
radicals. Tobacco smoke and environmental air pollution are the major sources of these 
particles. Therefore, the redox balance regulation can be an important factor for the 
development of bronchial hyperresponsiveness, excess decline in lung function, and 
development of COPD. We showed that SOD-2, containing the mutant allele of the C7693T 
SNP, is a risk factor for bronchial hyperresponsiveness. In the general population and 
exclusively in subjects who have smoked, COPD was more prevalent in carriers of two 
copies of the mutant allele compared to wild type carriers. The SOD-3 Arg213Gly 
substitution, that has previously been shown to be protective for COPD 17' 20, was 
associated with slower FEV1 decline in never-smokers only. 
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Figure 1: Adjusted means for the annual change in FEVifor the SOD-3 
Arg213Gly genotypes in the total population and according to smoking habits 
FEV1 Forced Expiratory Volume in one second; SOD Superoxide Dismutase 
Our finding is of interest since SOD-2 dysfunction and inactivation has been recently 
described ex vivo in bronchial epithelial cells derived from airways of asthmatic patients 9• 
This confirms the importance of SOD-2 in lung homeostasis where reactive oxygen species 
can impair epithelial ciliary function and increase airway smooth muscle contraction in 
response to histamine 4, which may contribute to the development of BHR. Our data 
suggest that this may also be the case in COPD. 
We found the mutant homozygosity of the SOD-2 SNP (C7693T), located in intron 3, to be 
a risk factor for the presence of COPD and BHR in the total population at the last survey. 
Although the role of SNPs localized in intrans is not clear yet, it is known that they may 
affect alternative splicing process 30' 31 which result in different amino acid sequence in 
mature protein. The main difference between the SOD-2 isoforms is the presence of an 
additional exon within the third intron 32, but the implication with respect to putative 
differences in activity between both isoforms is yet unknown. However, it is indeed 
confirmed that SOD-2 isoforms formation may depend on genetic variations which has 
been in vitro shown for a polymorphism (single base pair deletion) that is prevalent in 
African-Americans 33• This study concluded however that other (cis-acting) factors are 
necessary for switching between two isoforms in vivo. Thus it is also possible that C7693T 
SNP is in high linkage disequilibrium with another (functional) SNP, which is actually 
responsible for the associations that we observed. 
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Theoretically, the Ala16Val substitution could be of importance as well, since in vitro 
studies have shown impaired transport of Val16-SOD-2 to the mitochondrion 12' 13, a major 
cellular source of reactive oxygen species. However, we did not find an association of the 
Alal6Val SNP with either the presence of COPD or with lung function decline. This finding 
is in concordance with results of two previous studies performed by Young et al. 17 and 
Mak et al. 18, who found no association of the Ala16Val with COPD in case-control studies 
(smokers with COPD versus non-susceptible smokers). 
Bronchial responsiveness may be modulated by superoxide anion production 7 and BHR is 
a known risk factor for COPD development 5' 6. Due to these facts, impaired superoxide 
radical detoxification, caused by loss of SOD-2 function, may increase the level of BHR and 
affect the development of COPD. Since it is difficult to disentangle the BHR and the COPD 
phenotype, we performed multinomial logistic regression analyses to estimate whether 
certain genotypes are more likely to lead to 'pure' BHR (with absence of COPD) or 'pure' 
COPD (with absence of BHR), or were likely to lead to both BHR and COPD, or neither. 
Remarkably, subjects with homozygous variants of the SOD-2 Alal6Val substitution or the 
SOD-2 C7693T SNP showed increased odds ratios (OR=2.1 and 3.7 respectively) for having 
'pure BHR', which suggests it is indeed the phenotype BHR that is associated with these 
SOD-2 SNPs, and the relation that we have found between C7693T SNP and COPD is driven 
by the association with BHR. We must, however, take into account that the power to 
identify genetic associations with the 'pure COPD' phenotype was limited due to the low 
number of BHR-/COPD+ subjects. 
The SOD-2 TT haplotype contains rare alleles of both investigated SOD-2 SNPs. Moreover, 
it is the only haplotype that contains the mutant allele of C7693T SNP. Remarkably, we 
found an association of the homozygous mutant of C7693T with BHR, but not with the 
heterozygous mutant of C7693T. Therefore, we conclude that the effect of this SNP, and 
consequently the TT haplotype, is important in the recessive mode. Similarly, within ever­
smokers and within the total population, C7693T homozygotes are at risk to develop 
COPD, whereas C7693T heterozygotes are not. Thus, we can also assume a recessive 
effect of this haplotype, and consequently of the C7693T SNP, with respect to COPD 
development. 
Juul and colleagues 20 have shown prospectively and cross-sectionally a lower risk for 
COPD for the SOD-3 Arg213Gly SNP heterozygotes while compared to the wild type. This 
has been confirmed by another cross-sectional study 17• The underlying mechanism of 
these associations may be explained by results from in vitro studies 19' 34, which showed 
mutated SOD-3 protein to be released from heparan sulphate in the cellular membrane 
into the tissue interstitium. We additionally found that the protective, effect of this SNP 
on longitudinal FEV1 change appears in never-smokers. Therefore we hypothesize that 
there are other antioxidant-related genetic factors that additionally contribute to the FEV1 
change in smokers. We must however admit that the low prevalence of this SNP might 
Sup1:.•roxide dismu!ases variants, lung /unction .,nd bronchial responsiveness in the genc'ra/ population 145 
have underpowered our study thus we were not able to detect possible associations 
neither with COPD in the general population nor with FEV1 decline in ever-smokers. 
We found no associations of the Ala40Thr with either the presence of COPD or BHR in the 
total population. More detailed analysis showed that this SNP may play a role in BHR 
presence in never smokers. However, since this substitution in SOD-3 is not yet examined 
for its functional implication, more research on its function is required. 
In summary, we conclude that SOD-2 is an antioxidant enzyme in which variations in DNA 
sequence can play a role in the development of BHR. By showing the protective effect of 
the Arg213Gly SNP in the SOD-3 on FEV1 course in never-smokers we put another piece of 
puzzle to the knowledge on the role of this substitution in pulmonary disease. Further 
stud ies are needed to confirm the possible role of SODs SNPs in COPD and BHR, and 
further functional studies are warranted. 
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Onl ine Data Supplement to paper: 
Superoxide Dismutases variants, lung function and bronchial 
hyperresponsiveness in the general population 
METHODS 
Subjects 
Mateusz Siedl iriski, C leo C van Diemen, Dirkje S Postma, 
Judith M Vonk, H Marike Boezen 
From all subjects information was collected on respiratory symptoms, smoking status, age, 
and sex by the Dutch version of the British Medical Council standardized questionnaire. 
Spirometry was performed using a standardized protocol 1. 
Subjects with forced expiratory volume (FEV1) lower than 1.5 L and those who could not 
perform a forced expiratory manoeuvre were excluded from responsiveness testing, as 
were subjects suffering from heart disease, hypertension, or acute respiratory infections. 
DNA extraction and genotyping 
Neutrophil depots from centrifuged blood samples were collected and stored at -20°C. 
DNA was extracted with a QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) and 
checked for purity and concentration with a NanoDrop ND-1000 UV-Vis spectrophoto­
meter (NanoDrop Technologies, Wilmington, DE). We genotyped DNA samples of those 
subjects with more than 1,500 ng of isolated DNA available (n = 1,390). Genotyping was 
performed using Applied Biosystems TaqMan® SNP Genotyping Assays (Nieuwekerk aan 
de IJssel, The Netherlands) as described previously 1. Sequences of primers and probes 
used for genotyping are shown in table Sl.Due to the low fluorescence signal at the end­
point measurement and in order to ensure genotyping quality, SNP rs2842958 in 500-2 
was genotyped two times. Subjects with conflicting (n=18) genotypes for both 
independent genotyping rounds were excluded from the further analyses. 
Statistics 
Linear Mixed Effects (LME) models were used to investigate the effect of SOD SNPs on the 
annual decline in FEV1. Time was defined as the time in years relative to the first FEV1 
measurement and corresponding age. FEV1 measurements were included from the age of 
30 years, because an individual's maximal achieved lung function is assumed to have been 
reached before that age and lung function is considered to be either in the plateau or 
decline phase 2• Variables included in the model were sex, packyears of smoking, and the 
first available FEV1 after age 30 years and their interaction with time. 
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Applied Biosystems assay ID :  C_8709053_10 





















Applied Biosystems assay ID: C_2307506_10 
*Underlined bases indicate specific polymorphic site recognized by each probe 
Table S2: COPD prevalence in selected subgroups 
SOD-2 
rs4880, 0.49 Ala/Ala 44 [12.5] 0.74 36 [15.1] 
Ala16Val Ala/Val 75 [11.7] 61 [13 .9] 
Val/Val 42 [13.4] 38 [17.9] 
rs2842958, 0.21 C/C 110 [12.9] 0.01 92 [15.6] 
C7693T C/T 38 [9.6] 31 [12.1] 
T/T 14 [23.0] 14 [29.8] 
SOD-3 
rs2536512, 0.34 Ala/Ala 72 [12.8] 0.27 58 [14.6] 
Ala58Thr Ala/Thr 68 [12.4] 58 [16.2] 
Thr/Thr 12 [8.0] 11 [10.5] 
rs1799895,A 0.02 Arg/Arg 154 [12.0] 0.20 128 [14.7] 
rg213Gly Arg/Gly 9 [17.6] 9 [23.1] 





Abbreviations: MAF Minor Allele Frequency in the investigated group; SNP Single Nucleotide polymorphism; ; SOD 
Superoxide Dismutase; COPD Chronic Obstructive Pulmonary Disease 
1 50 
rs4880, 0.45 Ala/Ala 48 [40.0] 0.16 34 [42.5] 0.21 
Ala16Val Ala/Val 88 [46.8] 72 [54.S] 
Val/Val 47 [53.4] 32 [53.3] 
rs2842958, 0.20 C/C 119 [44.6] 0.07 93 [49.7] 0.29 
C7693T C/T 52 [48.1] 34 [50.7] 
T/T 13 [72.2] 10 [71.4] 
rs2536512, 0.32 Ala/Ala 84 [46.9] 0.89 70 [54.7] 0.33 
Ala40Thr Ala/Thr 74 [45.1] 51 [49.0] 
Thr/Thr 21 [48.8] 13 [40.6] 
s1799895, 0.01 Arg/Arg 184 [46.7] 0.23 135 [50.2] 0.72 
Arg213Gly Arg/Gly 3 [27.3] 3 [42.9] 
§ within each genotype *in X2 tests with all genotypes (2 df) 
Abbreviations: MAF Minor Allele Frequency in the investigated group; SOD Superoxide Dismutase; BHR Bronchial 
Hyperresponsiveness; SNP Single Nucleotide Polymorphism 








§ within each genotype *in X2 tests with all genotypes (2 df) 
Abbreviations: SOD Superoxide Dismutase; BHR Bronchial Hyperresponsiveness; SNP Single Nucleotide 
Polymorphism 
rs4880 0.49 -0.96 [-3.26 - 1.34] 0.42 -0.23 [-2.93 - 2.47] 0.87 
Ala16Val 
rs2842958 0.21 0.91 [-1.22 - 3.04] 0.40 2.66 [-1.84 - 7.16] 0.25 
C7693T 
rs2536512 0.34 0.05 [-2.05 - 2.15] 0.96 0.91 [-2.96 - 4.16] 0.58 
Ala40Thr 
rs1799895 0.02 4.28 [-1.40 - 9.96] 0.14 
Arg213Gly 
*compared to homozygotes wild type (reference); negative values indicate faster FEV1 decline 
Abbreviations: LME linear Mixed Effect; MAF Minor Allele Frequency; SOD Superoxide Dismutase; FEV1 Forced 
Expiratory Volume in one second; SNP Single Nucleotide Polymorphism; C.I. Confidence Interval 
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Pulmonary surfactant maintains alveolar structures, improves bronchial clearance, acts in  
innate immunity and attracts eosinophils. Therefore, changes in surfactant quantity or 
composition may contribute to lung function decline and development of Chronic 
Obstructive Pulmonary Disease {COPD}. 
Aim 
To investigate 1} associations of single nucleotide polymorphisms {SNPs} in surfactant 
protein (SFTP} genes with decline in Forced Expiratory Volume in 1 second (FEV1} and 
COPD development, and on well-known risk factors of COPD, i.e. bronchial 
hyperresponsiveness {BHR} and blood eosinophilia; 2} surfactant lipids and their 
degradation products in sputum of COPD patients and controls and their association with 
lung function. 
Methods 
SFTP genetics: we used longitudinal data from a cohort of the Dutch general population 
{follow-up 25 years, n=l,390}. We estimated effects of SNPs in SFTPAl, SFTPA2, SFTPB and 
SFTPD on FEV1 decline, COPD development, BHR and blood eosinophilia, adjusted for 
potential confounders. Lipid profiling: we analyzed surfactant phospholipids in sputum 
from 17 ex-smoking COPD patients and 11 ex-smoking healthy controls. 
Results 
SNPs SFTPAl LeuS0Val and SFTPD Met11Thr were significant predictors of excess FEV1 
decline and COPD development. SFTPD Met11 Thr was associated with blood eosinophilia. 
COPD patients had significantly lower phosphatidylcholine and higher 
lysophosphatidylcholine levels than controls. Accordingly, phosphatidylcholine levels were 
positively and lysophosphatidylcholine levels were negatively associated with lung 
function parameters. 
Discussion 
SFTP SNPs are associated with blood eosinophilia, a risk factor for accelerated FEV1 
decline. We show for the first time that genetic factors and lipid composition in surfactant 
can negatively affect lung function, thereby contributing to COPD development. 
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I NTRODUCTION 
Pulmonary surfactant covers all airway surfaces and alveolar spaces. Its major role is to 
decrease surface tension at the air-liquid interface, thereby reducing the tendency of 
alveoli to collapse during expiration. It also improves bronchial clearance and functions as 
part of the innate immune response against inhaled infectious agents and exposure to 
environmental pollutants. 
The surfactant layer is produced by type I I  pneumocytes and consists of a complex mixture 
of lipids (about 90%) and specific surfactant proteins (SPs) (10%}. The lipids consist for 80-
90% of phospholipids and for 10-20% of cholesterol, triglycerides and free fatty acids. The 
principal phospholipids are phosphatidylcholine (PC) species (approximately 85%) 
containing high amounts of saturated palmitic acid (C16:0) and phosphatidylglycerol. 
Phospholipids can be degraded to lysophospholipids (LP) by loss of one of the fatty acids; 
lysophosphatidylcholines (LPC) are the most abundantly present LP species 1. 
The main SPs are SP-A, B, C, and D (coded by the genes SFTPAl, SFTPA2, SFTPB, SFTPC, 
and SFTPD). SP-A and D are hydrophilic, while SP-B and C are hydrophobic. The SPs 
facilitate the phospholipid arrangement in the lining of the alveoli to optimize their 
surface-tension reducing properties. 
There is suggestive evidence that surfactant dysfunction plays a role in the development 
of Chronic Obstructive Pulmonary Disease (COPD), and this may be genetically 
determined. The SFTP genes are very good candidate genes for COPD development, 
although they have not been studied thoroughly in genetic research of COPD. The 
emphasis in this field of research has been on genes involved in the disturbed protease­
antiprotease and oxidant-antioxidant balance in COPD. Single Nucleotide Polymorphisms 
(SNPs) in SFTPA, SFTPB and SFTPD have been associated previously with respiratory 
distress syndrome, COPD, and severe respiratory infections 2•6• A lack in this field is a 
prospective cohort study to analyze the effects of SNPs in SFTPs on decline in lung 
function and development of COPD. 
COPD is a disease characterized by chronic airway inflammation, airway obstruction and 
tissue remodeling, often accompanied by bronchial hyperresponsiveness (BHR).7 We have 
previously shown that the presence of BHR in the general population predicts the onset of 
COPD-like symptoms such as chronic cough, phlegm and bronchitis, especially if 
eosinophilia is present 8• Additionally, blood eosinophilia itself is an independent predictor 
of reduced lung function levels and accelerated lung function decline and indicates worse 
prognosis in chronic bronchitis 9' 10• 11• Interestingly, SP-D regulates chemotaxis and 
degranulation of eosinophils which may connect the surfactant proteins, eosinophilia and 
reduced lung function 12' 13• In the current study, we for the first time investigated the role 
of SFTP variants on lung function decline, BHR, blood eosinophilia, and development of 
COPD in a general population based cohort. 
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Surfactant dysfunction may also be caused by altered levels of surfactant phospholipids. 
Smoking is the major risk factor for COPD, and smokers have decreased phospholipid 
levels in bronchoalveolar lavage fluid (BALF) and an impaired surface activity of 
surfactants recovered from BALF 14'15• In this study, we analyzed surfactant lipids in 
sputum of COPD patients and age- and smoking-matched controls without airflow 
limitation. Since smoking may affect surfactant directly, we included only ex-smokers. 
METHODS 
Subjects 
For the genetic study, we used data from 1390 subjects of the Vlagtwedde/ Vlaardingen 
cohort who participated in the last survey (1989/1990). This Caucasian general 
population-based cohort started in 1965 and surveys took place every three years at 
which participants performed lung function measurements and completed questionnaires. 
Approximately 25% of the population underwent BHR testing. Cohort details and selection 
have been described previously 16• 
For the sputum lipid analysis, we used material from a previously published cohort of ex­
smoking, non-atopic COPD patients and non-atopic healthy ex-smoking controls 17' 18• 
Table 1 presents the characteristics of all populations studied. The local university 
hospital's medical ethics committee approved the study protocols and participants gave 
written informed consent. 
Genoyping 
DNA collection and the genotyping protocol are described in the online supplement. 
SFTPA1 and SFTPA2 are homologous genes, and SNP combinations from different alleles: 
SFTPA1 6A, 6A2, 6A3, 6A4 and SFTPA2 lA, 1A0, 1A1, 1A2, 1A3, 1A4, 1A5• We determined 
which SFTPA1 and SFTPA2 SNPs tag these alleles and genotyped SFTPA1 Val19Ala, 
LeuS0Val, Arg219Trp; SFTPA2 Asn9Thr, Pro91Ala, Ser140Ser. We genotyped functional 
SNPs in SFTPB and SFTPD, previously associated with COPD: SFTPB lle131Thr; SFTPD 
Metll Thr, SFTPD Thr160Ala 3' 19' 20• 
Sputum sample preparation and l ipid analysis with high performance l iquid 
chromatography /mass spectrometry 
Sputum was collected from 17 COPD patients and 11 ex-smoking healthy controls as 
described previously 17;18• Sputum lipid extraction was performed as described by Folch et 
al 21' 22• Lipid analysis was performed as described previously (see online supplement) 23• 
Several lipids were measured including different PC and LPC species, cholesterol and 
tocopherol . 
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Table 1: Characteristics of the total Vlagtwedde/Vlaardingen cohort study population, its 
subpopulations with and without COPD (GOLD stage � II at the last 2 surveys) and the 
phospholipid study population of COPD patients and controls. Data a re presented as median va lues 
( interquarti le ranges) 
Number of 1390 1204 186 17 11  
ind ividuals 
Age, years 52 (43-60) so (42-59) 59 (52 - 64) 63 (57-70) 58 (51-65) 
Sex, %male 51 48 74 82 73 
Pack-years 9.0 (0-24.0) 6.7 (0-18.0) 21.5 (3.9-32.3) 25.0 (7.5-42.5) 20.0 (10.1-35.0) 
smoking 
FEV1%pred 93.5(83.8-104.0) 95.8 (87.9-104.5) 71.1 (61.1-77.1) 63.0 (51.0-0.3) 102.0 (93.0-110.0) 
FEVi/VC, % 75.1 (69.6-79.8) 86.6 (72.1-80.5) 60. 1  (54.4-65.7) 53.0 (44.5-59.5) 77.0 (72.0-78.0) 
LlFEV1, ml/yr
t -21.1 (-9.9;-32.7) 18.9 (-7.9;-30.0) -36.8 (-23.5;-S0.3) n.a. n.a . 
FEV1 values, n 7 (S-8) 7 (5-8) 7 (S-8) 1 1 
t calculated as last minus first available FEVi/years participated 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease; GOLD Global initiative for Chronic Lung Diseases; 
FEV1 Forced Expiratory Volume in one second; VC Vital Capacity 
Statistics 
Using Linear Mixed Effect (LME) models, we investigate SNP effects on annual decline in 
Forced Expiratory Volume in 1 second (FEV1) in the total general population and in 
subjects with established COPD from this population (defined as GOLD stage I I  or higher at 
the last 2 surveys), adjusting for sex, first FEV1 after age 30, and pack-years smoking 
24' 16
. 
Since smoking affects SP levels, we additionally performed analyses with interaction terms 
of pack-years and genotypes, and performed stratified analyses by smoking in the total 
general population. We analyzed genotype effects on first and last available FEV1 and 
FEV1/Vital Capacity (VC) with linear regression (adjusted for sex, age, pack-years, and 
height). Differences in genotype and haplotype distribution between subjects with and 
without COPD in the general population were tested using Chi-square tests. BHR and 
blood eosinophilia were defined dichotomously as respectively PC10 s 8 mg/ml histamine 
and >275 eosinophils/µI in blood 12• Genotype and haplotype effects on BHR and 
eosinophilia were estimated using logistic regression, adjusting for sex, age, smoking and 
FEV1 %predicted when appropriate. 
We analyzed relations of phospholipid concentrations in sputum with lung function 
parameters, and blood and sputum eosinophils using Spearman's correlation. Differences 
in phospholipid concentrations between COPD patients and controls were tested using 
Mann-Whitney tests. 
Statistical analyses were performed using SPSS (version 14.0.1 for Windows), S-Plus 
(version 7), R (version 1.9.1), and Chaplin 25' 26' 27• 
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RESULTS 
Association of SFTP SNPs with lung function parameters, COPD development, 
BHR and blood eosinophil ia in the general population 
In the Vlagtwedde/Vlaardingen cohort, minor allelic frequencies for the SFTP SNPs were: 
SFTPA1 Val19Ala 0.08, LeuS0Val 0.10, Arg219Trp 0.09; SFTPA2 Asn9Thr 0.08, Pro91Ala 
0.16, Ser140Ser 0.28; SFTPB lle131Thr 0.47; SFTPD MetllThr 0.45, Thr160Ala 0.60. All 
SNPs were in Hardy Weinberg equilibrium. 
Subjects heterozygous for the SFTPD MetllThr SNP had 2.9 ml/yr excess decline in FEV1 
compared to subjects with the wild type genotype (p=0.034, figure 1). We found 
significant interaction terms of SNPs SFTPA1 LeuS0Val and SFTPA1 Ala19Val with pack­
years of smoking. Stratified analyses according to smoking showed that SNPs SFTPA1 
LeuS0Val and SFTPD MetllThr were significantly associated with FEV1 decline in ever­
smokers, but not in never-smokers (figure 1). In addition, ever-smokers who were 
heterozygous for SNP SFTPA1 Ala19Val had 4.8 ml/yr excess FEV1 decline compared to 
ever-smokers with the wild type genotype (p=0.046). This effect was not observed in 
never-smokers. In subjects with established COPD, those who were heterozygous for SNP 
SFTPA1 LeuS0Val had 11.0 ml/yr less FEV1 decline compared to those with the wild type 
genotype (p=0.025, figure 1). 
We did not find significant associations between SFTP SNPs and BHR (see online 
supplement, table El). SFTPA1 Val19Ala, SFTPD MetllThr and SFTPD Thr160Ala, but not 
the other SNPs, were significantly associated with blood eosinophilia (figure 2). 
Haplotypes of SFTPA1 and SFTPA2 were not associated with BHR or eosinophilia. 
Association of surfactant lipids with COPD and lung function parameters 
Table 3 shows the surfactant lipids that were detected in the sputum of COPD patients 
and controls. We found significantly lower levels of PC-C16:0/C16:1, PC-C16:0/C16:0, PC­
C16:1/C18:1 or PC-Cl6:0/C18:2, PC-C16:l/C18:1 and PC-C18:0/C18:2 or PC-C18:1/C18:l in 
COPD patients than controls, whereas levels of LPC-C16:0 were significantly higher in 
COPD patients (table 3). 
Higher PC-C16:0/C16:l, PC-C16:1/C18:1 or PC-C16:0/C18:2, PC-Cl6:0/C18:1 and PC­
C18:0/C18:2 or PC-Cl8:1/C18:1 were significantly associated with higher values of FEVi/VC 
and FEV1 %predicted (table 4). Higher LPC-C16:0 was significantly associated with lower 
values of FEV1/VC and FEV1 %predicted. Higher LPC-C18:1 was associated with lower 
values of FEVi/VC (table 4). Figure 3 shows the correlations between PC-C16:0/C16:1 and 
LPC-C16:0 with FEV1 %predicted and FEVi/VC. The other significant correlations of PC and 
LPC species with lung function parameters resulted in comparable figures. We did not find 
significant correlations of PCs or LPCs with levels of eosinophils in blood and sputum. 
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Figure 1: Associations of SFTPAl Leu50Val and SFTPD Metll Thr with excess FEV1 decline in the 
V/agtwedde/Vlaardingen population, and stratified by ever smokers, never smokers and subjects with 
COPD (GOLD 2 11) Mean declines per genotype are adjusted for sex, first FEV1, age and pack-years of smoking 
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Figure 2: Associations of SFTPAl Va/19Ala, SFTPD Met11Thr, SFTPD Thr160Ala SNPs with blood eosinophilia 
in the V/agtwedde/Vlaardingen population Odds ratios with 95% confidence intervals are presented for 
blood eosinophilia, adjusted for age, sex and pack-years of smoking. 
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Table 2: Distribution of SNPs in surfactant proteins in subjects with and without COPD (GOLD 
stage � II) in the Vlagtwedde/Vlaardingen population 
SFTPA1 TT 149 (82.6) 970 (85.7) 0.106 SFTPA2 cc 90 (50.8) 601 (53.4) 0.816 
Val19Ala TC 31 (17.4) 145 (12.8) Ser140Ser CT 71 (40.2) 427 (38.0) 
cc 0 (0.0) 17 (1.5) TT 16 (9.0) 97 (8.6) 
SFTPA1 GG 120 (76.0) 743 (75.8) 0.002 SFTPB cc 57 (31.1) 313 (27.6) 0.376 
Leu50Val GC 23 (14.7) 203 (20.7) l le131Thr CT 86 (47.6) 594 (52.3) 
cc 15 (9.3) 34 (3.5) TT 41 (22.3) 229 (20.1) -- --
SFTPA1 cc 157 (88.2) 942 (83.3) 0.239 SFTPD TT 41 (22.7) 360 (31.7) 0.045 
Arg219Trp CT 20 (11.2) 176 (15.6) MetllThr TC 104 (57.8) 544 (47.9) 
TT 1 (0.6) 13 (1.1) cc 35 (19.5) 232 (20.4) 
SFTPA2 AA 65 (34.9) 425 (37.1) 0.732 SFTPD AA 34 (19.2) 171 (15.2) 0.363 
Asn9Thr AC 89 (47.8) 546 (47.7) Thr160Ala AG 80 (45.2) 551 (48.8) 
cc 32 (17.3) 174 (15.2) GG 63 (35.6) 406 (36.0) 
SFTPA2 GG 131 (72.0) 804 (71.1) 0.590 
Ala91Pro GC 48 (26.4) 293 (25.9) 
cc 3 (1.6) 34 (3.0) 
Abbreviations: SNP Single Nucleotide Polymorphism; COPD Chronic Obstructive Pulmonary Disease; GOLD Global 
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initiative for Chronic Lung Diseases; SFTP Surfactant Protein 
Table 3: Different lipid concentrations in sputum of COPD patients and controls 
369.8 cholesterol 231,210 (150,872-470,651) 186,323 (51,086-601,240) 
429.9 tocopherol 18.1 * 106 (5.7*106 -31.1 *106) 9.9*106 (8.3*106-424.1 *106) 
468.8 LPC-C14:0 35.6 (5.9-64.3) 7.1 (4.6-15.8) 
496.8 LPC-C16:0 614.4 (176.2-840.3) 155.4 (123.2-421.8) 
522.8 LPC-C18:1 204.6 (61.6-840.3) 55.4 (47.8-187.4) 
707.1 PC-C16:0/C14:0 3,718 (2,905-5,818) 5,242 (3,939-8,203) 
733.2 PC-C16:0/C16:1 4,977 (3,318-13,577) 11,917 (9,547-27,448) 
735.2 PC-C16:0/C16:0 12,536 (8,001-18,551) 18,354 (12,682-24,794) 
759.2 PC-C16:1/C18:1 or 3,077 (2,389-9,166) 9,674 (5,783-15,093) 
PC16:0/C18:2# 
761.2 PC-C16:1/C18:1 4,736 (3,060-11,340) 11,120 (8,670-18,143) 
787.2 PC-C18:0/C18:2 or 1,044 (859-3,465) 3,484 (2,060-5,950) 
PC-18:1/C18:1 * --- � --
*Data are presented as median (interquartile range) 
tp value from Mann Whitney test for difference in concentration between COPD patients and controls 
#based on molecular weight, phospholipid species can be either one of these conformations. 
Abbreviations:COPD Chronic Obstructive Pulmonary Disease; MW Molecular Weight; LPC 


















468.8 LPC-C14:0 FEVJVC -0.516 0.006 
496.8 LPC-C16:0 FEV1%pred -0.452 0.018 
FEVJVC -0.646 <0.001 
522.8 LPC-C18:1 FEVJVC -0.538 0.004 
707.1 PC-C16:0/C14:0 
733.2 PC-C16:0/C16:1 FEV1%pred 0.424 0.027 
FEVJVC 0.431 0.025 
735.2 PC-C16:0/C16:0 
759.2 PC-C16:1/C18 :1  or FEV1%pred 0.458 0.016 
PC-16:0/C18:2* FEVJVC 0.434 0.024 
761.2 PC-C16:1/C18:1 FEV1%pred 0.478 0.012 
FEVJVC 0.491 0.009 
787.2 PC-C18:0/C18:2 or FEV1%pred 0.472 0.013 
PC-C18:1/C18:1 * FEVJVC 0.445 0.020 
*based on molecular weight, phospholipid species can be either one of these. 
Abbreviations:COPD Chronic Obstructive Pulmonary Disease; MW Molecular Weight; r Pearson's correlation 
coefficient; LPC Lysophosphotidylcholine; PC Phosphotidylcholine; FEV1 Forced Expiratory Volume in one second; 
VC Vital Capacity 
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Figure 3: Correlation of sputum phosphatidylcholine species PC-C16:0/C16:1 and LPC-C16:0 with 
FEV/J6predicted and FEVi/VC Black solid triangles represent COPD patients, open squares controls. 
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DISCUSSION 
This study sheds l ight on mu lt iple factors involved in pu lmonary surfactant function and 
composition in relation to COPD. We demonstrate that both genetic factors and l ipid 
variations in surfactant can affect l ung function, thereby contributing to the deve lopment 
of COPD. We show for the first t ime that SNPs in SFTP genes a re associated with 
accelerated lung function decl ine .  Moreover, they a re associated with h igh blood 
eosinophi l  numbers in the genera l  population, a known risk factor for lower l ung function 
and accelerated lung function decl ine by itself. In addition, we show that sputum PC 
fractions are lower in COPD patients than in  contro ls, ind icati ng that degradation of PC is 
enhanced in COPD. This find ing is of clin ica l importance, si nce we show that h igher levels 
of degraded PC species are associated with lower l ung function .  
In our genetic study in the genera l  popu lation, the heterozygous genotype of SFTPD 
MetllThr was associated with excess FEV1 decline in the tota l popu lation and to a lesser 
extent in ever smokers. We found no significant interaction between the SFTPD MetllThr 
genotypes and pack-years smoked. Therefore, the detrimenta l  effect of the heterozygous 
genotype of SFTPD MetllThr SNP on lung function decl ine seems to be independent of 
smoking. In contrast, we found a significant positive interaction between the effect of this 
genotype is modified by smoking. Our stratified ana lyses accord ing to smoking indeed 
showed a protective effect of the heterozygous genotype of SFTPAl LeuS0Va l on FEV1 
decl ine in ever-smokers, whereas this effect was not shown i n  never-smokers. The 
heterozygous genotype of SFTPAl LeuS0Val thus appears to protect the l ungs aga inst lung 
function decl ine due to smoking. 
To our su rprise, heterozygosity but not homozygosity for SN Ps SFTPAl LeuS0Val and 
SFTPD MetllThr was associated with respectively slower and faster FEV1 decl ine. 
Accordingly, the heterozygous genotype of SFTPAl LeuS0Va l was less preva lent and SFTPD 
MetllThr was more preva lent in subjects with COPD than in those without COPD. Th is 
phenomenon is known as molecular heterosis, i.e. the heterozygous effect of a specific 
genetic polymorph ism is sign ificantly greater or smal ler than the homozygous or wi ld-type 
effect. We cannot speculate a bout an advantageous role of h eterozygosity for SFTPAl 
LeuS0Va l, si nce the function of this SNP is unknown. However, we can hypothesize about 
a detrimental role of SFTPD heterozygosity, since it has been shown that the MetllThr 
substitution influences the assembly, function and concentration of SP-D 28' 29• I nd ividuals 
with Thr/Thr genotypes have sign ificantly lower SP-D serum levels than Met/Met 
individua ls 28' 29• Met/Met ind ividua ls  have two distinct forms of SP-D in  serum with a h igh 
and low molecu lar weight, whereas Thr/Thr individua ls have only the low molecu lar 
weight band 29• The two forms of SP-D d isplay d ifferentia l b ind ing to intact 
microorganisms and l ipopolysaccha ride (LPS). The h igh molecu la r weight SP-D may be 
important in the binding, aggregation and clea rance of microorganisms, whereas low 
thdpfc, JO 
molecular weight SP-D preferentially binds to simpler ligands, like LPS, and may therefore 
have alternative physiological functions. From this point of view, carrying both allelic 
variants might be advantageous, since it allows a broader response to microorganisms 
compared to that of individuals homozygous for either one of the alleles. However, our 
results point toward the opposite, since the heterozygous genotype was associated with 
the fastest FEV1 decline and was more prevalent in COPD subjects. Our data therefore 
suggest that heterozygous subjects have too low levels of either one of the two molecular 
weight forms to withstand infections and appropriately clear established infections. This 
may then result in damage to the lungs and excess decline in lung function. 
Surfactant proteins have been previously associated with eosinophil numbers and 
function, since SP-D regulates eosinophil chemotaxis and degranulation 13• Eosinophils can 
produce secretory phospholipases (sPLA2) and eosinophil lysophospholipase, that induce 
surfactant dysfunction by phospholipid hydrolysis 30• sPLA2 hydrolyses PC to LPC, which is 
the substrate for eosinophil lysophospholipases. Interestingly, our study is the first to link 
the occurrence of higher numbers of blood eosinophils to degradation of phospholipids in 
both healthy individuals and COPD patients. We show that SFTPD SNPs are associated with 
a high number of eosinophils in peripheral blood. These eosinophils may induce 
degradation of phospholipids in the lung as indicated by high levels of LPC. Indeed, we 
found that LPC levels in sputum are higher in COPD patients than in controls. We did not 
find direct significant associations of SFTPD SNPs with levels of sputum LPC, which might 
be due to the small population size. It would be interesting in further studies to assess 
such functional relations. 
In the lung, surfactant PC is degraded by phospholipase A2 to LPC, which is normally 
present in small quantities in surfactant. Our COPD patients had significantly lower levels 
of saturated PC-species and higher levels of LPC-species in sputum than controls, 
indicating higher degradation of PC in COPD. We observed comparable associations of PC­
and LPC-species with lung function parameters. These results are similar to those from a 
study in asthmatics, showing that higher levels of PC-species were also associated with 
higher levels of lung function 31• High levels of LPC in sputum may indicate damage to the 
surfactant layer, since high concentrations of LPC have been shown to enhance 
bronchoconstriction in guinea pigs 32' 33• Our findings furthermore show that high levels of 
PC are critical in maintaining an optimal lung function as well, because PC levels were 
higher in our controls than in our COPD patients, and higher PC levels were associated 
with a better lung function. 
Our study has some limitations. For instance, we did not measure levels of surfactant 
proteins in sputum of the COPD patients and controls, since levels of SP were too low to 
detect. We therefore can not determine the link between levels of surfactant lipids and 
proteins in our population of COPD patients and controls. Another limitation of the 
current study is that our groups of COPD cases and controls were too small to analyze 
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genetic effects of variants in surfactant proteins on phospholipid content in sputum. 
Additionally, we did not have sputum of our general population to analyze surfactant 
fractions and relate them to decline in lung function and specific genotypes. 
In conclusion, our study is the first to provide suggestive evidence that alterations in 
surfactant as caused by effects of both genetic and lipid alterations, affect lung function 
and development of COPD. We show that genetic variants in SFTP genes are associated 
with higher blood eosinophil numbers, accelerated lung function decline and COPD 
development in the general population. Furthermore, surfactant phospholipids appear to 
be important in maintaining an optimal lung function since the PC fraction of lung 
surfactant is lower and the LPC fraction higher in COPD patients than control subjects. A 
study by Anzueto et al. already showed that treatment with aerosolized surfactant for 2 
weeks improves pulmonary function in patients with chronic bronchitis 34• Since COPD is a 
disease that is still not appropriately manageable with current available medications, we 
put forward that therapies directed at improving surfactant levels need attention for 
benefit of COPD management. 
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Online Data Supplement to paper: 
Pulmonary surfactant: genetic and lipidomic risk factors for 
Chronic Obstructive Pulmonary Disease 
Cleo C van Diemen, Dirkje S Postma, Begona Barroso, Judith M Vonk, 
Rainer B ischoff, H Marike Boezen 
METHODS 
Sputum sample preparation and analysis of l ipids i n  sputum with h igh 
performance l iquid chromatography (HPLC)/mass spectrometry (MS) 
Sputum was collected from 16 COPD patients and 11 ex-smoking healthy controls as 
described previously. 1' 2 Extraction of lipids from sputum was performed by the method 
described by Folch et al. 3' 4• In short, 1.5 ml of a mixture of chloroform/methanol/SO mM 
acetic acid 8/4/0.5 (v/v/v) was mixed with 0.5 ml of  sputum supernatant and manually 
shaken for 2 min. The mixture was centrifuged for 5 min at 1500 g, and the organic layer 
separated. The aqueous phase was extracted again and both organic extracts were pooled 
together and evaporated to dryness under a stream of nitrogen. The residue was 
reconstituted in 50 µI of DMSO by ultrasonication and vortex mixing. 5 µI were injected in 
the HPLC/MS system. Glassware was used throughout the whole sample preparation 
procedure. 
The HPLC part of the analytical system consisted of an Agilent Series 1100 capillary LC 
system (Waldbronn, Germany) comprising a degasser, a binary pump, a thermostatted 
autosampler and a thermostatted column compartment. Chromatographic separation 
took place on a reversed-phase column (Poroshell 300SB-C8, 5 µm, 1 mm i.d. x 75 mm 
length) (Agilent, Waldbronn, Germany). Mobile phase A consisted of 0.1% formic acid in 
ultra pure water. Mobile phase B was 0.1% formic acid in acetonitrile. Separation was 
performed with an increasing gradient of B (25-95% in 50 min). Flow rate employed was 
60 µI/min and the column temperature was 60 °C. The analytes were detected by an 
Agilent SL ion-trap mass spectrometer equipped with an electrospray ionization (ESI) 
source operated in the positive mode. MS data were acquired over a scan range of 100-
1200 amu and 5500 m/z per second scan rate. Several lipids were measured including 
different phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) species, cholesterol 
and tocopherol. 
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DNA col lection 
DNA in the Vlagtwedde/Vlaardingen cohort was extracted from neutrophil depot as 
previously published. 5 We used the classical chloroform extraction for genomic DNA 
isolation from the sputum samples and checked the DNA for purity and concentration 
with the NanoDrop ® ND-1000 UV-Vis Spectrophotometer (Nanodrop Technologies, 
Wilmington, Delaware, USA). 
Genotyping 
Primers and probes were obtained from Applied Biosystems TaqMan® SNP Genotyping 
Assays (Nieuwekerk aan de IJssel, The Netherlands), using the Assay-on demand service. 
Sequences of primers and probes are available upon request. Reactions were performed 
in 5 µI volumes and contained 10 ng DNA, lx Taqman Universal Mastermix (Applied 
Biosystems), 200 nM of each probe and 900 nM of each primer. Cycling conditions on the 
ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems) were 10 min 95°C 
followed by 40 cycles of 15 seconds 95°C and 1 minute 60°C. End-point fluorescence was 
measured immediately after cycling. Alleles were assigned using SDS 2.1 software (Applied 
Biosystems). We regenotyped 6% of the samples and found no errors in the genotypes. 
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Chapter 10 
Table El: Association of SFTP SNPs with blood eosinophilia and BHR in the total 
Vlagtwedde/Vlaardingen population 
SFTPA1 TC 1.55 1.05 - 2.28 0.026 1.07 0.58 - 2 .00 
Val19Ala cc 0.64 0.15 - 2.83 0.560 0.81 0.12 - 0.95 
SFTPA1 GC 1.23 0.86 - 1.75 0.253 1.55 0.87- 2.76 
Leu50Val cc 0.80 0.37 - 1.74 0.579 1.13 0.44 - 2.90 
SFTPA1 CT 0.64 0.41 - 1.01 0.057 0.77 0.41 - 1.45 
Arg219Trp TT 1.57 0.49 - 4.96 0.442 
SFTPA2 AC 0.90 0.66 - 1.24 0.531 0.79 0.48 - 1.30 
Asn9Thr cc 1.12 0.74 - 0.70 0.579 1.04 0.52 - 2.07 
SFTPA2 GC 1.22 0.88 - 1.67 0.225 1.00 0.61 - 1.65 
Ala91Pro cc 0.54 0.19 - 1 .55 0.255 0.41 0.07 - 2.32 
SFTPA2 CT 0.91 0.67 - 1.22 0.514 1.17 0.72 - 1.89 
Ser140Ser TT 0.66 0.37 - 1.16 0.149 1.63 0.73 - 3.63 
SFTPB CT 1.06 0.76 - 1.49 0.733 1.75 0.45 - 1.27 
l le131Thr TT 1.08 0.72 - 1.64 0.703 0.73 0.38 - 1.39 
SFTPD TC 1.42 1.00 - 2.01 0.048 1.05 0.63 - 1.77 
MetllThr cc 1.67 1.11 - 2.52 0.014 1.75 0.94 - 3.23 
SFTPD AG 1.67 1.04 - 2.69 0.032 1.56 0.77 - 3.17 
Thr160Ala GG 1.76 1.08 - 2.86 0.023 1.89 0.92 - 3.89 


















t Odds ratio compared to wild-type genotype, adjusted for sex, age, pack-years of smoking, FEV1 percent 
predicted. 
Abbreviations: SFTP Surfactant Protein; SNP Single Nucleotide Polymorphism; BHR Bronchial 
Hyperresponsiveness; Eos Eosinophilia; OR Odds Ratio; Cl Confidence Interval 
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Novel strategy to identify genetic risk 
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Genetic determinants for Chronic Obstructive Pulmonary Disease (COPD) are difficult to 
study, since COPD develops at later ages and involves multiple genetic and environmental 
factors. Studies using genetically isolated populations with limited genetic variation may 
be useful in COPD genetics, but are thus far lacking. 
Aim 
To study associations between Single Nucleotide Polymorphisms (SNPs) in candidate 
genes and severity of airway obstruction in COPD in a genetically isolated population, and 
to replicate results in the general population. 
Methods 
We collected spirometry and questionnaire information from 157 subjects with a doctor's 
diagnosed COPD from the Genetic Research in Isolated Population (GRIP) study. We 
analyzed 32 SNPs in 13 candidate genes: ADAM33, TGF61, MMPl, MMP2, MMP9, 
MMP12, TIMPl, SFTPAl, SFTPA2, SFTPB, SFTPD, GSTPl and HMOXl. We analyzed FEV1, 
FVC, and FEVi/FVC levels in COPD patients using restricted maximum likelihood linear 
mixed modeling, accounting for pedigree structure. We replicated significant associations 
in 351 COPD patients selected from the general Vlagtwedde/Vlaardingen study. 
Results 
We studied 106 spirometry confirmed COPD GOLD stage � I subjects, members of an 
extended pedigree including 6,175 people. Seven SNPs in ADAM33, TGFBl, SFTPAl, 
SFTPA2 and SFTPD were significantly associated with FEV1/FVC level. The ADAM33 and 
TGFBl associations with FEV1/FVC were replicated in the Vlagtwedde/Vlaardingen 
population, with similar effect sizes. Allele frequencies were similar in both populations. 
Discussion 
We show for the first time that a genetic isolate can be used to determine genetic risk 




Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide and 
is expected to increase in prevalence in the forthcoming decades 1;2 • The disease has a 
large personal, societal, and economic impact. COPD is characterized by chronic airway 
inflammation, airway remodeling, and airflow limitation that is not fully reversible. Since 
not all smokers develop COPD, genetic susceptibility has to/may play a role in 
development of this disease, in addition to environmental factors. The genetic 
determinants for COPD are difficult to study, since COPD is a disease that becomes 
clinically manifest only at later ages, when parents of COPD patients have already died, 
and their children are likely to young to manifest airway obstruction. This limits the option 
to perform family based genetic research. Moreover, published studies frequently use 
various definitions of disease status, which makes it difficult to compare their results. 
Therefore, it makes sense to choose a robust phenotype to define COPD like the level of 
lung function, which can be more easily compared between studies. Moreover, a low level 
of lung function is a predictor for mortality from COPD 3-5• 
Another complicating factor in studies on genetics of COPD is that COPD is considered a 
complex genetic trait, i.e. multiple, possibly interacting, genetic and environmental factors 
are involved. Therefore it has advantages to try and identify risk genes in populations that 
are relatively genetically and environmentally homogeneous, such as genetically isolated 
populations. Due to the small number of founders and drift in genetically isolated 
populations, the genetic variation is reduced 6• However, these processes raise the 
question whether findings can be extrapolated to the general population. Previous 
simulation studies suggest that this is the case for common variants with a frequency of 
>1% 6, but no empirical evidence is available. 
We conducted a candidate gene study for level of airflow limitation in patients with COPD 
who were ascertained as part of the Genetic Research in Isolated Populations (GRIP) study 
that is conducted in a young genetically isolated population from the southwestern part of 
the Netherlands. All patients were genotyped using 32 Single Nucleotide Polymorphisms 
(SNPs) in 13 candidate genes for COPD, chosen based on their previously published 
association with either COPD, level of lung function, or lung function decline as reported in 
the open population. Extensive genealogy information was collected resulting in an 
extremely large and complex pedigree of 6,175 members. Finally, we studied 1390 
individuals from the general Dutch population, including 351 patients with COPD, to 
establish whether our findings could be replicated in the general population. In both 
studies, we investigated whether the severity of the disease, as reflected by lung function 
reduction is genetically influenced in established COPD. 





Our study is part of the GRIP program 7;8• GRIP is based in a recent genetically isolated 
population from the southwestern of the Netherlands, which was founded in the middle 
of the 18th century by approximately 150 individuals and was genetically isolated until the 
last few decades. The population now includes approximately 20,000 inhabitants in 8 
adjacent communities. GRIP participants are generally related via multiple lines of descent 
and are inbred via multiple consanguineous loops 9;10• 
We invited subjects with general practitioner's diagnosed COPD to the research center to 
undergo spirometry and complete a questionnaire 11• Spirometry was performed by 
trained pulmonary research technicians using a Pneumotagograph (Viasys, formerly Jaeger 
Spirometer system). Predicted values for FEV1 were calculated using adjusted Quanjer­
equations for Caucasian subjects 12• We isolated DNA from blood using Puregene® DNA 
Purification Kits (Gentra, Inc, Minneapolis, USA). All participants gave written informed 
consent. 
To test the findings from GRIP in the general population, we used cross-sectional data 
from the general population-based Vlagtwedde/Vlaardingen cohort. Questionnaires, 
spirometry and DNA were collected 13;14• For this study, we selected 351 subjects 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria with 
GOLD stage � I COPD at the last 1989/1990 survey (table 1) 18• Since we did not collect FVC 
values in the Vlagtwedde/Vlaardingen cohort, we used VC values for the analyses. 
Genotyping 
We have genotyped SNPs in candidate genes for lung function and COPD, based on their 
previously published significant associations (table 2). Genotyping was performed using 
Applied Biosystems TaqMan® SNP Genotyping Assays (Nieuwekerk aan de IJssel, The 
Netherlands). Sequences of primers and probes are available on request. 
Statistical analysis 
To analyze pedigree data, we used Measured Genotype (MG) approach 15, which models 
quantitative traits as 
Y; = µ + kg; + Lf31cji + G; + e; 
j 
where y;: the phenotype of the i-th individual, g: the vector of genotypes at the marker 
under study, k: is the marker genotype effect, cij: the value of the j-th covariate or fixed 
effect for the individual i, Bi: an estimate of the j-th fixed effect or covariate, and G; and e; 
are random additive polygenic and residual effects, respectively. The random effects are 
assumed to follow multivariate normal distribution with mean zero. The variance for the 
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polygenic effects is defined as <l>c;G 
2, where <I> is the relationship matrix and c;G 
2 the 
additive genetic variance due to polygenes. For the residual random effects, the variance 
is defined as lcr/, where I is the identity matrix and cr/ the residual variance. 
Because the pedigree under analyses was very large, we used fast GRAMMAR 
approximation to the full MG approach 16• The GRAMMAR consist of a fast though 
conservative test at screening stage, followed up with full MG analysis of polymorphisms 
which pass the relaxed (P<0.1) screening significance threshold. All analysis involving 
pedigree were performed using ASReml v 2.0 17 - a package for linear mixed model analysis 
using restricted maximum likelihood. 
In the Vlagtwedde/Vlaardingen population, we tested significant associations using linear 
regression analyses. All analyses were adjusted for age, height and sex. 
Table 1: Differences in characteristics of the GRIP and Vlagtwedde study populations 
Data a re presented as median (range). 
Age 65.5 (37-84) 58.0 (35-76) <0.001 66.0 (43-82) 59.0 (35-76) 
Sex m/f, n 53/53 244/107 <0.001 37/30 122/45 
Smoking, 
% Never 3.8 18.8 <0.001 2.9 16.2 
% Ex 34.0 35.9 38.3 33.5 
% Current 58.5 45.3 58.8 50.3 
Pack-years 32.3 (0-120) 21.4 (0-262) 0.002 39.0 (0-120) 26.0 (0-262) 
FEV1 % of 71.2 80.7 0.001 63.9 69.9 
predicted (26.4-132.8) (36.0-115.0) (26.4-79.0) (36.0-79.8) 
FEVJFVC # 57.7 64.9 <0.001 53.1 59.2 
(27.7-69.2) (29.0-69.9) (27.7-68.9) (29.4-69.8) 
Chronic 60.6 14.5 <0.001 60.9 22.2 
cough, % 










*P value for difference between study populations derived from X2-test for comparison of discrete variables; 
Mann-Whitney U test for test between continuous variables 
#In GR IP FEVJFVC was used; in Vlagtwedde/Vlaardingen FEVJVC 
Abbreviations: GRIP Genetic Research in Isolated populations; VlaNla Vlagtwedde/Vlaardingen; GOLD Global 
initiative for Obstructive Lung Diseases; m male; f female; FEV1 Forced Expiratory Volume in 1 second; FVC Forced 
Vital Capacity 
Novel strategy to identify genetic risk factors for COPD severity: genetically isolated 
populations 
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Table 2: Candidate genes and single nucleotide polymorphisms genotyped in the study population 
ADAM33 A Disintegrin And Meta lloprotease 33: exact function unknown; rs17548913 ADAM33F+l 
identified by genome wide screen as susceptibil ity gene for rs17548907 ADAM33Q-1 
asthma; associated with decline in FEV1 and development of COPD rs3918396 ADAM33Sl 





TGF81 Transforming Growth Factor-(31:a chemotactic cytokine for rs1800469 TGFB1C-509T 
fibroblasts, inducing synthesis of matrix proteins and glycoproteins rs1982073 TGFBlleul0Pro 
and inhibiting col lagen degradation by induction of protease rs6957 TGFB13UTR 
inhibitors and reduction of metalloproteases; TGF-(31 levels are 
increased in COPD; SNPs have been associated with COPD 
SFTPA1 Surfactant protein Al: Surfactant proteins (SP) are involved in the rs1059047 SPA1Val19Ala 
first response to microorganisms in the lung, regulation of rs1136450 SPA1Leu50Val 
inflammation and structure of a lveoli . SP reduce surface tension at rs4253527 SPA1Arg219Trp 
the air-liquid interface and therefore prevent alveolar col lapse 
during expiration 
SFTPA2 Surfactant protein A2: idem SP-Al, homologous gene rs1059046 SPA2Asn9Thr, 
rs17886395 SPA2Pro91Ala, 
rs1965707 SPA2Ser140Ser 
SFTPB Surfactant protein 8 :  hydrophobic component of pulmonary rs1130866 SPBlle131Thr 
surfactant 
SFTPD Surfactant protein D:  a C-type lectin present in pulmonary rs721917 SPDMetllThr 
surfactant and several other mucosa( surfaces. It modulates innate rs2243639 SPDThr160Ala 
immunity, al lergic response, expression of matrix 
metal loproteases, a lveolar wall remodeling, emphysema, fibrosis 
and lipid and macrophage homeostasis 
MMP1 Matrix Metalloprotease 1: an interstitial col lagenase involved in rs1799750 MMP1G-1607GG 
tissue remodeling and repair associated with lung development 
and inflammation.  Levels are increased in sputum of COPD patients 
compared to healthy controls. 
MMP2 Matrix Meta l loprotease 2 :  a type IV collagenase specifically rs243865 MMP2C-1306T 
cleaving type IV col lagen, the major structural component of 
basement membranes 
MMP9 Matrix Metalloprotease 9: a gelatinase B involved in tissue rs3918278 mmp9_rs3918278 
remodeling; smokers with airway obstruction show higher MMP9 rs6065912 mmp9_rs6065912 
expression than smokers without COPD and non-smokers rs8113877 mmp9 _rs8113877 
MMP12 Matrix Metal loprotease 12: a human macrophage elastase rs2276109 MMP12A-82G 
involved in degradation of extracellular matrix in lungs of patients rs652438 MMP12Asn357Ser 
with COPD 
TIMP1 Tissue Inhibitor of Matrix Meta lloprotease 1: inhibitor of several rs11551797 timpll le158 
MMPs, including MMPl, MMP9 and MMP12. X-chromosomal rs4898 timp1Phe124 
HMOX1 Hemoxygenase 1: role in oxidant-antioxidant balance in the lung rs2071747 HO1Asp7His 
GSTP1 Glutathione S-transferase Pl:  role in oxidant-antioxidant balance in rs1695 gstpl l le105Val 
the lung rs1138272 gstp1Ala114Val 
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RESULTS 
GRIP study population 
We ascertained 157 individuals who were diagnosed with COPD by their general 
practitioners. Spirometry measures confirmed COPD in 106 subjects, i.e. 36 with COPD 
GOLD stage I (FEV1/FVC<70%), 43 with GOLD stage II (FEV1/FVC <70% and FEV150-80% 
predicted) and 37 with GOLD � Ill (FEV1/FVC<70% and FEV1/FVC<50% predicted) 
18
• Fifty­
one subjects could not be defined as having COPD according to their spirometry (see 
online supplement table El) and were therefore excluded from the analyses. The 
characteristics of the GRIP COPD population are shown in table 1. We determined the 
familial relationship of the 106 subjects with COPD in the larger GRIP study database. This 
resulted in a large extended pedigree structure of 6,175 members. 
Association of genes with lung function parameters 
We analyzed the effects of SNPs in the studied genes on FEV1 % predicted, FVC and 
FEVi/FVC in the 106 subjects with COPD defined as GOLD stage � I. When analyzing 
FEV1/FVC, 7 SNPs located in ADAM33, TGFBl, SFTPAl, SFTPA2 and SFTPD passed the 
screening stage and were followed up using full MG model. This analysis revealed 
significant association between FEVi/FVC and 7 SNPs in genes ADAM33, TGFBl, SFTPAl, 
SFTPA2 and SFTPD (table 3). 
None of the SNPs was associated with FEV1 % predicted or FVC. 
Repl ication of GRIP findings in the Vlagtwedde/Vlaardingen population 
We found no significant associations of any of the SNPs with FEV1/VC or with FEV1% 
predicted within subjects with GOLD stage � I in Vlagtwedde/Vlaardingen. The GRIP COPD 
GOLD stage � I patients were significantly different compared to the 
Vlagtwedde/Vlaardingen COPD GOLD stage � I patients for amongst others age, lung 
function, and smoking history COPD (see table 1). The GRIP COPD patients had more 
severe COPD than the Vlagtwedde/Vlaardingen GOLD stage � I patients. To compare COPD 
populations with more similar phenotypes, we performed additional linear regression 
analyses in the GRIP and the Vlagtwedde/Vlaardingen populations specifically in subjects 
with GOLD stage � II (characteristics, see table 1). We found that in both populations SNPs 
ADAM33 ST +5, TGFBl C-509T and TGFBl LeulOPro were significantly or suggestively 
associated with FEV1/(F)VC (p<0.10, table 3). 




Table 3: Significant associations of SNPs with FEVi/FVC in subjects from the GRIP study with COPD 
GOLD stage � I, and subjects from the Vlagtwedde/Vlaardingen population with COPD GOLD stage 
� I I  Est imates are adjusted for sex, height, age and ped igree structure (a ppl icable in GR IP) 
ADAM33 Wt 15 ref 27 ref 
ST+5 het vs. wt 53 5 .2 2.8 0.070 86 2.9 1.7 0.082 
horn vs. wt 36 5.4 3.0 0.064 51 0.8 1.8 0.668 
TGF61 Wt 46 ref 94 ref 
C-509T het vs. wt 45 -3.7 1.9 0.055 60 -1.3 1.2 0.298 
horn vs. wt 12 -8.0 3.0 0.008 8 -5 .0 2.8 0.070 
TGF61 Wt 35 ref 68 ref 
Leul0Pro het vs. wt 50 -3.6 2.1 0.087 65 -0.8 1.3 0.952 
horn vs. wt 14 -7.1 3.0 0.019 17 -4.5 2.0 0.028 
SFTPA1 Wt 70 ref 12 ref 
Leu50Val het vs. wt 20 -5. 1 2.4 0.033 20 2.7 1.9 0.159 
horn vs. wt 6 6.9 4.1 0.093 11 1.8 2.4 0.474 
SFTPA2 Wt 70 ref 11 ref 
Pro91Ala het vs. wt 32 -1.1 2.1 0.589 41 -1.1 1.4 0.423 
hom vs. wt 3 -12.5 5.6 0.026 3 0.4 4.5 0.923 
SFTPD Wt 40 ref 44 ref 
MetllThr het vs. wt 42 -4.2 2.1 0.048 85 -0.9 1 .4 0.512 
horn vs. wt 20 -5.8 2.7 0.031 31 -0.3 1.8 0.888 
SFTPD Wt 37 ref 54 ref 
Ala160Thr het vs. wt 47 4.3 2.1 0.041 73 2.1 1.4 0.112 
horn vs. wt 16 6.1 3.0 0.042 29 -1.6 1.8 0.376 
* Model of inheritance: general model :  het vs. wt: effect of heterozygous genotype compared to wild type 
genotype; horn vs. wt: effect of homozygous mutant genotype compared to wild type genotype 
Abbreviations: GRIP Genetic Research in Isolated populations; Via/Via Vlagtwedde/Vlaardingen; GOLD Global 
initiative for Obstructive Lung Diseases;ADAM33 A Disintegrin and Metal/oprotease 33; TGF61 Transforming 
Growth Factor 61; SFTP Surfactant Protein; ref reference; se standard error 
DISCUSSION 
Our study is the first to use a genetically isolated population to analyze genetic effects on 
level of lung function in COPD. Interestingly, we found significant effects of SNPs in COPD 
candidate genes on the severity of COPD, assessed by lung function in subjects with COPD 
even though our study population is small. Our results show that levels of FEV1/FVC, a 
measure of airway obstruction, are genetically influenced in established COPD. This means 
that even within patients with phenotypical COPD, we can identify genotypes that are 
associated with severity of the disease. This is of clinical importance since low lung 
function levels have been shown to predict mortality of COPD not only in the general 
population, but also within COPD patients 3-5. 
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The SNPs that were associated with level of FEV1/FVC in the current study have been 
shown to affect severity of COPD in previous studies. The wild type allele of the ADAM33 
ST +5 SNP has been associated with more severe bronchial hyperresponsiveness and more 
inflammation in bronchial biopsies and sputum in another Dutch cohort of patients with 
mild to moderate COPD 19• In patients with severe COPD, the ADAM33 ST +5 wild type 
allele has been associated with excess decline in FEV1 
20
. The current finding that this 
genotype is associated with lower FEV1/FVC levels in patients with COPD complements the 
previous studies, and suggests that the ADAM33 ST +5 SNP is a modifier SNP for COPD 
severity. 
The TGFBl SNPs that were associated with FEV1/FVC in our populations have previously 
been associated with development of COPD or with lower levels of FEV1 and FEV1/FVC in 
several 21-23, but not all previous studies 14;24;25. Our results (in both the genetically isolated 
and general population) thus confirm the former studies that implicate a role of TGF81 in 
the severity of airflow limitation. The associated SFTPAl, SFTPA2 and SFTPD SNPs have 
been associated with COPD previously 26;27. We now for the first time show that these 
SNPs may also play a role in severity of COPD. This is plausible, since surfactant proteins 
decrease surface tension at the air-liquid interface and, therefore, reduce the tendency of 
alveoli to collapse during expiration. The latter contributes to the severity of airway 
obstruction as measured by FEV 1/FVC. 
We found no significant associations of MMPl, MMP2, MMP9, MMP12, TIMPl, SFTPB, 
GSTPl and HMOXl with level of lung function in COPD patients. This does not imply that 
these genes do not play a role in COPD whatsoever. So far, no studies have analyzed 
genetic effects on the severity of airway obstruction within patients with established 
COPD. Our study shows that SNPs in ADAM33, TGF81, SFTPAl, SFTPA2 and SFTPD may be 
important in progression of COPD, whereas the SNPs in other genes, i.e. MMPl, MMP2, 
MMP9, MMP12, TIMPl, GSTPl and HMOXl, may simply constitute genes that are 
important in development of COPD. 
One important advantage of testing genes in a genetically isolated population is that it 
provides the opportunity to find genes associated with disease in a relatively small sample 
size due to increased homogeneity of the population. Thus for a lower cost and effort, one 
can test many genes as to their significance in contributing to disease severity, which 
subsequently can then be replicated in a larger sample of the general population. The 
most important requirement for such studies is that the genetic isolate is representative 
for the general population or disease-specific study populations. This is indeed the case 
since we showed that in selected subjects with COPD from the general population, we can 
replicate the associations found in the young genetic isolate for a substantial part. Thus, 
we are able to translate findings in a genetic isolate to the general population, but correct 
and comparable phenotyping of the study populations is still crucial to replicate 
association between populations. We were unable to replicate results of any of the SNPs 




in subjects with GOLD stage � I from the Vlagtwedde/Vlaardingen population. When 
looking more closely, it appeared that the GRIP COPD patients with GOLD stage � I had 
more severe COPD, i.e. lower lung function and more symptoms, than COPD patients with 
similar stage of disease in the Vlagtwedde/Vlaardingen population (table 1). The most 
important explanation for this difference is that we included COPD patients based on VC 
values in the Vlagtwedde/Vlaardingen population, whereas they were selected on the 
basis of FVC values in GRIP. Due to the maneuver of measurement, a VC is generally larger 
than an FVC and therefore the inclusion based on the cut-off value of FEV1/FVC< 70% 
leads to inclusion of more patients in Vlagtwedde/Vlaardingen. A more strict definition of 
COPD (GOLD stage � II) in Vlagtwedde/Vlaardingen gives a phenotypically better 
comparison between patients in GRIP and Vlagtwedde/Vlaardingen (table 1). Indeed, 
when analyzing subjects with subjects with GOLD � II from Vlagtwedde/Vlaardingen 
population, SNPs ADAM33 ST +5, TGF81 C-509T and TGFB1 LeulOPro were significantly 
associated with FEV1/VC, as they were in the GRIP GOLD � I COPD patients. 
Several explanations may exist for the lack of replication for SFTPA1, SFTPA2 and SFTPD 
SNPs with FEV1/VC in the Vlagtwedde/Vlaardingen COPD GOLD stage � II. First, the 
original GRIP findings on these genes could be false-positive. Indeed, multiple (though 
correlated) outcomes and SNPs were studied in GRIP. Another, more biological 
explanation, for the lack of replication may be that the prevalence of certain alleles in 
genetically isolated populations differs from a general population as a result of genetic 
drift and founder effects. However, genotype frequencies were not statistically different 
between the two populations (see table 4). Yet a third explanation may be that differences 
exist in characteristics between the study populations. The GRIP population had more 
severe COPD and was slightly older than the Vlagtwedde/ Vlaardingen COPD population 
(see table 1). In addition, differences in environment may affect the lack of replication of 
the SFTP genes. The genetically isolated population shares the same environment, similar 
socio-economic status, and the same general practitioners. We cannot rule out that the 
COPD patients in GRIP have a higher prevalence of chronic bronchitis and airway disease 
whereas the airway obstruction in the Vlagtwedde/Vlaardingen population may have been 
caused by emphysema 28-30• Further research is needed to separately assess these 
phenomena, since CT scans are necessary, which we unfortunately do not have of these 
patients. 
In conclusion, this study provides two important messages. Firstly, we found significant 
effects of SNPs on the severity of COPD, i.e. level of lung function in patients with 
established COPD in a relatively small genetically isolated population with a large pedigree 
structure. Secondly, we replicated many of these associations in COPD patients selected 
from the general population on the condition that they were phenotypically similar. These 
findings are important since more severe airway obstruction is associated with 
progression and mortality of COPD. Future studies using this genetic isolate should focus 
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on progression of COPD, since th is popu lation seems to be h ighly usable to determine 
genetic r i sk factors for severity of a i rway obstruction in establ ished COPD that can be 
translated to the genera l  popu lation. 
Table 4: Genotype frequencies of the significant SNPs in the GRIP population GOLD stage � I 
compared to the genotype frequencies in the Vlagtwedde/Vlaardingen population GOLD stage � I 
and comparison of genotype frequencies between GOLD stage � II populations 
ADAM33 AA 15 (14.4) 63 (18.1) 0.682 12 (17.1) 27 (16.5) 0.475 
ST+5 AG 53 (51.0) 171 (49.1) 31 (44.3) 86 (52.4) 
GG 36 (34.6) 114 (32.8) 27 (38.6) 51 (31.1) 
TGFB1 GG 46 (44.7) 187 (54.0) 0.100 30 (42.9) 94 (58.0) 0.049 
C-509T GA 45 (43.7) 137 (39.6) 32 (45.7) 60 (37.0) 
AA 12 (11.6) 22 (6.4) 8 (11.4) 8 (4.9) 
TGFB1 AA 35 (35.4) 131 (40.4) 0.655 23 (34.8) 68 (45.3) 0.341 
Leul0Pro AG so (50.S) 149 (46.0) 35 (53.0) 65 (43.3) 
GG 14 (14.1) 44 (13.6) 8 (12.1) 17 (11.3) 
SFTPA1 GG 70 (72.9) 258 (78.4) 0.513 47 (73.4) 123 (79.9) 0.103 
LeuS0Val GC 20 (20.8) 53 (16.1) 15 (23.4) 20 (13.0) 
cc 6 (6.3) 18 (5.5) 2 (3.1) 11 (7.1) 
SFTPA2 GG 70 (66.6) 250 (72.7) 0.480 45 (64.3) 117 (72.7) 0.328 
Pro91Ala GC 32 (30.5) 87 (25.3) 22 (31.4) 41 (25.S) 
cc 3 (2.9) 7 (2.0) 3 (4.3) 3 (1.9) 
SFTPD TT 40 (39.2) 105 (30.9) 0.229 24 (35.8) 44 (27.5) 0.419 
MetllThr TC 42 (41.2) 170 (50.0) 30 (44.8) 85 53.1) 
cc 20 (19.6) 65 (19.1) 13 (19.4) 31 (19.4) 
SFTPD AA 37 (37.0) 111 (32.9) 0.730 27 (40.3) 54 (34.6) 0.664 
Ala160Thr AG 47 (47.0) 165 (49.0) 30 944.8) 73 (46.8) 
GG 16 (16.0) 61 (18.1) 10 (14.9) 29 (18.6) 
Abbreviations: GRIP Genetic Research in Isolated populations; Via/Via Vlagtwedde/Vlaardingen; GOLD Global 
initiative for Obstructive Lung Diseases;ADAM33 A Disintegrin and Metalloprotease 33; TGFB1 Transforming 
Growth Factor 81; SFTP Surfactant Protein 
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Novel strategy to identify genetic risk factors for COPD severity: 
genetically isolated populations 
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Table El: Characteristics of the GRIP study populations by GOLD staging 
Data a re presented as median (range). 
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Age 65.5 (37-84) 66.0 {43-82) 61.0 (28-83) -- ----- - --
Gender m/f 53/53 37/33 18/33 ---- - -- - ----
Smoking status 
Never smoker, % 3.8 2.9 9.8 
Ex-smoker, % 34.0 37.1 33.3 
Current smoker, % 58.5 57.1 47.1 
Missing smoking history, % 3.8 2.9 9.8 
Pack-years smoking 32.3 (0-120) 39 (0-120) 28 (0-74) 
FEV1 % predicted 71.2 (26.4-132.8) 63.9 (26.4-79.0) 95.2 (64.1-129.3) 
FEVJFVC, % 57.7 (27.7-69.2) 53.1 (27.7-68.9) 76.0 (70.1-90.1) 










Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of morbidity 
and mortality worldwide. Central to the definition of COPD is a reduced level of lung 
function and this provides the most important and robust phenotype of COPD. Smoking is 
the major risk factor for COPD development. However, not all smokers develop COPD, 
indicating a genetic predisposition for this disease. This thesis deals with genetic factors 
influencing COPD development and accelerated decline in lung function in the general 
population, and the severity of the disease in patients with established COPD. 
GENETIC EPIDEMIOLOGY OF LUNG FUNCTION 
In chapter 2, several study designs have been discussed that are being used in genetic 
epidemiology to study genetic determinants of reduced lung function. Family and twin 
studies provided the first evidence for familial aggregation of lung function measures, 
indicating that genetic factors are important for level of lung function. Difficulties in 
obtaining large sample sizes are a problem in this type of study design and especially in 
genetic epidemiology of COPD such studies are difficult to perform due to the late onset 
of disease. Genome wide linkage analysis is an approach to identify which chromosomal 
areas are involved in disease. This method compares the inheritance of disease with 
segregation of genetic markers in families with multiple affected members. If the disease 
is co-inherited with the marker, this suggests that a disease susceptibility gene is located 
close to the marker on that chromosome. Linkage analyses for lung function have 
provided multiple chromosomal regions thus far, but only a few candidate genes have 
been identified. In case-control association studies, a large number of candidate genes, 
chosen for their biological role in the pathogenesis in COPD, have been associated with 
lung function or COPD. However, for every studied gene there is (at least) one study in 
which the results contradict results of other studies. Replication of results in different 
studies is difficult due to population stratification, ethnic differences, and small numbers 
of cases and controls that are usually included in studies. Longitudinal cohort studies that 
evaluate genetic influences on lung function decline in combination with environmental 
factors are important for identifying subjects at risk for COPD. However, since such studies 
are scarce, limited knowledge on the effect of genes on the course of lung function on a 
general population level is available. Studies in isolated populations can be used in genetic 
epidemiology to identify candidate regions in a relatively small population because of their 
decreased genetic heterogeneity, increased linkage disequilibrium and more 
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homogeneous environmental exposures. Studying isolated populations has the advantage 
that data collection for phenotyping (e.g. lung function measurements) and genotyping 
can usually be performed in a logistically small area, with additionally low cost. 
Overall, every type of design has its restrictions, varying e.g. from high cost to relatively 
low costs, and hypothesis-generating to hypothesis-testing. Choices about the most 
appropriate study design, or the population under study are usually made dependent of 
the goal of the study, e.g. whether one sets out to confirm a previously found association 
in a different population, or one searches for new genes or gene-pathways that have not 
been studied so far. 
A DISINTEGRIN AND METALLOPROTEASE 33 
A Disintegrin and Metalloprotease 33 (ADAM33} has been identified by positional cloning 
as a susceptibility gene for asthma, and especially in asthma with bronchial 
hyperresponsiveness (BHR). Single nucleotide polymorphisms (SNPs) in this gene have 
been associated with excess decline in the Forced Expiratory Volume in 1 second (FEV1) in 
asthmatics and with BHR 1. We hypothesized that ADAM33 may not only be associated 
with excess FEV1 decline and BHR in asthmatics, but that it could constitute a broader 
phenomenon that might be observed in the general population and COPD as well. 
Therefore, we performed 3 studies to assess the effect of genetic variation in ADAM33 on 
lung function, COPD and COPD severity. 
In chapter 3, we describe the role of SNPs in ADAM33 on lung function decline in 1,390 
subjects of the Vlagtwedde/Vlaardingen cohort who have been followed up from 1965 
to1990. We analyzed 8 SNPs in ADAM33 and used linear mixed effects models to analyze 
FEV1 decline according to genotype, adjusting for sex, age, first available FEV1 and pack­
years of smoking. The mean unadjusted decline in the cohort was 18.6 ml/per year. 
Individuals homozygous for minor alleles of SNPs 5_2 and Q-1 and heterozygous for SNP 
S_l had a significantly excess decline in FEV1 of respectively 4.9, 9.6 and 3.6 ml/y 
compared to the wild type allele. In addition, we found a significantly higher prevalence of 
the minor alleles of SNPs F+l, S_l, 5_2 and T_2 in subjects with COPD (defined according 
to the Global Initiative for Obstructive Lung Diseases (GOLD) stage � II at the last 2 
surveys) compared to subjects without COPD (respectively 61.3 vs. 53.3%; 22.9 vs. 14.3%; 
51.9 vs. 41.7%; 30.6 vs. 23.6%). 
We conclude that SNPs in ADAM33 are associated with accelerated lung function decline 
in the general population and they also confer a risk to develop COPD. 
Since ADAM33 has previously been associated with BHR in asthma 1•5 and the vast 
majority of COPD patients displays BHR 6, ADAM33 may also play a role in the severity of 
BHR within COPD patients. In chapter 4� we therefore studied the effect of ADAM33 SNPs 
Summary, general discussion ,� future perspectives 191 
on BHR severity and inflammation in sputum and bronchial biopsies in 114 patients with 
mild to moderate COPD (GOLD stages II and Ill) from the GLUCOLD study. COPD patients 
with the ADAM33 ST+S AA genotype had more severe BHR, higher numbers of sputum 
inflammatory cells and higher numbers of CD8+ cells in bronchial biopsies than patients 
with the GG-genotype. CDS+ cell numbers in bronchial biopsies were significantly higher in 
subjects carrying the minor allele of SNP 5_2 or T _2 than those with the wild-type. 
This study shows that ADAM33 plays a role not only in the development of COPD, but also 
affects severity of BHR and inflammation in patients with established COPD. 
As ADAM33 appeared to be associated with phenotypes reflecting COPD severity such as 
BHR -by itself a risk factor for accelerated lung function decline in COPD patients- ADAM33 
SNPs may also play a role in excess FEV1 decline within COPD patients. Hence, we 
investigated ADAM33 SNPs on FEV1 decline in 79 patients with severe COPD with and 
without al-antitrypsin (AAT)-deficiency with longitudinal lung function data prior to lung 
transplantation (LTX) (chapter 5) . AAT-deficiency is a genetic constitution, thought to be 
the main factor for excess lung function decline and development of COPD at a young age 
in carriers of AAT-deficiency, even without cigarette smoking. We found that the ADAM33 
ST+S and T_2 SNPs were associated with excess FEV1 decline, adjusted for sex, AAT­
deficiency, pack-years smoking and baseline FEV1 . Stratified analyses according to AAT­
deficiency showed comparable results. 
This study shows that ADAM33 SNPs are predictive of excess FEV1 decline in severe COPD, 
and interestingly also in patients with accelerated FEV1 loss due to AAT-deficiency. 
It is clear from genetic studies that ADAM33 plays a role in the origin and progression of 
lung diseases. The focus of current studies should lie in gaining knowledge on the function 
of ADAM33 and its role in respiratory disorders. ADAM33 protein and mRNA expression 
has previously been demonstrated in fibroblasts, airway smooth muscle and mesenchymal 
cells from asthmatics and recently to a smaller extent in epithelial cells from both 
asthmatics and controls 7-11• However, so far it has remained unclear if and where 
ADAM33 is expressed in COPD lung tissue. In chapter 5, we have therefore performed 
immunohistochemical staining of ADAM33 on lung tissue of the 79 COPD patients from 
the LTX study, as well as control tissue. We found expression in endothelium, airway 
smooth muscle, alveoli, inflammatory cells and bronchial epithelium, predominantly in the 
basal part of the epithelium, with antibodies directed against the cytoplasmic and catalytic 
domain of ADAM33. There were no differences in level or location of ADAM33 expression 
between tissue samples from control, AAT-deficient and non-AAT-deficient subjects. The 
expression pattern and intensity was similar using the different antibodies. These results 
show that it is not likely a difference in level or location of ADAM33 expression that 
confers a risk for lung disease, but merely a functional change in ADAM33. 
-------------------- -- - -
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MATRIX METALLOPROTEASES, THEIR TISSUE I NHIBITORS AND GENES 
INVOLVED IN TISSUE REPAIR 
A generally accepted underlying mechanism in COPD pathology is a disturbed balance 
between matrix metalloproteinases {MMPs) and Tissue Inhibitors of MMPs (TIMPs) in lung 
tissue of COPD patients, causing degradation of extracellular matrix (ECM). In addition, 
repair of ECM is impaired in COPD tissue, which contributes to accelerated lung function 
decline. These processes of disturbed protease-antiprotease balances and repair may be 
genetically determined due to SNPs in the genes involved in these processes. 
In chapter 6, we assessed the association of SNPs in MMP and TIMP genes with COPD and 
accelerated FEV1 decline in the Vlagtwedde/Vlaardingen cohort. We analyzed SNPs in 
MMP1 (-1607 G/GG), MMP2 (-1306 C/T), MMP9 (3 haplotype tagging SNPs), MMP12 (-82 
A/G and Asn357Ser) and the X-linked geneTIMP1 (Phe124Phe and lle1581 1e). All significant 
associations were repeated in an independent general population cohort, the Doetinchem 
cohort (n=l,152). In the Vlagtwedde/Vlaardingen cohort, MMP2 -1306 TT genotype 
carriers had excess FEV1 decline (-4.0 ml/yr, p=0.03) compared to wild type carriers. TIMP1 
l le1581 1e predicted significant excess FEV1 decline in males and females. TIMPl Phe124Phe 
predicted significant excess FEV1 decline in males only, which was replicated in the 
Doetinchem cohort. The MMP2 and TIMP1 lle1581 1e associations were not replicated. 
This study shows that TIMP1 Phe124Phe contributes to excess FEV1 decline in two 
independent prospective cohorts. Further research is needed to assess the functionality of 
TIMP1 Phel24Phe Genetic variations in MMPs, although they have functional effects on 
MMP expression levels, evidently do not contribute to FEV1 decline in the general 
population. 
Decorin, an ECM proteoglycan, and Transforming Growth Factor-�1 (TGF-�i) are both 
involved in lung ECM turnover. Decorin and TGF-�1 expression are decreased respectively 
increased in COPD lung tissue. Interestingly, they act as each other's feedback regulator, 
as depicted in figure 1 below. 
Figure 1: Loop of a sustained surplus of TGF-81 
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We hypothesized that the reciprocal regulation of the TGF-81 and decorin genes is 
disturbed in COPD due to a genetic mutation in one or both of these genes. In chapter 7, 
we have tested this hypothesis by investigating three SNPs in TGF-81 and five SNPs in 
decorin on the development of COPD and on lung function decline in the 
Vlagtwedde/Vlaardingen cohort. We tested five SNPs in decorin (3'untranslated region 
(UTR) and four intron SNPs) and three SNPs in TGF-81 (3'UTR (rs6957), C-509T (rs1800469) 
and LeulOPro (rs1982073)), and their haplotypes. We found a significantly higher 
prevalence of carriers of the minor allele of the TGF-81 rs6957 SNP (p=0.001) in subjects 
with COPD (GOLD stage � II). Additionally, we found a significantly lower prevalence of the 
haplotype with the major allele of rs6957 and minor alleles for rs1800469 and rs1982073 
SNPs in TGF-81 in subjects with COPD (p=0.030), indicating that this association is due to 
the rs6957 SNP. TGF-81 SNPs were not associated with FEV1 decline. SNPs in decorin, and 
haplotypes constructed of both TGF-81 and decorin SNPs were not associated with 
development of COPD or with FEV1 decline. 
Contrary to our hypothesis, we were not able to identify the decorin gene as a genetic risk 
factor for the development of COPD. Consequently, SNPs in decorin do not seem to 
underlie a disturbed regulation of this gene and TGF-81 resulting in COPD, nor can they be 
held responsible for the development of COPD and decline in FEV1 in the general 
population. We found that TGF-81 SNPs are associated with the development of COPD but 
not with accelerated lung function decline or other lung function measures in the general 
population. Together with previous findings, this study establishes the TGF-81 gene as a 
risk factor for the development of COPD. 
GENES INVOLVED IN OXIDATIVE STRESS 
COPD may develop due to excess oxidants in the lungs that are not properly 
counterbalanced by either exogenous or endogenous antioxidants or antioxidant 
enzymes. This leads to oxidative stress which is associated with inflammation of the 
airways. 
The glutathione system is the major antioxidant system in the lungs that protects the 
lungs against inhaled oxidants. The Glutathion S-Transferase (GST) enzymes are key 
enzymes in this oxidant-antioxidant balance and GSTs can detoxify certain components of 
cigarette smoke. In chapter 8, we analyzed the effect of deletion alleles of GSTMl and 
GSTTl and 2 SNPs (lle105Val and Ala114Val) in GSTPl on the course of lung function and 
COPD development in the Vlagtwedde/Vlaardingen population. We found that subjects 
heterozygous for the GSTTl null allele had a significantly higher risk to develop COPD 
(odds ratio 2.03, p=0.002) and also had significant excess FEV1 decline (-17.3 vs. -20.7 
ml/yr) compared to subjects with the homozygous wild type null allele. Subjects 
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homozygous for the G5TM1 null allele had excess FEV1 decline compared to carriers of at 
least one wild type allele (-16.5 vs. -18.9 ml/yr). Stratified analyses according to smoking 
(never vs. ever) and gender showed a significant association of the G5TM1 null allele with 
excess FEV1 decline in male ever smokers, but not in male never smokers. G5TT1 was 
significantly associated with FEV1 decline in males only, irrespective of smoking. The 
G5TM1 and G5TT1 null alleles were not associated with excess FEV1 decline in females, 
also not when stratified according to smoking. 
In conclusion, the G5TM1 and G5TT1 null alleles confer risk for excess FEV1 decline 
especially in male smokers. The GSTTl null allele additionally confers a risk to develop 
COPD. The G5TP1 SNPs do not appear to be important in lung function decline or COPD 
development in the general population. 
Oxidative stress can be counterbalanced by different mechanisms. Superoxide Dismutases 
(SODs) act in a different pathway than the glutathion system and prevent the elevation of 
oxidative stress by degradation of superoxide anions. In chapter 9, we investigated the 
association of SNPs located in S00-2 and 500-3 with development of bronchial 
hyperresponsiveness (BHR) and COPD, and the longitudinal course of FEV1 over time in the 
Vlagtwedde/Vlaardingen cohort. We genotyped 2 haplotype-tagging SNPs (Ala16Val 
(rs4880) and C7693T (rs2842958)) in 500-2 and 3 nonsynonymous SNPs (Ala40Thr 
(rs2536512), Arg213Gly (rs1799895) and Phe131Cys) in 500-3. The C7693T SNP, located in 
intron 3 of 500-21 was significantly associated with the presence of COPD and BHR 
(defined as PC10 S 8 mg/ml of histamine at the last survey) in the total population. The T/T 
genotype for this SNP and the Val/Val genotype for the 500-2 Ala16Val substitution were 
risk factors for BHR in individuals without COPD. The 500-3 Arg213Gly substitution was 
associated with slower FEV1 decline in never-smokers, e.g. 9.3 ml less decline per year in 
carriers of the Arg/Gly genotype while compared to the wild type. 
We concluded from this study that the two 500-2 SNPs are risk factors for BHR in absence 
of COPD while the 500-2 C7693T SNP is a risk factor for COPD in the total population. 
Finally, the 500-3 Arg213Gly SNP is protective for FEV1 decline in never-smokers. 
GENETIC AND LIPIDOMIC ASSOCIATIONS OF SURFACTANT COMPONENTS WITH 
LUNG FUNCTION 
Pulmonary surfactant functions in the first response to microorganisms in the lung, 
regulation of inflammation and structure of alveoli. It consists of lipids and specific 
surfactant proteins. A dysfunctional surfactant may be involved in COPD development, 
lower lung function, faster lung function decline and related traits. Chapter 10 describes 
our study to determine risk factors for COPD in both the protein and lipid part of the 
pulmonary surfactant. We analyzed the effect of SNPs in the surfactant protein (5FTP) 
-------------------------- - --- -- -
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genes SFTPAl, SFTPA2, SFTPB and SFTPD on l ung function decl i ne, deve lopment of COPD 
and on wel l-known risk factors of COPD, i .e .  BHR and blood eosinophi l ia in the 
Vlagtwedde/Vlaardingen cohort. SNPs SFTPAl LeuS0Va l and SFTPD MetllThr were 
significant predictors of excess FEV1 decl ine and COPD development. SFTPD MetllThr was 
associated with blood eosinophi l ia, a risk factor for accelerated FEV1 decl ine.  
I n  addit ion to the genetic study, we ana lyzed surfactant l ipids and thei r degradation 
products in sputum of 17 ex-smoking COPD patients and 11 ex-smoking healthy controls 
and tested their association with l ung function parameters. COPD patients had 
significantly lower phosphatidylchol ine and h igher lysophosphatidylchol ine levels than 
controls . Accord ingly, phosphatidylchol ine levels were positive ly and 
lysophosphatidylchol ine leve ls were negative ly associated with lung function parameters. 
We thus show for the first time that genetic factors and l ipid composition in surfactant can 
negative ly affect lung function, thereby contributing to COPD development. 
IDENTIFICATION OF GENETIC RISK FACTORS FOR COPD SEVERITY IN A 
GENETICALLY ISOLATED POPULATION 
Genetic determinants for COPD a re d ifficult to study, since COPD deve lops at later ages 
and involves mu ltiple genetic and envi ron mental factors. Stud ies using genetica l ly isolated 
popu lations with l imited genetic va riation may be usefu l in COPD genetics, but are thus far 
lacking. I n  chapter 11, we stud ied the association between SN Ps in cand idate genes for 
COPD and  severity of COPD in a genetica l ly iso lated popu lation .  We col lected spirometry 
and questionnaire information from 157 subjects with a doctor's diagnosed COPD from 
the larger Genetic Research in Isolated Popu lation (GR IP) study. We genotyped SNPs in 13 
candidate genes: ADAM33, TGF-81, MMPl, MMP2, MMP9, MMP12, TIMPl, SFTPAl, 
SFTPA2, SFTPB, SFTPD and GSTPl and studied their associations with FEV1, FVC and 
FEVi/FVC levels within COPD patients. Using spirometry, we confirmed COPD GOLD stage 
� I in 106 subjects, who were members of an extended pedigree inc luding 6, 175 people. 
SNPs in  ADAM33, TGF-81, SFTPAl, SFTPA2 and SFTPD were significantly associated with 
FEVi/Forced Vita l Capacity ( FVC) level .  We repl icated the sign ificant associations from the 
GRIP popu lation in COPD patients selected from the general popu lation of 
Vlagtwedde/Vlaardingen .  We fou nd that the same ADAM33 and TGF-81 SNPs were 
associated with FEV1/FVC in COPD patients from the general popu lation .  In this study, we 
have shown for the first time that a genetic isolate can be used to determine genetic risk 
factors for lung function level, which can be repl icated in COPD patients from an  
independent popu lation .  
MAIN CONCLUSIONS 
The chapters in this thesis describe multiple studies in which many genes and SNPs have 
been tested in different study populations with diverse phenotypes. To make the results 
of this thesis more comprehensible, table 1 presents an overview of all genes and SNP 
studied, the (lack of) associations found, the cohorts in which these associations were 
found and with which phenotype. 
The main conclusions of this thesis are: 
1. ADAM33 SNPs are associated with excess decline in lung function and 
development of COPD in the general population and with severity of COPD in 
patients with established COPD. 
2. The X-chromosomal TIMPl gene is a risk factor for excess FEV1 decline in males in 
two independent cohorts of the general population. 
3. TGF-81 SNPs play a role in development of COPD in the general population, and 
with the severity of airway obstruction in COPD patients. 
4. Null alleles of the antioxidant enzymes GSTMl and GSTTl interact with smoking 
and gender, and affect FEV1 decline in the general population. 
5. SNPs in the antioxidant enzymes SOD-2 and 50D-3 are associated with BH R and 
FEV1 decline in the general population. 
6. Surfactant protein SNPs are associated with FEV1 decline, COPD development, 
and blood eosinophilia in the general population, and with severity of airway 
obstruction in COPD patients. 
7. Surfactant l ipid degradation in sputum is associated with lower lung function. 
8. The SNPs studied in decorin, MMPl, MMP9, MMP12, SFTPB, GSTPl do not 
appear to be important in excess FEV1 decline and COPD development on a 
general population level. 
9. Genetically isolated populations can be used to identify genetic risk factors for 
COPD severity in a relatively small sample size that can be replicated in the 
general population. 
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excess FEV1 decline (Q-1, Sl, S2); 
COPD development (F+l, S2, Tl, T2); 
lower levels of FEVJVC in COPD 
patients GOLD � stage I I  (ST +5) 
severity of inflammation in sputum 
and bronchial biopsies (ST +5, S2, T2); 
severity of BHR (ST+5) 
excess FEV1 decl ine (ST+5) 
lower levels of FEVJFVC in COPD 













excess FEV1 decline in males and 
females (TIMP1Phe124Phe, 
T/MP1l le15811e) 
excess FEV1 decl ine in males 
(TIMP1 Phe124Phe) 
no association 
COPD development (TGFB13UTR); 
lower levels of FEVJVC in COPD 
patients GOLD c!: stage I I  
(TGFB1C-509T, TGF61Leu10Pro) 
lower levels of FEVJFVC in COPD 




GSTP1 rs1695 GSTP1 l le105Val Via/Via no association 
rs1138272 G5TP1Ala114Val GRIP no association 
GSTM1 Nul l  a l le le Via/Via excess FEV1 decline in male smokers 
GSTT1 Nul l  a l lele Via/Via excess FEV1 decline; COPD 
development 
50D-2 rs4880 5OD2Ala 16Va I Via/Via BHR in absence of COPD 
rs2842958 SOD2C7693T (5OD2Ala16Val, SOD2C7693T); 
COPD (5OD2C7693T) 
50D-3 rs2536512 5OD3Ala40Thr Via/Via excess FEV1 decline (5OD3Phe131Cys) 
rs1799895 5OD3Arg213Gly 
5OD3Phe131Cys 
SFTPA1 rs1059047 5FTPA1Val19Ala Via/Via excess FEV1 decline; COPD 
rs1136450 5FTPA1Leu50Val development; blood eosinophi l ia 
rs4253527 5FTPA1Arg219Trp (SFTPA1 LeuS0Val) 
GRIP lower levels of FEVJFVC in COPD 
patients GOLD � stage I 
(SFTPA1 LeuS0Val )  
SFTPA2 rs1059046 5FTPA2Asn9Thr Via/Via COPD development 
rs17886395 5FTPA2Pro91Ala (5FTPA2Pro91Ala) 
rs1965707 SFTPA2Ser140Ser GRIP lower levels of FEVJFVC in COPD 
patients GOLD <?: stage I 
(5FTPA2Pro91Ala) 
SFTPB rs1130866 SFTPBlle131Thr Via/Via no association 
GRIP no association 
SFTPD rs721917 SFTPDMet11Thr Via/Via excess FEV1 decline 
rs2243639 5FTPDThr160Ala (5FTPDMet11Thr); COPD 
development (5FTPDMet11 Thr); 
b lood eosinophil ia (5FTPDMet11Thr, 
5FTPDAla160Thr) 
GRIP lower levels of FEVJFVC in COPD 
patients GOLD � stage I 
(5FTPDMet11Thr, 5FTPDThr160Ala) ----
Abbreviations: SNP Single Nucleotide Polymorphism; Via/Via V/agtwedde/Vlaardingen; GLUCOLD Groningen 
Leiden Universities Corticosteroids in Obstructive Lung Disease; L TX lung transplantation; GRIP Genetic Research 
in Isolated Population; COPD Chronic Obstructive Pulmonary Disease; GOLD Global initiative for Obstructive Lung 
Diseases; FEV1 Forced Expiratory Volume in 1 second; FVC Forced Expiratory Volume; BHR Bronchial 
Hyperresponsiveness 
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Genera l  d iscussion & future perspectives 
INTRODUCTION 
Many people suffer from COPD nowadays, and the disease is expected to increase even 
more worldwide 12 • The ultimate goal of performing genetic research is to find out why 
certain people develop the disease, identify those people and give them appropriate 
treatment at an early stage before the disease has progressed irreversibly. Since the major 
risk factor for COPD development is cigarette smoking, a complete ban on cigarette 
smoking would diminish the incidence of COPD a great deal. Still when cigarettes will be 
banned out completely, millions of people will suffer from cigarette smoke induced COPD 
for the upcoming years since the disease has a slowly progressive course and becomes 
only clinically apparent after many years of smoking and smoking cessation does not 
completely prevent this. Moreover, occupational exposures, environmental cigarette 
smoke and air pollution are responsible for approximately 10% of COPD cases, and with 
the increasing air pollution worldwide this number may grow in the future. Thus, the 
burden of COPD is high now and will remain so in the future decades. Therefore, 
identifying genetic risk factors will remain an important strategy to understand the 
mechanism of disease, and identify subjects who are at particular risk to develop this 
disease and/or are prone to {severe) progression. 
Current standards define COPD by progressive loss of FEV1, and thus longitudinal decline in 
FEV1 will be the primary outcome variable for intervention studies aimed at preventing or 
reducing the loss of pulmonary function. It is therefore of importance to study genetic 
determinants for excess lung function decline as well as COPD development and COPD 
severity 13• 
COPD is considered a complex genetic disease. The results from the studies presented in 
this thesis underline this and furthermore show that lung function level and decline in the 
general population is not influenced by one single gene, but by many genetic factors. We 
show that multiple genes are associated with COPD and with associated phenotypes, such 
as lung function level and decline, BHR and airway inflammation. We have used different 
cohorts to study COPD genetics from multiple points of view: from a general population 
based cohort consisting of respiratory healthy subjects to patients with very severe COPD. 
In addition, we have analyzed gene-environment interactions to assess which subjects are 
at particular risk for excess lung function decline or for development of COPD. The studies 
performed in the Vlagtwedde/Vlaardingen cohort and the different COPD patient 
populations thus provide different information and require different interpretations. 
Although it may seem to complicate matters to obtain associations with so many different 
phenotypes, the outcomes of these studies do supplement each other and provide a full 
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representation of how a gene may affect different aspects of COPD development and 
severity. Future studies should continue to take advantage of the possibilities these study 
populations provide. Therefore, in the following paragraphs, we will discuss some 
limitations of our studies and provide recommendations for future research in genetics of 
COPD. 
USE OF DIFFERENT COHORTS AND INTERPRETATION OF RESULTS 
General population 
The majority of research described in this thesis has been carried out in the longitudinal 
general population based Vlagtwedde/Vlaardingen cohort, and thereby distinguishes itself 
from most other research in genetics of lung function. Case-control studies are generally 
used in genetic studies of COPD, and in these studies, COPD has already developed 
without acknowledging how the disease has evolved into clinically manifest disease. Other 
studies used selections from the general population with a specific phenotype or 
exposition, i.e. smokers with either a fast versus no decline in lung function, without 
phenotypic COPD 14-16• Our studies in a longitudinal population-based cohort are 
particularly useful in that they allow determining which genetic risk factors are important 
in an early stage of lung function loss before clinical symptoms appear. In addition, they 
provide information that is applicable to the whole general population independent of 
disease. Moreover, our results may be used in an even broader perspective, since a low 
lung function is not only an important predictor for COPD development and progression, 
but also for cardiovascular diseases 17-20. Recently, funding has been granted to study 
mortality within the participants of the Vlagtwedde/ Vlaardingen cohort. These mortality 
data are currently being collected, and it will be interesting to analyze genetic variation on 
the course of lung function, development of COPD and their relation to cause of mortality. 
In the studies in Vlagtwedde/Vlaardingen population, we have merely looked at 
association of SNPs with excess decline in FEV1. There are however other mechanisms that 
may lead to lung function impairment and COPD development, i.e. reduced maximal 
attained level of lung function, or abnormal early age of onset of (excess) lung function 
decline. Already in utero, altered branching of bronchi may take place, leading to impaired 
lung function in childhood. It has already been shown that some genes are associated with 
lung function in childhood in interaction with pre- or post natal smoke exposure, such as 
GSTMl and ADAM33 21-23. Interesting future perspectives are to analyze whether SNPs 
affect more specifically these mechanisms in the general population. For such studies we 
need larger study populations with multiple lung function measurements from birth until 
the age where maximal attained lung function is reached (at approximately 35 years). 
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COPD patient studies 
In the COPD patient populations, we have studied the genetic determinants of severity of 
lung function impairment rather than genetic determinants of initiation of lung function 
impairment. The genetics of COPD susceptibility and COPD severity may be different. 
Some genes may only contribute to disease susceptibility and other genes may contribute 
to disease severity, whereas again a third group of genes contribute to both. We have 
shown that some genes were indeed involved in the development of COPD or excess lung 
function decline in the general population, like SFTPA SFTPD and TIMPl, whereas 
ADAM33 and TGF-61 were associated with features of lung function both in the general 
population and in COPD patient cohorts, thus in both disease development and disease 
progression. Another interesting finding presented in this thesis is that we have shown 
that SNPs in ADAM33 may affect lung function decline even in the presence of AAT­
deficiency. It is generally accepted that AAT-deficiency is the main underlying genetic 
cause of rapid FEV1 decline in early onset COPD, but we show that other genetic factors 
may additionally play a role. Recently, another study has also shown that SNPs in 
lnterleukin-10 increase the risk for lower lung function, independent of AAT-deficiency 24• 
It is important to determine whether polymorphisms are associated with COPD severity 
and progression, because it may help to target more aggressive and effective therapeutic 
approaches to groups with specific genetic background in the future. 
ASSOCIATION WITH DIFFERENT PHENOTYPES 
Lung function level and decline 
ADAM33 is the most thoroughly investigated gene in this thesis, and SNPs in this gene 
have been associated with multiple clinical and immunological phenotypes in different 
study populations. We therefore hypothesize that the ADAM33 gene may be a gene that 
affects lung function decline irrespective of disease, and that it modifies the severity of 
disease in established COPD as shown by lower lung function levels, faster FEV1 decline, 
and more severe BHR and inflammation in COPD patients. Carriers of one or more 
ADAM33 SNPs may develop different types of respiratory disease dependent on 
environmental factors and other genetic risk factors. 
The TGF-61 3'UTR SNP was associated with COPD development, whereas the LeulOPro 
and C-509T SNPs in the same gene are associated with lower levels of FEV1/VC in subjects 
with COPD from both the GRIP and Vlagtwedde/Vlaardingen population. This indicates 
again that it may well be that certain SNPs are only important in COPD development, 
whereas other SNPs are important in progression of the disease. 
The importance of correct phenotyping has been shown in chapter 11 in which we could 
only replicate associations from the genetically isolated population in the general 
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population of Vlagtwedde/Vlaardingen when we compared COPD patients with similar 
disease severity. Even when using an objective measure like lung function, it is important 
to carefully select patient groups with similar disease severity when comparing them. 
Definition of COPD 
We have defined COPD according to the internationally used GOLD criteria 25• A current 
debate is ongoing whether these definitions are correct since they are based on a fixed 
ratio of the post-bronchodilator FEVi/FVC of 0.70 as a threshold. The choice for this 
threshold was a pragmatic one, based on the desire for simplicity, as perception of the 
complexity of spirometry and its interpretation has been one of the barriers to more 
widespread uptake of this clinical tool. A clinical diagnosis of COPD requires a history of 
chronic progressive symptoms, which are corroborated by abnormalities found on 
physical examination and a consideration of risk factors. However, objective evidence of 
airway obstruction determined by forced expiratory spirometry is the standard for 
demonstrating and quantifying airway obstruction 25. Since the FEV1/FVC ratio declines 
with age, using the fixed ratio to define COPD may over-diagnose COPD in older 
populations. Following the same rationale, the fixed ratio potentially under-diagnoses 
COPD in younger adults 26-28• A recent American Thoracic Society and European 
Respiratory Society joint Task Force report recommends using a lower limit of normal 
(LLN) FEV1/FVC as opposed to a fixed ratio of <0.70 to diagnose airway obstruction, in 
order to reduce false positive diagnoses of COPD as defined by the GOLD criteria. Yet, the 
GOLD criteria may prove to be valuable since in a longitudinal study subjects classified as 
"normal" using the LLN but abnormal when using the fixed ratio were more likely to die 
and to have a COPD-related hospitalization during follow-up. This suggests that a fixed 
FEVi/FVC ratio of <0.70 may identify at-risk patients, even among older adults 
29
• In the 
Vlagtwedde/Vlaardingen cohort, we have potentially overestimated the number of COPD 
cases by using the GOLD criteria. It would be worthwhile to take into account different 
definitions of COPD in future studies, and moreover to focus on phenotypes that are 
unquestionably valuable like levels of crude lung function and decline in lung function. 
COPD occurs in different morphological subtypes. Some patients develop more airway 
obstruction, without emphysema, whereas others develop more small airways disease, or 
a combination of these two phenomena. The severity of emphysema varies widely even in 
patients with the same stage of COPD, and chronic bronchitis symptoms are equally 
distributed irrespective of emphysema severity 30• Evidence of emphysema has been 
documented on CT scan images, even in subjects who have no airway obstruction as 
assessed by spirometry 31;32• Abnormalities in FEV1 have been associated with basal­
predominant emphysema 33• In addition to different COPD subtypes, there exist different 
morphologies between male and female COPD patients. As visible on CT-scans, males 
develop more regional and total emphysema and females more airways disease on all 
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stages of COPD severity 34;35 • These differences in phenotypes and between gender may 
have a genetic background as already demonstrated by Demeo et al 36• The usage of CT 
scans should be incorporated in new studies on genetics of COPD. 
Bronchial hyperresponsiveness (BHR) 
BHR is defined as an exaggerated airway response to non-specific stimuli resulting in 
airway obstruction. BHR is a known risk factor for COPD development 37;38 and a majority 
of COPD patients demonstrates BHR 6;39• The genetics of BHR is difficult to perform and is 
not very well described in existing literature in the context of the general population, and 
even less well in the context of COPD. The major problem in studying BHR is that it often 
co-occurs with other phenotypes like lower lung function, which makes it difficult to 
disentangle whether a SNP is associated with BHR or the co-occurring phenotype. In 
chapter 9 we therefore used multinomial regression to analyze whether SOD SNPs were 
associated with pure BHR, pure COPD, or a combination of the two phenotypes. These 
analyses showed that the pure phenotype BHR was associated with the 500-2 Ala16Val 
substitution and the 500-2 C7693T SNP with BHR with co-occurring COPD. This type of 
analyses is difficult to perform since large sample sizes are needed to obtain sufficiently 
large groups for comparisons. 
In the GLUCOLD study, we determined that the A0AM33 ST +5 SNP was associated with 
severity of BHR. Interestingly, A0AM33 has originally been identified as a candidate gene 
for asthma, but the linkage reached the highest significance when including BHR in the 
asthma phenotype in the populations under study 1. We did not find association of this 
gene with BHR in the general population (unpublished data). Our studies thus suggest that 
A0AM33 is a gene that affects BHR severity in patients with existing COPD. 
Markers of inflammation 
In the GLUCOLD population, we had the unique opportunity to directly link genes to 
inflammation in sputum and bronchial biopsies. In the general population it would, apart 
from ethical aspects, not be feasible to perform biopsies and sputum induction on a large 
scale. On a population level, it would therefore be interesting to find systemic biomarkers 
in blood that reflect the inflammatory patterns in the lung. C reactive protein (CRP) is a 
marker of systemic inflammation and is associated with reduced FEV1 and a predictor of 
accelerated decline in FEV1 
40
. Moreover, CRP is a strong and independent predictor of 
future COPD outcomes in individuals with airway obstruction 41• A study by Hersh et al. 
has shown a significant genetic influence on CRP levels in COPD with a heritability of 0.25 
42• Genome-wide linkage analysis demonstrated no significant linkage of CRP to any 
chromosomal region, but revealed several potentially interesting chromosomal regions of 
borderline significance. A short tandem repeat marker near the 5FTPB gene was 
significantly associated with CRP levels. In another study, surfactant protein D has recently 
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been identified as a serum marker for FEV1 change and change in health status as 
reflected by CRQ scores 43• It is yet unknown if genetic variation in SFTPD gene has an 
effect on serum levels of surfactant protein D. 
Currently, more studies are ongoing to identify new serum biomarkers for COPD with 
promising results 44;45• In future studies in the general population as well as in COPD 
patient cohorts, such serum biomarkers should be collected and used to determine the 
effect of genetic variation on levels of these markers. 
SELECTION OF GENES AND POLYMORPHISMS 
In our studies, we have investigated genes that had either previously been associated with 
COPD or phenotypes closely related to this disease or the genes had a biologically 
plausible role in COPD pathogenesis. The genotyped SNPs were consistently chosen based 
on data present in previous literature. This causes a deficiency in our studies, since these 
SNPs do not cover all the genetic variation in the gene, and hence we can miss 
associations or cannot pinpoint to the causal genetic variation. The way genes are 
analyzed nowadays is by using data from the Hapmap program, which has been 
introduced in 2003 and is updated regularly 46;47• The recent update of the Hapmap 
database (Phase II) contains more than 3.1 million genetic variations, and maps 
approximately 1 SNP per 1000 basepairs in the genome 48• The more precise the genomic 
map is the more precise genetic loci for disease can be identified. The Hapmap database 
not only shows the genetic variation, but also shows how strong the linkage disequilibrium 
(LD) is between SNPs. Many SNPs are inherited together in haplotype blocks and with a 
limited number of SNPs (so-called 'haplotype tagging SNPs') we can thus cover all genetic 
variation of a particular gene or chromosomal regions. In this thesis we have used the 
haplotype tagging SNP approach for MMP9 and decorin, and we found no significant 
associations with these SNPs, indicating that these genes do not play a role in lung 
function decline and COPD development. However, we did find significant association with 
candidate SNPs for COPD selected based on previous literature (i.e. in ADAM33, TGF-61, 
MMP2, TIMP1, SFTPA, SFTPD). We cannot be sure though that these SNPs are the true 
causative SNPs for the associated phenotype, or that they represent association of a 
nearby SNP in LD with the associated SNP. In case of the association of ADAM33 it is 
known that there exists a strong LD within the gene, but the LD is also extended around 
the gene 49• Therefore, it is possible that we are analyzing completely the wrong gene, 
even though ADAM33 is one of the most reproduced genes in genetics of lung diseases. 
In addition to the improvement in availability of genetic information, genotyping 
techniques have advanced and have become easier and in its applicability and are offered 
at lower costs nowadays, which makes it also economically feasible to study more SNPs in 
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practice. H igh throughput SNP genotyping has become ava i lab le by DNA micro a rrays from 
Affymetrix, bead array technology from l l l umina and matrix assisted laser 
desorption/ion ization-of fl ight mass spectrometry (MALDI-TOF) .  Such advances in genetic 
research have it made possible to perform whole genome association studies using panels 
of 300,000 or more SNPs across the genome to cover 90% or more of al l  genetic va riation 
of the genome. The costs for such screens have dropped to a few hundred Euros per 
sample and are becoming more and more affordable for a larger number of resea rch 
groups. Since large sample sizes are requ i red for genome wide association stud ies, 
international col laborations are formed to pool phenotypic a nd genotypic data from 
affected patients and controls. In these pooled datasets, one should be aware of 
population stratification due to d ifferences in genetic make-up  between popu lations 50;51• 
A very interesting futu re perspective is performing a genome wide association ana lysis for 
l ung function leve l and decl ine in the Vlagtwedde/Vlaard ingen cohort. In addition, this 
provides us with the un ique opportun ity to assess genome wide association for BHR and 
eosinophi l ia, both r isk factors for development of COPD, and to assess gene-smoking 
interactions. 
STATISTICAL ISSUES 
As a l ready mentioned in a previous paragraph, developments in genetic resea rch have 
taken a fast track. La rge sca le genotyping possib i l ities make it possible to inc lude larger 
sample s izes for genetic association studies .  With the avai lab i l ity of large databases with 
genetic i nformation, new techniques m ust be incorporated to adequately ana lyze the 
data . 
False positive associations 
The chance of finding associations due to chance becomes greater when mu lt ip le 
comparisons are made by testing association of many SNPs with different outcomes. The 
best test to prove that an association is true is repl ication of the effect in an  independent 
cohort. The Vlagtwedde/Vlaardingen cohort is un ique in its size and the time of fol low-up, 
and therefore it is d ifficult to find a su itable repl ication cohort. The Doetinchem cohort is 
pa rtly su itable, but the fol low-up period is much shorter (approximately 5 years) and there 
a re on ly 2 measu rement of lung function, a lthough data from a th ird cross-sectional 
su rvey in the Doetinchem study wi l l  fol low soon .  Nevertheless, these are low numbers of 
l ung function measurements at su rveys compared to the med ian of 7 we have from the 
Vlagtwedde/Vlaard ingen participants. This makes the Doetinchem cohort less powerfu l to 
detect smal l  genetic effects. However, if the associations a re repl icated in both cohorts, it 
is very l i kely a true effect. Since the Doetinchem cohort just recently became avai lab le as a 
repl ication cohort, we have tested on ly a few SNPs that were significant in our  other 
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studies, for replication. Out of 5 SNPs that showed significant associations with lung 
function parameters in our previous studies, we could only replicate one significant 
association (TIMPl Phe124Phe). Since replication is increasingly becoming the golden 
standard in genetic epidemiology, we are indebted to continue with replication of 
significant associations in both cohorts. Lack of replication may be due to an initially false 
positive association, or may be the result of differences in study design, i.e. case 
definition, control selection, sample size, or population specific genetic or environmental 
specific modifiers 52-55• Another strong warranty for successful replication is the need for 
large populations to ensure sufficient power to detect relatively small genetic effects 56• 
Another strategy to deal with potential false positive associations is multiple testing 
corrections. Since SNPs in a gene are correlated and often phenotypes are related as well, 
a Bonferroni correction may be too rigid. Alternatively, in some of our studies, we used 
permutation testing and bootstrapping to generate a distribution of the beta-estimates 
under the null hypothesis. If the observed estimate occurs in less than 5% of the empiric 
cumulative distribution (p=0.05), one can assume that the observed beta-estimate is not 
found due to chance. In our studies, these types of methods confirmed the significant 
associations. 
Haplotype ana lyses 
Haplotypes are arrangements of alleles on the same chromosome inherited as a unit. In 
family based research, the precise combination of alleles in a haplotype can be 
determined using inheritance information of parent to child. In studies based on unrelated 
individuals, the parental origin of each allele is unknown and therefore the haplotypes for 
double heterozygous alleles must be estimated. There are several online tools available 
now to analyze haplotype associations with dichotomous outcomes, such as Merlin, 
Haploview, and Chaplin 57-62• Most programs use similar modifications of the maximum 
likelihood method. Caution must be taken, however, to the proper use of these programs, 
since the slight differences in the way these programs estimate haplotype frequencies and 
differ in testing for associations may subsequently lead to different outcomes in different 
studies. 
Haplotype analyses with quantitative traits was until recently not possible, but there are 
now available since a short period of time 63;64• In these types of analyses, haplotype 
frequencies are estimated in the total population and an estimated chance per haplotype 
is established per subject in the dataset. These estimated chances can be used in the 
standard association analyses for quantitative traits. In our studies, we have not yet 
performed such analyses, but merely constructed phased multi-locus genotypes and 
tested for associations with quantitative phenotypes. In future studies the new techniques 
of using estimated haplotype frequencies should be incorporated. 
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Gene-environment interactions 
Environmenta l factors may cause residual confounding and cloud genetic effects or 
obscure true associations. The envi ronmental factor ciga rette smoking plays a major role 
in COPD pathogenesis, and may in  pa rticu lar influence genetic factors l ike antioxidant 
genes. If subjects a re not exposed to substances that induce oxidative stress, genetic 
va riants will not be important in onset of the disease, u nder  study compared to subjects 
with the sa me genetic make-up but with such exposures. A good example for such a 
phenomenon is the outcome of our own study in chapter 8. We observed that the effects 
of the GSTMl and GSTTl nu l l  a l le les were particu larly associated in male smokers. If we 
had not ana lyzed interaction of the genes with smoking we would not be ab le to identify 
subjects at risk .  
Simi larly, other  environmental factors may cloud the genetic effects, or  may obscure the 
populations at pa rticu lar risk. Recently, Harber et al. showed that occupationa l  exposu re 
to fumes is a risk factor for lower annua l  lung function levels in ea rly COPD 65• This 
increased risk may be associated, and possib ly partia l ly be exp lained, by genetic 
susceptibi l ity to the noxious effects of exposure to fumes. I n  our chapter on GSTs we a lso 
addressed the effects of exogenous intake of antioxida nt intake such as vitamin C. We 
unfortunately do not have information on dieta ry intake in the Vlagtwedde/Vlaa rdingen 
cohort. An interesting future perspective is that we have extensive data on d iet via food 
questionna ires in the Doetinchem cohort. This makes th is cohort suitab le to assess 
interaction of genes and diet (and smoking) on the course of l ung function prospective ly. 
Another option is to perform stratified ana lyses or select study populations with s imi lar 
environmental exposu res 66• 
Gene-gene interactions 
SNPs in a gene may modify the action of SNPs in other genes that act in the same 
pathway. This phenomenon is known as epistasis. Such gene-gene interaction effects may 
enhance the r isk for a particu lar phenotype in  an additive o r  even multipl icative way, or 
may neutra l ize the negative effect of one SNP by the positive effect of another SNP 67 • 
Epistasis may p lay a major role in complex genetic d iseases, s ince many genes a re involved 
and it is therefore important to test for gene-gene interaction .  However, large sample 
s izes with sufficient power a re requ i red to detect such gene-gene interactions, and 
appropriate soph isticated statistical methods, l ike the m u ltifactor dimensiona l ity 
reduction (MDR) method, a re warranted to detect gene-gene interactions or gene­
environment interactions 68-70• Thus far, we have assessed gene-gene interactions 
between decorin and TGF-81 and add itive effects of the combination of ca rrying GSTMl 
and GSTTl nu l l  a l le les. These ana lyses did not provide sign ificant resu lts. However, we 
cannot exc lude that the lack of association may have been caused by insuffic ient power. 
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FUNCTIONAL EFFECTS OF POLYMORPHISMS 
The first step that needs to be made after a SNP has been proven to be associated with a 
certain phenotype in multiple independent studies is to analyze the functional effects of 
SNPs. The function of promoter SNPs is probably the most easy to determine as they may 
affect transcription levels of the gene. There are tools on the internet to analyze whether 
DNA sequences harbor transcription factor binding sites, and whether they are modified 
by SNPs or microsatellites in the promoter region. If this is theoretically the case, further 
experiments using for example luciferase assays may prove the effect in an in vitro assay. 
The final step is to assess whether in vivo such effects are observed as well, indicated in 
COPD for example by higher levels of the protein product in sputum. The TGF-81 C-509T 
SNP has proven to affect transcription levels of TGF-81 and also higher levels of TGF-�1 
have been found in sputum from COPD patients. It is, however, still unclear if the 
increased TGF-�1 levels in sputum are related to SNPs in the gene. 
Specific types of polymorphisms that often occur in promoter regions are microsatellites. 
These polymorphisms are repetitive sequences in the DNA and may affect transcription 
levels as suggested for example for the microsatellite polymorphisms in the 
hemeoxygenase-1 gene in susceptibility for emphysema 71• We have not studied 
microsatellites thus far in the Vlagtwedde/Vlaardingen cohort, but they may be studied in 
the future. 
SNPs that are located in exons may change the amino acid sequence of a gene and can 
thereby modify the protein structure. This may alter the function of the protein directly, 
for example by altering the affinity of the protein to bind to its substrates. An amino acid 
change may also indirectly modify protein function, by altering the three dimensional 
folding of the protein. The advances in analyzing the functional effects of SNPs in the 
context of COPD are scarce. Some of the SNPs described in this thesis have been proven to 
have functional effects: TGF-81 Leul0Pro, GSTPl l lel0SVal, SFTPD MetllThr 72-78• The 
same phenomenon applies for coding SNPs as for the promoter SNPs: studies on their 
functional relevance have been performed in in vitro systems, and the functional 
relevance has not been examined in humans with a direct link of SNP and effect, in COPD 
pathogenesis. 
The function of non coding SNPs is difficult to comprehend, since they do not change the 
amino acid sequence and a direct effect on protein structure cannot be determined. 
However, a recent study in cardiovascular disease reported the first functional effect of a 
non coding polymorphism in the 3'UTR of a gene 79• A polymorphism in the angiotensin II 
type 1 receptor (+1166 A/C) caused a decreased affinity of the RNA product with a specific 
microRNA (miRNA: miR-155). miRNAs are noncoding RNAs that silence gene expression by 
base-pairing with complementary sequences in the 3'UTR region of target RNAs. When the 
+1166 C-allele is present, base-pairing complementarity is interrupted, and the ability of 
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miR-155 to interact with the cis-regulatory site is decreased. As a resu lt, miR-155 no 
longer attenuates translation as efficiently as with the A a l lele. The identification of such 
epi-genetic mechanisms is very compl icated and the resea rch is time consuming, but it 
shows that all genetic variations, and not just the easily comprehensible ones, deserve 
fu rther investigation. 
The th i rd type of SNPs that a re described i n  this thesis a re the SNPs located in intrans. 
Si nce intrans are non cod ing gene regions, the effect of SNPs located in  these regions is 
difficu lt to establ ish. Recently, an intron SNP in ADAM33 has been described to influence 
expression of ADAM33 80• The a l le le that was associated with increased risk of asthma had 
a repressive effect on the promoter resulting in no detection of ADAM33 protein product. 
As a consequence, SNP BC+l may have an important role in the modu lation of ADAM33 
gene expression. We d id not genotype this SNP in  our population, and th is should be 
performed in futu re studies on ADAM33. 
Another suggested effect of intron SNPs is a lternative spl icing of genes, which is an 
efficient means of generating va riation in protei n  function. Hu l l  et al. suggested that 
phenotypic va riation in  spl ic ing patterns is determined by the presence of SNPs with in  
fla nking intrans or exons. Effects on sp l icing may represent an important mechanism by 
which SNPs influence gene function 81 . The intron SNPs that we have studied in this thesis 
(among others in decorin and ADAM33) do not possess functiona l  effects, as fa r as we a re 
aware of. 
F ina l ly, deletion polymorph isms may play a role i n  d isease. The deletion a l leles of GSTMl 
a nd GSTTl cause enzymatic deficiencies and therefore have an  obvious effect on onset of 
d isease. However, such large deletions do not occur very frequently and  wi l l  not play a big 
role in  complex genetic d isorders. 
USE OF GENETIC RISK FACTORS IN CLINICAL PRACTICE 
It is of interest to know who is at risk for a d isease by means of ana lyzing the genetic 
make-up in  the future, which makes it possible to intervene at an ea rly stage of d isease. 
Another intriguing opportun ity of knowing genetic risk factors is using specific medication 
ta rgeted to solving deficits or excess expression of certa in protei ns due to genetic 
va riat ion. One could th ink of supplements of antioxidant substances in case of a lack of 
a ntioxidant enzyme activity due to GSTMl de letion a l le les, or supplying meta l loprotease 
i nh ibitors in case of excess MMP  expression .  SNPs may a lso a lter the responsiveness to 
medication. Coding SNPs in the �-adrenergic receptor have been shown to a lter 
responsiveness to steroids i n  asthma and in COPD 82• Such pharmacogenetic approaches 
may hopeful ly prove to be feasible in treatment of COPD patients 83• 
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FUTURE STUDIES 
In the previous paragraphs several issues have been discussed that could be improved, or 
that are currently lacking, in genetic studies in COPD. In already existing cohorts, l ike the 
Vlagtwedde/Vlaardingen cohort for which data collection has stopped, we can only 
improve the method for analyzing the data and the choice of SNPs that are to be 
genotyped. In new to set-up studies, we should include, if financially possible, CT scans to 
disentangle the different subtypes of COPD. Currently lacking aspects in COPD genetics are 
a genome wide association of lung function level and decline in the general population, as 
well as mRNA profiles and proteomic profiles of subjects from the general population to 
identify new candidate genes for COPD. As previously stressed, it is important to identify 
genes that play a role in COPD development before the disease has become clinically 
manifest. Therefore such studies should be performed in a population with diverse, yet 
clearly defined, phenotypes and environmental exposures. 
A diagram reflecting a potential study design is depicted in Figure 2. The diagram shows 
the starting point of collecting materials and data from COPD patients and subjects form 
the general population, such as exhaled breath condensate blood, DNA, sputum, lung and 
airway wall tissue, lung function data and CT-scans. These materials can be analyzed in 
whole genome association studies, mRNA profiling and proteomic analysis for novel 
genetic risk factors and biomarkers for COPD. Subsequently, the identified candidate 
genes and SNPs should ideally be replicated in multiple populations with similar power to 
detect the associations. In the next stage, the functionality of the replicated genes and 
SNPs should be assessed using both in vitro en in vivo models. In the last stage, it may be 
possible to develop genetic and proteomic risk profiles for subjects at risk to develop 
COPD or within patients with COPD, who are at risk to develop a more severe outcome of 
COPD. 
An intriguing example of such a study, integrating data from genome wide association and 
mRNA data is the international multi-centre COPACETIC study (COPD Pathology: 
Addressing Critical gaps, Early Treatment & diagnosis and Innovative Concepts). This study 
will be performed in, among others, the University Medical Center Groningen. A genome 
wide association study will be performed on 4000 Dutch subjects with CT scans and lung 
function measurements (the NELSON study), and the 400 SNPs with the highest 
significance will be replicated in 5 populations, including the Vlagtwedde/Vlaardingen 
cohort. In addition, mRNA samples from subjects who are at high risk to develop COPD will 
be collected to discover molecular pathways. These pathways will be integrated with the 
significant SNPs from the genomic study. Using the information from these extended 
datasets, prediction models can be built to assess the capability to estimate the chance to 
develop COPD using both genomic and mRNA data. Moreover it allows assessing genetic 
profiles for specific types of COPD, i.e. (small) airway disease and emphysema. 
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Figure 2: Flowchart of how future genetic studies for COPD may be set up, and to 
which purposes they can lead. 
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IN LEIDING 
Bij vrijwel ieder mens neemt de longfunctie met het ouder worden af, gemiddeld met 30 
ml per jaar. Mensen die roken hebben vaak een versnelde achteruitgang van de 
longfunctie wat aanleiding kan geven tot klachten van de luchtwegen en longziekte. Een 
van de ziekten die kan ontstaan door roken is Chronic Obstructive Pulmonary Disease 
(COPD). COPD is de verzamelnaam voor chronische bronchitis en longemfyseem, 
aandoeningen die warden gekarakteriseerd door luchtwegobstructie, luchtwegontsteking 
en afbraak van longweefsel. Bij chronische bronchitis zijn er meer slijmproducerende 
cellen, waardoor er meer slijm in de luchtwegen komt en mensen benauwd worden en 
moeten hoesten. Bij emfyseem vindt afbraak plaats van de longblaasjes, zodat er minder 
zuurstof uit de ingeademde lucht kan worden opgenomen door het lichaam. Dit leidt tot 
kortademigheid en in ernstige gevallen van COPD moeten patienten extra zuurstof 
toegediend krijgen. Veel COPD patienten hebben zowel kenmerken van chronische 
bronchitis als van longemfyseem. Ongeveer 10% van de Nederlandse bevolking leidt aan 
COPD. De ziekte is chronisch en er zijn tot op heden nog geen goede medicijnen om de 
ziekte tot stilstand te kunnen brengen. 
KARAKTERISERING VAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Een groot deel van de diagnose van COPD wordt gebaseerd op basis van longfunctietesten 
(spirometrie). Bij deze testen worden onder meer het totale longvolume en de maximale 
hoeveelheid uitgeademde lucht in 1 seconde gemeten, respectievelijk de vitale capaciteit 
(VC) en het Forced Expiratory Volume in 1 seconde (FEV1). De inhoud van de longen kan 
ook geschat worden op basis van wat normaal is gegeven de leeftijd, lengte en het 
geslacht van een individu. Hoe verder de geblazen waarden afwijken van deze normaal­
waarden, hoe ernstiger de COPD. Een indeling voor de ernst van COPD die wereldwijd veel 
gebruikt wordt is de zogenaamde GOLD indeling (Global Initiative for Obstructive Lung 
Diseases). Er bestaan 4 stadia, gebaseerd op de waarde van de FEV1 en de VC (tabel 1). 
I: Mi ld COPD 
I I :  Matig COPD 
I l l :  Ernstig COPD 
IV:  Zeer ernstig COPD 
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• FEVJFVC < 70% 
• FEV1 .!: 80% voorspeld 
• FEV JFVC < 70% 
• 50% s FEV1 < 80% voorspeld 
• FEVJFVC < 70% 
• 30% s FEV1 < 50% voorspeld 
• FEV JFVC < 70% 
• FEV1 < 30% voorspeld of FEV1 < 50% voorspeld plus chronisch 
respiratoir falen 
RISICOFACTOREN VOOR COPD 
Roken is vaak de belangrijkste oorzaak van COPD, hoewel niet iedere roker COPD 
ontwikkelt. In het bevolkingsonderzoek van Vlagtwedde/Vlaardingen, waarin mensen 
gedurende 30 jaar zijn vervolgd, bleken er naast roken nog een aantal andere 
risicofactoren te bestaan voor COPD. Mensen die hyperreactief zijn hebben bij inademen 
van prikkels als kou en mist luchtwegvernauwing en klachten als hoesten en 
benauwdheid. Deze mensen hebben een snellere achteruitgang van de longfunctie. 
Daarnaast hebben mensen met een hoger aantal eosinofiele cellen in het bloed en een 
verhoogd totaal serum lgE een toegenomen achteruitgang. 
Uit de literatuur lijkt de hoogte van de longfunctie ook genetisch bepaald te zijn. Bij 
eeneiige tweelingen die roken blijkt de afname van de longfunctie vergelijkbaar te zijn, 
maar dat is minder het geval bij twee-eiige tweelingen die roken. Bovendien komt in 
families van COPD patienten vaker COPD voor. Dat wijst erop dat er een erfelijke 
component aanwezig is. Vaak wordt genetisch onderzoek, om genen op te sporen die 
betrokken zijn bij een ziekte, verricht in families. Dat is bij COPD echter moeilijk omdat 
deze longaandoening meestal pas op middelbare leeftijd tot uiting komt, wanneer de 
ouders van de persoon met COPD vaak al zijn overleden. 
GENETICA 
De genetische informatie van ieder organisme, ook wel het genoom genoemd, ligt 
opgeslagen in de chromosomen. Het humane genoom bestaat uit 23 paren van 
chromosomen, waarvan 1 paar de geslachtschromosomen zijn (X en Y). Chromosomen zijn 
opgebouwd uit DNA. Het DNA molecuul bestaat uit twee koordachtige strengen, lijkend 
op een ladder, die om elkaar heen zijn gedraaid. Deze structuur wordt ook wel de dubbele 
helix genoemd. DNA is opgebouwd uit 4 verschillende nucleotiden: Adenine, Cytosine, 
Thymine en Guanine, afgekort tot A, C, T, G. Deze komen altijd in paren voor op 
tegenovergestelde strengen DNA: A+ T en C+G. 
Een enkele streng van DNA bestaat dus uit deze 4 letters: 
ATGCTCGAATAAATGATTTGA 
Deze letters maken woorden van drie nucleotiden die ieder coderen voor een aminozuur: 
ATG CTC GAA TAA ATG ATT TGA 
Een combinatie van deze woorden (aminozuren) vormen zinnen, de genen: 
<ATG CTC GAA TAA> <ATG ATT TGA> 
Aminozuren zijn de bouwstenen van eiwitten, en genen bevatten dus de informatie hoe 
eiwitten geproduceerd moeten warden. Eiwitten zijn nodig voor de structuur, functie, en 
regulering van de cellen, weefsels en organen van het lichaam. 
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Een mutatie of polymorfisme is een verandering in  het DNA in  de chromosomen.  
Polymorfismen zijn  veel voorkomende veranderingen in de volgorde van het DNA, die bij 
tenminste 1% van de a lgemene bevolking voorkomen. Een zogeheten mutatie komt in 
minder dan 1% van de a lgemene bevolking voor. De meeste va riatie in DNA in neutraa l, 
dat wil zeggen dat het geen negatieve of positieve consequenties heeft voor de functie 
van eiwitten, cel len of organen .  Het kan echter voorkomen dat een verandering in een gen 
resu lteert in een verandering van een eiwit, zodat dit een andere werki ng heeft of n iet 
meer functioneert. Dergel ij ke variaties kunnen bijdragen aan de ontwikkel ing van ziekte, 
de ernst van ziekte, of hoe het l ichaam reageert op medicatie. 
Van elk chromosoom hebben we er twee: 1 overgeerfd van de vader en 1 van de moeder. 
Het is dus mogelij k  dat we van een polymorfisme op een chromosoom de normale va riant 
hebben (het 'wi ld type'), en op de andere de mutatie. Dit noemen we heterozygoot. Als 
we op beide chromosomen de mutante vorm dragen, noemen we dit een homozygote 
variant. 
DOEL VAN HET ONDERZOEK IN DIT PROEFSCHRIFT 
Wij wi l len in het hu id ige onderzoek vastste l len of genetisch factoren het longfunctie­
beloop tijdens het leven bepalen. Dit kan u iteinde l ijk tot COPD aanleiding geven .  Wij 
hebben de un ieke mogel ij kheid om DNA te ana lyseren van deelnemers aan het 
Vlagtwedde/Vlaa rd ingen onderzoek die 25 jaar vervolgd zijn  en waarbij gegevens zijn 
verzameld zoals longfunctiemetingen, vragen l ijsten met betrekking tot luchtwegklachten 
en rookgewoonten .  Dit maakt dat wij grote groepen personen kunnen vergel ijken met 
snel le of langzame achteruitgang in de longfunctie in relatie tot genetische en reeds 
bekende risicofactoren .  We hebben onderzocht of polymorfismen in  genen relevant zijn 
bij het ontstaan van COPD en de ernst van COPD. Hiertoe hebben we naast het 
Vlagtwedde/Vlaardingen cohort nog 3 groepen COPD patienten onderzocht. In tabel 1 
staan de onderzoekspopu laties weergegeven met hun belangrijkste ken merken.  
--- -- -- - ----- -- -
label 1: Studie populaties beschreven in dit proefschrift -------------===------, 
Selectie Algemene Algemene COPD patienten COPD patienten COPD patienten 
criteria bevolking bevolking GOLD stadium � II GOLD stadium � I l l  GOLD stadium � I 
die een L TX hebben van een genetisch 
ondergaan isolaat 
Aantal 1390 1152 114 79 106 
Type Longitudinale Longitudinale Cross-sectionele Longitudinale long - Cross-sectionele 
data longfunctie longfunctie data van functiedata longfunctie data 
data, BHR, data en inflammatie in verkregen voor L TX in een genetisch 
bloed eosino- klachten sputum, bloed en van patienten met ge ·soleerde 
filie en klachten gedurende 5 bronchiale en zonder al-anti- popu latie met 
gedurende 25 jaar biopten, BHR, trypsine deficientie genea logie data 
jaar longfunctie 
Afkortingen: GLUCOLD Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease; LTX long 
transplantatie; GRIP Genetic Research in Isolated Populations; COPD Chronic Obstructive Pulmonary Disease; 
GOLD Global initiative for Obstructive Lung Diseases; BHR Bronchiole Hyperreactiviteit 
GENETISCHE EPIDEMIOLOGIE VAN LONGFUNCTIE 
Er bestaan verschillende methoden om de genetische achtergrond van een ziekte te 
bestuderen. Hoofdstuk 2 van dit proefschrift beschrijft een aantal veel gebruikte 
technieken in de genetica van longziekten. In familie- en tweelingonderzoek wordt 
onderzocht of er clustering is van een bepaalde ziekte in families of tussen tweelingen. Zo 
blijkt de hoogte van de longfunctie meer gelijk te zijn in een-ei·ge tweelingen (die 100% 
gelijk DNA hebben) dan in twee-ei ·ge tweelingen (die voor 50% hetzelfde DNA hebben). In 
'genomewide linkage analysis' wordt bepaald we Ike delen van de chromosomen 
betrokken zijn bij het ontstaan van de ziekte. In de chromosomen bevinden zich kleine 
stukjes DNA die als 'marker' kunnen dienen. Als meerdere familieleden met ziekte steeds 
dezelfde marker hebben overgeerfd is dit een indicatie dat in de buurt van die marker zich 
een ziekteveroorzakend gen bevindt. In het onderzoek naar de erfelijkheid van longfunctie 
zijn al een aantal chromosomale gebieden gevonden die te maken hebben met de hoagte 
van de langfunctie, maar de causale genen zijn nag niet ge ·t:1entificeerd. 
De meeste studies in genetische epidemialagie warden uitgevoerd in een 'case-control' 
opzet. Hierbij warden genen onderzacht die op basis van hun biologische functie een rol 
zouden kunnen spelen in het ontstaan van ziekte ('kandidaat-genen' ) . Er wardt dan 
onderzocht of een bepaalde variant van een gen vaker voorkomt bij mensen met de ziekte 
dan bij mensen zonder de ziekte. Het is vaak moeilijk om exact dezelfde resultaten van 
dergelijke studies in andere populaties te vinden, omdat de ziekte verschillend 
gedefinieerd wordt, er etnische verschillen zijn, of omdat de anderzoekspopulaties te klein 
zijn. 
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I n  /ongitudinale cohort studies van de a lgemene bevolking is het mogel ijk  om genetische 
effecten op te sporen d ie betrokken z ijn  bij een verlaagde longfunctie voordat k l in isch 
relevante ziekte is ontstaan.  Helaas zijn dergel ijke stud ies erg duur  omdat veel personen 
moeten warden onderzocht en de stud ies l ang duren.  
Een genetisch geisoleerde popu/atie i s  gesticht door een beperkt aanta l voorvaders, en 
waarbij bovendien wein ig u itwissel ing is geweest met andere popu laties in  de loop der 
tijd .  H ierdoor is de genetische d iversiteit beperkt en kunnen bepaalde 
ziekteveroorzakende mutaties vaker voorkomen dan in  een genetisch d iverse popu latie. 
Dit maakt genetisch ge ·r;oleerde populaties geschikt om in  een relatief kleine opzet toch 
ziektegeassocieerde genen op te sporen .  
DE R0L VAN P0LYM0RFISMEN IN ADAM33 BIJ DALING VAN L0NGFUNCTIE IN 
DE ALGEMENE BEV0LKING EN ERNST VAN ZIEKTE BINNEN COPD PATIENTEN 
In 2003 is een gen gevonden via 'genome wide l inkage ana lyse' dat een sterke associatie 
had met astma. U it nader onderzoek in G ron ingen, bleek dat d it gen, genaamd ADAM33 
(A Disintegrin And Metal/oprotease 33} geassocieerd is met een versnelde 
longfunctiedal ing in  astmapatienten .  Naar aan leid ing van d it resu ltaat veronderstelden we 
dat dit gen oak betrokken kon zijn  bij versne lde achteru itgang van longfunctie in de 
a lgemene bevolking. I n  hoofdstuk 3, hebben we de rol onderzocht van 8 polymorfismen in 
ADAM33 in de Vlagtwedde/Vlaard ingen bevolking. De da l ing in longfunctie voor de gehele 
popu latie was gemiddeld 19 .2  m l/jaar. Orie van de onderzochte polymorfismen bleken 
geassocieerd te zij n  met versnelde achteru itgang van longfunctie (namel ijk  Q-1, S1 en S2} ; 
dragers van 1 bepaald polymorfisme (Q-1} hadden een 9 .6  m l  snel lere da l ing van 
longfunctie per jaa r dan dragers van de wi ld type va riant. Oak b leken 4 polymorfismen 
(F+l, Sl, S2 en T2} vaker voor te komen b ij personen met COPD dan bij personen zonder 
COPD. U it d it onderzoek bl ijkt ADAM33 n iet a I leen een rol  te spelen in de ontwikkel ing van 
astma, maar ook in het verloop van longfunctie in de a lgemene bevolking en de 
ontwikke l ing van COPD. 
Vervolgens hebben we onderzocht of genetische variatie i n  ADAM33 oak geassocieerd is 
met de ernst van COPD binnen patienten met COPD (hoofdstuk 4}. We hebben 111 
patienten met een mi ld  tot matig ernstige vorm van COPD u it de GLUCOLD stud ie 
gegenotypeerd met 8 SNPs van ADAM33. Met l inea i re regressiemodel len hebben we 
gekeken of SNPs geassocieerd waren met bronchiale hyperreactiviteit en 
ontstekingsce l len in sputum en weefselbiopten van de l uchtwegwand. We vonden een 
associatie van 1 SNP (ST +5} met zowel minder ernstige hyperreactiviteit, minder cel len in 
sputum en minder CD8+ cel len (een bepaa ld  type immuuncel} in biopten. Ook waren twee 
andere SNPs geassocieerd met minder  ontstekingscel len in biopten .  Deze stud ie laat zien 
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dat SNPs in ADAM33 ook betrokken zijn bij de ernst van COPD en het ontstekingsproces 
dat betrokken is bij het ontstaan van COPD. 
al-Antitrypsinedeficientie is een aangeboren afwijking die kan leiden tot de ontwikkeling 
van COPD op jonge leeftijd zonder dat de patient gerookt hoeft te hebben. Mensen met 
al-antitrypsine deficientie hebben vanaf de geboorte een tekort aan het eiwit al­
antitrypsine, dat nodig is voor de bescherming van de longen tegen afbraak van 
longweefsel. 
We hebben de rol van ADAM33 bestudeerd in 79 patienten met ernstig COPD, met en 
zonder al-antitrypsinedeficientie, die een longtransplantatie hebben moeten ondergaan 
vanwege de ernst van hun COPD (hoofdstuk 5). We hebben longitudinale data van 79 
patienten teruggevraagd en uiteindelijk longfunctiegegevens van gemiddeld 5 jaar voor 
hun transplantatie verkregen (6 longfunctiemetingen, 42 personen met al­
antitrypsinedeficientie). Van deze patienten hebben we DNA ge ·5oleerd uit bevroren 
longweefsel. We hebben SNPs in ADAM33 gegenotypeerd in deze patienten en 
geanalyseerd of er een associatie was met daling in FEV1 . We stelden vast dat 2 SNPs 
(ST+S en T_2) geassocieerd waren met extra daling in FEV1, onafhankelijk van al­
antitrypsinedeficientie. Deze resultaten laten voor het eerst zien dat genetische factoren 
anders dan al-antitrypsinedeficientie, en onafhankelijk van het effect van al­
antitrypsinedeficientie, kunnen bijdragen aan versnelde longfunctiedaling bij COPD 
patienten. Nader onderzoek naar die genetische factoren zou kunnen resulteren in het 
vinden van aangrijpingspunten voor andere dan tot nu toe in Nederland gebruikelijke 
behandelingen voor patienten met al-antitrypsinedeficientie. 
Omdat de functie van ADAM33 nog niet bekend is, en ook niet bekend is welke cellen 
ADAM33 tot expressie brengen, hebben we de expressie van ADAM33 bepaald in 
longweefsel van deze patienten met behulp van immunohistochemie (hoofdstuk 5). 
Hierbij wordt longweefsel ge ·ncubeerd met een eiwit dat specifiek ADAM33 herkent (een 
antilichaam). Dit antilichaam wordt vervolgens voorzien van een label, waardoor onder de 
microscoop zichtbaar wordt waar het eiwit (en dus ADAM33) zich bevindt. Met deze 
techniek hebben we sterke ADAM33 expressie in endotheel, spierweefsel, mesenchymale 
cellen en epitheel gevonden. Er waren geen verschillen in expressie tussen patienten met 
en zonder al-antitrypsinedeficientie, of tussen COPD en controle longweefsel. Aangezien 
de mate en locatie van expressie gelijk was tussen de patienten konden we niet 
analyseren of de expressie verschillend was tussen patienten met verschillende genetische 
varianten. 
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GENEN BETROKKEN BIJ AFBRAAK EN HERSTEL VAN LONGWEEFSEL IN COPD 
COPD is geka rakteriseerd door l uchtwegobstructie, chron ische inflammatie van de 
luchtwegen en afbraak van longweefsel .  Matrix Meta l loproteases (MMPs) zijn  enzymen 
die eiwitten kunnen knippen en betrokken zijn  bij de normaal voorkomende repa ratie van 
weefsel . U it de l iteratuu r  is bekend dat deze M MPs verhoogd aanwezig zijn  in de longen 
van emfyseempatienten en betrokken zij n bij de afbraak van longweefsel i n  deze 
patienten. Verder is gebleken dat SNPs in een aantal van deze MMPs geassocieerd zijn  
met da l ing i n  longfunctie. De Tissue Inh ibitors van Meta l loproteases (TIM Ps) z ijn de 
natuurl ijke remmers van M M Ps en kunnen de afbraak  van longweefsel tegengaan .  Een 
van de heersende hypotheses over de ontwikke l ing van COPD is dat de balans tussen 
MMPs en Tl M Ps n iet goed geregu leerd is in COPD. Dit zou mogelijk een genetische 
achtergrond kunnen hebben. In hoofdstuk 6 hebben we onderzocht of SNPs in MMPl, 
MMP2, MMP9, MMP12 en TIMPl geassocieerd waren met ontwikkel ing van COPD en 
jaa rlijkse da l ing in FEV1 in het Vlagtwedde/ Vlaard ingen cohort. Aangezien TIMPl op het X­
chromosoom l igt, hebben we mannen en vrouwen apart geana lyseerd; vrouwen dragen 
immers 2 kopieen van het gen en mannen 1 .  We vonden dat de TIMPl l le158Va l SNP 
vaker voorkwam bij vrouwen met COPD dan bij vrouwen zonder COPD. Ook was deze SN P 
geassocieerd met snel lere da l ing in FEV1 bij zowel mannen a ls  vrouwen. De TIMPl SNP 
Phe124Phe was a l leen bij mannen significant geassocieerd met snel lere FEV1 dal ing. De 
MMPl en MMP12 SNPs waren n iet geassocieerd met COPD of met longitudina le da l ing in  
FEV1 . We hebben vervolgens in een ander cohort van de a lgemene bevolking (het 
Doetinchem cohort) gekeken of de significante SNPs oak in een onafhankel ij ke a lgemene 
populatie geassocieerd waren met COPD en extra longfunctieverlies. Het bleek dat a l leen 
de TIMPl Phe124Phe SNP geassocieerd was met longfunctieachteruitgang bij mannen. De 
andere twee associaties waren n iet significant in het Doetinchem cohort, wat erop kan 
duiden dat het een foutpositieve bevinding was. Echter, het is ook mogel ijk  dat de 
associaties n iet konden warden gerepl iceerd door het feit dat de power om in  het 
Doetinchem cohort significante associaties te vinden k le iner is dan in het 
Vlagtwedde/Vlaard ingen cohort. 
N iet a l leen de afbraak van longweefsel kan van belang zijn in het ontstaan van COPD, 
maar ook een defect in het herstel van longweefsel . Een belangrijk  gen h ierbij is 
transforming growth factor-Bl (TGF-81 ) doordat het veel stoffen kan aantrekken die het 
beschadigde longweefsel herste l len . Een eiwit dat de functie van TGF-�1 kan remmen is 
decorine. Decorine expressie wordt vice versa gereguleerd door TGF-�1 .  U it eerder 
onderzoek is gebleken dat TGF-�1 verhoogd en decorine verlaagd tot expressie komt in 
bronchia le biopten van patienten met ernstig emfyseem .  Het l ijkt erop dat de balans 
tussen TGF-�1 en decorine verstoord is in COPD. Omdat het mogel ij k  is dat deze 
verstoorde balans veroorzaakt wordt door polymorfismen in TGF-61 en/of decorine, 
hebben we 3 SNPs in TGF-81 en 4 SNPs in decorine onderzocht in het 
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Vlagtwedde/Vlaardingen cohort (hoofdstuk 7). 1 SNP in TGF-81 (gelokaliseerd in de 3'UTR) 
kwam vaker voor bij mensen met COPD en een combinatie van twee SNPs (een 
zogenaamd haplotype) van twee andere SNPs in TGF-81 (C-509T en LeulOPro) kwam 
significant minder vaak voor bij mensen met COPD. Decorine SNPs waren niet 
geassocieerd met ontwikkeling van COPD. We hebben ook geanalyseerd of SNPs in TGF-81 
en decorine geassocieerd waren met extra daling in FEV1 in de gehele populatie, maar we 
vonden geen associaties. 
EFFECT VAN POLYMORFISMEN IN ANTIOXIDANT ENZYMEN OP 
LONGFUNCTIEVERLIES EN ONTWIKKELING VAN COPD EN BHR 
Sigarettenrook bevat veel zuurstofradicalen (oxidanten) die schadelijk zijn voor de 
luchtwegen en longen, en een ontstekingsreactie veroorzaken. Doordat de immuuncellen 
die hierdoor aangetrokken worden ook zuurstofradicalen produceren, ontstaat een 
situatie van chronische oxidatieve stress en ontsteking. De chronische ontsteking kan 
zorgen voor beschadiging van de longen, en bijdragen aan de ontwikkeling van COPD. In 
hoofdstuk 8 en 9 hebben we onderzocht of genen die betrokken zijn in de reactie van 
lichaam tegen oxidatieve stress betrokken zijn bij de ontwikkeling van COPD. 
Hoofdstuk 8 beschrijft de studie naar de zogeheten glutathion s-transferases (GSTs). 
Glutathion is een klein molecuul dat erg veel voorkomt in de longen en vrije radicalen kan 
neutraliseren. De GSTs zijn enzymen die ervoor zorgen dat glutathion ook kan binden aan 
grotere toxische stoffen in sigarettenrook. Er bestaan verschillende GST enzymen, 
waarvan wij GSTPl, GSTMl en GSTTl hebben onderzocht. Van de GSTTl en GSTMl genen 
bestaan twee bijzondere polymorfismen, namelijk deletie polymorfismen, wat betekent 
dat een deel van het gen uit het DNA is verdwenen, en het enzym dus ook niet gevormd 
kan worden. In GSTPl hebben we twee SNPs onderzocht. Het bleek dat zowel de deleties 
van GSTMl als GSTTl geassocieerd waren met verlies van longfunctie in de 
Vlagtwedde/Vlaardingen populatie. Omdat deze genen vooral betrokken zijn bij de 
neutralisatie van oxidanten in sigarettenrook, hebben we de genen verder onderzocht in 
rokers en niet-rokers apart. Het bleek dat rokers meer schade ondervonden van het 
verlies van deze enzymen dan niet-rokers, wat zich uitte in een groter longfunctieverlies 
bij rokers met de deletie dan rokers zonder de deletie polymorfismen. De SNPs in GSTPl 
waren niet geassocieerd met ontwikkeling van COPD en versnelde longfunctiedaling. Deze 
studie heeft laten zien dat een deficientie in enzymen betrokken bij neutralisatie van 
oxidanten in sigarettenrook een belangrijke bijdrage zou kunnen vormen bij de 
ontwikkeling van COPD bij rokers. 
Er zijn meerdere enzymen betrokken bij het tegengaan van oxidatieve stress. De 
Superoxide Dismutases (SODs) neutraliseren zuurstofradicalen en verlagen daarmee de 
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oxidatieve stress. We hebben in hoofdstuk 9 het effect van SN Ps in  500-2 en 500-3 
geana lyseerd op het verloop van longfunctie en de ontwikke l ing van COPD. Aangezien 
oxidatieve stress ook een rol spelt in de ontwikkel ing van bronchia le hyperreactiviteit 
( BHR) hebben we tevens geana lyseerd of deze SNPs ook gerelateerd waren aan de 
ontwikkel ing van BHR in het Vlagtwedde/Vlaardingen cohort. De 5OO-2C7693T SNP was 
sign ificant geassocieerd met de ontwikke l ing van zowel COPD als BHR in de gehele 
bevolking. Aangezien COPD en BHR sterk gecorreleerde fenotypes zijn hebben we groepen 
gemaakt van COPD+/BHR\ COPD+/BH R-, COP□-/BHR- en COPD-/BHR+ personen. In  deze 
groepen hebben we geanalyseerd of de SNPs geassocieerd waren met ofwel COPD of BHR. 
Deze ana lyses l ieten zien dat de 500-2 C7693T SN P en de 500-2 Ala 16Va l SNP 
geassocieerd waren met BHR in personen zonder COPD. De 500-3 Arg213Gly SNP was 
geassocieerd met een langzamere da l ing in longfunctie in nooit rokers. Deze studie heeft 
aangetoond dat genetische va riatie in 500 genen een belangrijke risicofactor zijn voor het 
ontstaan van COPD, en dat ze tevens belangrijk zijn  in de ontwikke l ing van BHR in de 
a lgemene bevol king. 
VERANDERING IN SURFACTANT GENEN EN SURFACTANT LIPIDESAMENSTELLING 
IN ONTWIKKELING VAN CQPD EN DALING VAN DE LONGFUNCTIE 
Surfactant prote ·nen (SFTP) spelen een rol in behoud van de structuur  van de longblaasjes, 
in de eerste respons van het immuunsysteem op pathogenen en in regu latie van 
infl ammatie in de longen.  Een aanta l polymorfismen in deze genen bleken in eerdere 
stud ies geassocieerd te z ijn met hogere preva lentie van COPD. Wij hebben in hoofdstuk 10 
onderzocht of polymorfismen in 5FTPA1, 5FTPA2, 5FTPB en 5FTP0 ook betrokken zijn  bij 
versnelde achteru itgang in longfunctie. We vonden dat personen die heterozygoot zijn 
voor  de 5FTP0 MetllThr SNP vaker COPD hadden en ook een snel lere achteru itgang 
hadden van de longfunctie (2,9 ml/jaar extra) vergeleken met personen met het wildtype 
genotype. Binnen personen met COPD daa lden heterozygoten voor de SFTPAl LeuS0Val 
SNP  11,6 m l/jaar minder hard dan personen met het wildtype genotype en deze hadden 
ook significant minder vaak  COPD. Dit geeft aan dat SNPs in SFTPAl mogelijk  slechts een 
functioneel effect kunnen hebben a ls  er a l  een inflammatoir m i l ieu is in de longen, zoa ls 
bij COPD patienten het geva l is. 
Longsu rfactant bestaat n iet a l leen u it eiwitten maar voor het grootste gedee lte uit vetten 
( l ip iden) .  Om te onderzoeken of een verandering in samenstel l ing van deze l ipiden ook 
samenhangt met de hoogte van de longfunctie en de ontwikkel ing van COPD hebben we 
sputum van COPD patienten en gezonde controles met e lkaar vergeleken .  De COPD 
patienten hadden meer gedegradeerde l ipiden in hun sputum dan de controles. De 
hoeveelheid gedegradeerde lipiden was ook significant gecorreleerd met de hoogte van 
de longfunctie. 
Uit deze studie is gebleken dat genetische variatie in surfactant genen bij zouden kunnen 
dragen aan de ontwikkeling van COPD, maar dat tevens de lipide samenstelling van belang 
is voor de hoogte van de longfunctie en ontwikkeling van COPD. Aangezien de groep met 
bekende lipidesamenstelling klein was, hebben we de relatie van genetische variatie en 
lipidesamenstelling niet kunnen onderzoeken. Dit is van belang voor vervolgonderzoek. 




COPD wordt beschouwd als genetisch complexe ziekte, wat inhoudt dat er meerdere 
genen en omgevingsfactoren betrokken zijn bij het ontstaan van de ziekte. Het kan 
daarom nuttig zijn om ziektegenen op te sporen in een populatie waarin de genetische 
variatie en diversiteit in omgevingsfactoren beperkter is dan in de algemene populatie. 
Een genetisch ge ·soleerde populatie is hiervoor erg geschikt. De GRIP (Genetic Research in 
Isolated Populations) populatie is gelegen in het zuidwesten van Nederland bij de 
gemeente Rucphen. Deze populatie is gesticht rond het midden van de 18e eeuw door 
ongeveer 150 personen en vrijwel ge ·soleerd gebleven tot een aantal decennia geleden. 
De populatie bestaat momenteel uit ongeveer 20,000 inwoners en van deze mensen is 
zeer gedetailleerd de familiegeschiedenis beschreven. Het is bekend dat veel inwoners 
verwant zijn via meerdere bloedlijnen en er bestaat een hoge mate van inteelt. Dit maakt 
dat de genetische diversiteit beperkt is en dus geschikt zou kunnen zijn voor genetisch 
onderzoek. 
Voor het onderzoek beschreven in hoofdstuk 11, hebben we via de huisartsen van de 
gemeente Rucphen patienten met een doktersdiagnose COPD gevraagd naar het 
onderzoekscentrum te komen om een longfunctietest te ondergaan, een vragenlijst te 
beantwoorden en bleed af te geven voor DNA isolatie. Dit resulteerde in een 
onderzoeksgroep van 111 personen met een matig tot ernstige vorm van COPD. 
Vervolgens hebben we SNPs in genen geselecteerd die in eerdere studies betrokken 
bleken te zijn bij de ontwikkeling van COPD, en gegenotypeerd in deze populatie. 
Het bleek dat een aantal van deze genen, namelijk ADAM33, TGF-61, SFTPA1 en SFTPD, 
geassocieerd waren met een lagere longfunctie bij patienten met COPD. Omdat het door 
het isolement mogelijk is dat de onderzochte populatie genetisch gezien afwijkt van de 
algemene populatie, hebben we 351 personen geselecteerd uit het 
Vlagtwedde/Vlaardingen cohort met een gelijke ernst van COPD. Vervolgens hebben we 
geanalyseerd of de significant geassocieerde genen ook in dit replicatiecohort 
geassocieerd waren met longfunctie. Dit bleek zo te zijn voor ADAM33 en TGF-61, maar 
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niet voor SFTPAl en SFTPD. Deze laatste twee associaties zouden dus toeva lsbevindingen 
kunnen zij n .  Deze studie laat ons zien dat genetisch ge ·15oleerde popu latie van G RIP  
gebru ikt kan worden om in een re latief kleine onderzoekspopu latie genen op te  sporen 
die geassocieerd zijn met de ernst van COPD. 
BELANGRIJKSTE CONCLUSIES VAN DIT PROEFSCHRIFT 
Onze resu ltaten hebben laten zien dat genetische factoren geassocieerd zijn  met de 
ontwikke l ing van COPD en de ernst van deze ziekte. Aangezien er nog steeds geen goede 
medicatie is voor COPD patienten zijn stud ies zoa ls door ons u itgevoerd belangrijk om het 
mechanisme achter het ontstaan van COPD beter in kaart te brengen en wel l icht om 
nieuwe therapieen te ontwikkelen. 
De belangrijkste conclusies van d it poefschrift zij n :  
1 .  Het ADAM33 gen speelt een rol i n  de  ontwikke l ing van COPD en  versnelde 
longfunctiedal ing in de a lgemene popu latie, en  is geassocieerd met de ernst van 
COPD 
2.  Genetische variatie in de proteases MMPl, MMP2, MMP9 en MMP12 draagt n iet 
b ij tot een verminderde longfunctie, genetische variatie in de remmer van deze 
proteases, TIMPl, echter wel 
3. TGF-81 is geassocieerd met ontwikkel ing van COPD en ernst van COPD, maar 
decorine n iet 
4. Deleties van de GSTMl en GSTTl enzymen, d ie de rookgerelateerde oxidatieve 
stress verminderen, zijn geassocieerd met versnelde longfunctieda l ing in rokers 
5 .  Polymorfismen in de genen van de Superoxide Dismutase enzymen zijn  betrokken 
b ij de aanwezigheid van bronch ia le hyperreactiviteit en achteru itgang van 
longfunctie in de a lgemene bevolking 
6. Zowel de samenstel l ing van l ipiden in  long surfactant a ls genetische varianten in 
surfactant genen zijn  risicofactoren voor de ontwikkel ing van COPD en het n iveau 
en verloop van longfunctie 
7. Genetisch ge ·15oleerde popu laties kunnen in genetisch onderzoek naar COPD 
gebru ikt worden voor identificatie van genen betrokken bij de ernst van COPD 





Promoveren doe je niet a l leen . lk wil graag iedereen bedanken die op welke manier dan 
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ik  h ierbij i n  het bijzonder noemen.  
D it  proefschrift zou er n iet zijn  geweest zonder de grate inzet en betrokkenheid van de 
deelnemers aan het Vlagtwedde/Vlaardingen onderzoek en a l le  medewerkers die hebben 
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